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In our modern western society, where the control of infectious diseases and general live 
conditions are of a high standard, cancer has emerged as one of the leading causes of 
death. In general, cancer results from changes in cells that release them from the 
normal control on differentiation, proliferation and survival. Cancer cells lose their 
normal function, accumulate into large quantities and destruct normal healthy tissues 
via invasion and metastasis. The process of tumor formation is known to comprise 
several steps: (i) interruption of terminal differentiation; (ii) increased growth rate; (ii i) 
escape from apoptosis; (iv) genetic instability; (v) evasion of the immune system; (vi) 
angiogenic ability; (v ii) ability to invade adjacent tissues (v iii) ability to spread and 
settle at new sites. These different steps may be caused by different cellular changes, 
but some may also be caused by the same alteration. Additionally, the order of cellular 
changes may differ per tumor type and it  is not always necessary to pass through all 
these steps to become a malignant cancer.
The different types of cancer are characterized by tissue type, site of origin and 
malignancy grade. Roughly, cancers can be divided into two groups: the hematopoetic 
tumors, subdivided in leukemias and lymphomas, and the solid tumors. Solid tumors can 
be classified into carcinomas and sarcomas, originating from epithelial and 
mesenchymal cells, respectively. However, there are many tumors which arise from cells 
that do not fit in either of these two categories, e.g. some brain tumors that originate 
from the neuroectoderm, making the strict subdivision into carcinomas and sarcomas 
incomplete.
1.1 Cancer
1.2 Chromosomal aberrations in cancer
1 .2 .1  Cancer is  a genetic disease
Already suggested in 1914 by Boveri, but now widely accepted, is that cancer is 
essentially a genetic disease: transformation from normal to malignant cells arises from 
a series of germ-line and/or somatic DNA alterations (Sandberg, 1990). In 1960 Nowell 
and Hungerford described the first specific and consistent DNA alteration (chromosomal 
abnormality) to be associated with cancer cells: the "Philadelphia" chromosome (Ph1) 
in chronic myelogenous leukemia (CML). Since then, increasing numbers of cancer- 
associated chromosomal aberrations have been identified, simultaneously with 
improving chromosome identification and cell culture methods (Seabright 1971; Sumner 
et a l., 1971; Patil et a l., 1971; Hagemeijer et a l., 1979; Yunis, 1981).
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1 .2 .2  Numerical and structural chromosomal aberrations
Normal human somatic cells carry 46 chromosomes, 22 pairs of autosomes (1-22) and 2 
sex-chromosomes (X, Y): a diploid karyotype (Figure 1A). Chromosomal aberrations 
occurring in cancer cells may involve both the number and, more frequently, the 
structure of chromosomes. Numerical changes may be due to losses or gains of whole 
chromosomes or fragments thereof, resulting in aneuploid karyotypes. Structural 
changes arise through errors in breakage and reunion and may involve deletions, 
translocations, insertions, inversions, rings (Figure 1B) and amplifications. Amplified 
sequences may be located within a chromosome, where they appear as homogeneously 
staining regions (HSRs; Figure 1C) or, alternatively, on tiny chromosomes called double 
minutes (DMs; Figure 1D). Also, ring chromosomes often contain amplified DNA 
sequences (Heim and Mitelman, 1995). In addition to classical cytogenetics, many 
molecular genetic techniques have been developed to yield more and qualitatively 
improved information on the genetic changes that may occur in malignant cells (Heim 
and Mitelman, 1995; Mitelman, 1998), including subtle sequence changes 
(substitutions, deletions, or insertions of a few nucleotides) which can not be detected 
through cytogenetic analysis.
1 .2 .3  In itia tion- and progression-related chromosomal aberrations
Different tumors may show different chromosomal constitutions. One can distinguish 
"simple" versus "complex" karyotypes for tumors exhibiting one or a few chromosomal 
aberrations versus tumors exhibiting many chromosomal aberrations (Figure 1E), 
respectively. Moreover, based on the timing of occurrence, genetic aberrations can be 
subdivided into primary and secondary changes (Heim and Mitelman, 1986, 1989, 1995; 
Mitelman and Heim, 1990; Sandberg, 1991). Primary changes are generally tumor type- 
specific, occur frequently, and are often solitary, indicating a causal role in 
tumorigenesis (tumor-initiation). Secondary aberrations mainly occur at later stages of 
tumor development and are rarely found alone and are less tumor-type specific. 
Nevertheless, these aberrations are thought to be related to tumor progression and may, 
as such, be indicative for a poor prognosis. "Cytogenetic noise" is a designation for 
random secondary aberrations often seen in advanced tumors, especially in solid tumors, 
without any tumor-specificity.
1 .2 .4  The m ulti-step nature of cancer
The step-wise process of tumor formation as mentioned above (1 .1) is thought to be 
related to the accumulation of genetic changes that occur in cancer cells. In fact, in the 
past two decades substantial evidence has been obtained for the so-called "multi-hit" 
model of carcinogenesis: cancer usually arises from a series of sequential genetic changes 
of which each drives a wave of cellular proliferation associated with gradual increases in 
tumor size, disorganization and malignancy (Bishop, 1987; Weinberg, 1989; Fearon and 
Vogelstein, 1990). Depending on the tumor type, it  is thought that three to six such 
mutations may be required to complete this process (Vogelstein and Kinzler, 1993).
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Figure 1. A. Normal male karyotype: 46,XY. B. Ring chromosomes (arrow heads). C. Homogeneously 
staining region (HSR; arrowhead). D double minutes (DMs). E. Complex karyotype of an osteosarcoma  
sample showing multiple structural and numerical abnorm alities. Figures are adapted from Sandberg 
(1990); Biedler and Spengler (1976); Sreekantaiah et a l., (1991); Bridge (1993); Simons (1999; 
unpublished data).
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1.3 Genes involved in cancer
1 .3 .1  Proto-oncogenes and tumor suppressor genes
Most genes playing a role(s) in cancer development encode proteins which normally 
regulate cellular growth and differentiation. During these processes, growth promoting 
(proto-oncogenes) and growth inhibiting (tumor-suppressor) genes are activated and 
inactivated in turn to keep the division and differentiation processes under control. When 
they are constitutively activated (oncogenes) or inactivated (tumor suppressor genes) as a 
result of chromosomal (genetic) aberrations, however, abnormal cellular growth or 
disruption of the processes of normal cellular differentiation and (programmed) cell death 
may occur. Tumor suppressor genes have, based on their function, been designated 
"gatekeepers": they guard the gate to cell cycle progression (Kinzler and Vogelstein, 1998). 
Oncogenes can be activated through point mutations, e.g. the ras oncogenes in colon and 
lung carcinomas (Bos, 1989), or through chromosomal translocations, e.g. the Ph' 
chromosome mentioned above (1 .2 .1 ). This Ph' chromosome results from a translocation 
between the chromosomes 9 and 22, t(9;22)(q34;q11) (Rowley, 1973) and leads to a fusion 
of the c-abl proto-oncogene on 9q34 and the bcr gene on 22q11. This fusion results in the 
formation of a chimeric bcr/abl gene encoding a chimeric mRNA (Groffen et a l., 1984; 
Grosveld et al., 1986; Chissoe et al., 1995). This transcript, in turn, codes for a novel fusion 
protein with altered tyrosine kinase properties, now known to be directly responsible for 
malignant transformation (Ben-Neriah et al., 1986; Daley et a l., 1990). Alternatively, proto­
oncogenes may become activated through juxtaposition to an active chromatin domain. 
This is e.g. seen in Burkitt's lymphoma, in which the c-MYC gene is translocated to one of 
the immunoglobulin genes which are actively transcribed in B cells, thus leading to 
overexpression of c-MYC (Croce and Nowel, 1985). Such an overexpression of proto­
oncogenes may also be accomplished by amplification, as is often seen for c-MYC and ERBB2 
in breast cancers (Garcia et al., 1989; Berns et al., 1992), N-MYC in neuroblastomas 
(Brodeur et al., 1981, 1984; Brodeur and Fong, 1989), and MDM2 and CDK4 in sarcomas 
(Leach et al., 1993; Florenes et al., 1994; Maelandsmo et al., 1995; Wunder et al., 1999). 
Such amplifications are usually associated with more advanced stages of malignancy and 
an unfavorable clinical course (Brodeur et al., 1984; Brison 1993; Forus et al., 1993). 
Genetic alterations involving proto-oncogenes are mostly dominantly acting.
In contrast to the activation of proto-oncogenes, recessive or loss-of-function alterations 
may occur in tumor suppressor genes. Knudson postulated that two successive mutations 
("hits"), inactivating both copies of a tumor suppressor gene, are required to turn a 
normal cell into a tumor cell (Knudson, 1971, 1993). This "two-hit" hypothesis was first 
validated by Cavenee et al. (1983) who identified the retinoblastoma susceptibility gene 
RB1. They found that in familial cases a germ-line mutation in one of the RB1 alleles has 
occurred, while in the tumors the remaining RB1 allele was lost somatically (Cavenee et 
a l., 1983; Friend et a l., 1986). Since then, many tumor suppressor genes which play roles 
in familial cancers have been identified, such as TP53 in Li-Fraumeni syndrome (Malkin
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et a l., 1990), WT1 in familial Wilms' tumor (Call et a l., 1990; Gessler et al., 1990), VHL 
in von Hippel-Lindau disease (Latif et a l., 1993), p16INK4A in familial melanoma (Kamb et 
al., 1994), and PTEN in Cowden's disease (Li et al., 1997; Liaw et a l., 1997). These genes 
also turned out to be affected in many sporadic cancers (TP53: see Sherr, 1996; Ko and 
Prives, 1996; Levine, 1997; Moll and Schramm, 1998; WT1: see Little and Wells, 1997; 
Tay, 1998; VHL: see Wagner and Linehan, 1996; Decker et a l., 1997; p16INK4A: see Sherr, 
1996; PTEN: see Maier et a l., 1997; Cairns et a l., 1997; Maxwell et a l., 1998).
1 .3 .2  DNA repair genes
Besides the tumor suppressor genes ("gatekeepers") mentioned above, another group of 
genes has been identified that may be impaired in cancer. This group, designated as 
"caretakers", consists of DNA repair genes which play a role(s) in maintaining DNA integrity 
during replication and, in general, during the lifespan of a cell (Kinzler and Vogelstein, 
1996, 1998). Their impairment does not promote tumor initiation directly but rather leads 
to genetic instability and, concomitantly, an increase in the mutation rate of genes, 
including tumor suppressor- and/or proto-oncogenes. Inactivation of DNA mismatch repair 
genes such as MSH2, PMS1 and MLH1 has been observed in various (hereditary) colorectal 
and other carcinomas (Kolodner, 1995; Kinzler and Vogelstein, 1996; Cahill et al., 1998).
1.4 The cell cycle and its regulatory genes
1 .4 .1  Cell cycle phases and control pathways
Normal somatic cells travel through life via the so called cell cycle (Clurman and Roberts, 
1998 and references therein), which is schematically depicted in Figure 2. Each cell 
generation starts after division of a parental cell into two genetically identical daughter 
cells. This division phase is termed mitosis or M-phase. Just after division a cell that is 
destined to divide again enters a gap phase called G1, whereas a cell that is not enters a 
resting phase called G0. A cell in G1 moves into a S phase, during which DNA synthesis 
(replication) occurs. In between the S phase and the actual mitosis there is another gap 
phase: G2. During the gap phases cells are checked for correctness and become prepared 
for entering the next phase. Unlike transition through the S, G2, and M phases, G1 
progression normally relies on stimulation by extracellular signals (growth factors). The 
actual decision to divide occurs in a so-called restriction point late in G1, after which cells 
become refractory to extracellular growth regulatory signals and, instead, commit to the 
autonomous program that carries them through to division (Sherr, 1996). The three cell 
cycle transition checkpoints, G0/G1, G1/S and G2/M, are carefully controlled by cell cycle 
control genes, i.e ., the above mentioned tumor suppressor genes and proto-oncogenes. 
Two main cell cycle regulatory pathways which are often affected in cancer cells are the 
TP53- and the RB1- tumor suppressor pathways (Weinberg, 1995; Sherr, 1996; Levine, 
1997). These pathways, with their associated control genes/proteins, are depicted 
schematically in Figure 2.
General Introduction 15
Figure 2. Top: The four phases of the ce ll cycle. S (synthesis) phase, during which DNA replication  
occurs. G1 and G2 (gap) phases, during which cells grow and become prepared for entering the next 
phase. M (m itosis) phase, during which chromosomes are distributed to two daughter cells (division­
phase). G0, resting phase. The three transition checkpoints, G1/S, G2/M and G0/G1 are depicted in open 
arrows. Bottom (grey boxes): TP53- and RB1- ce ll cycle regulatory pathways. Indicated are im portant 
components (proteins/genes; sm all white squares and ovals) of these pathways and their modes of 
action (inh ib ition , activation , upregulation, transition ; see w hite box in the middle).
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1 .4 .2  TP53
This protein, discovered in 1979 (Linzer and Levine), is generally considered to act as a 
tumor suppressor (Ghebranious and Donehower, 1998 and references therein). The 
corresponding gene, located on 17p13, is the most frequently mutated gene in a wide 
variety of human cancers (for reviews, see Sherr, 1996; Ko and Prives, 1996; Levine, 1997; 
Moll and Schramm, 1998). TP53 suppresses tumorigenesis through two major mechanisms: 
(i) induction of a G1 cell cycle arrest (G1/S transition checkpoint) and (ii) induction of 
apoptosis. Depending on cellular circumstances, e.g. cell type, growth factor 
concentrations, levels of TP53 or degree of DNA damage, the decision between the 
initiation of an arrest or the apoptotic pathway is made (Ko and Prives, 1996; Levine, 
1997). The cell cycle arrest function of TP53 is mediated through its ability to regulate 
transcription of a large series of growth regulatory genes, both positive and negative 
(Levine, 1997; Ghebranious and Donehower, 1998). One important target gene of TP53 is 
p21WAF1 (El-Deiry et al., 1993) which stops the cell from entering the S-phase via the 
inhibition of cyclin dependent kinases (CDKs), resulting in the activation of the RB1 tumor 
suppressor (Sherr, 1996; see below). Another target gene is MDM2 which acts as a negative 
regulator of TP53 (Chen et a l., 1995, Levine, 1997). Besides the function of TP53 in G1/S 
cell cycle arrest, it  also plays a role in the G2/M checkpoint via the regulation of the 
number of centrosomes. When TP53 is absent or mutated, multiple centrosomes may be 
generated, ultimately resulting in aberrant chromosomal segregation during mitosis 
(Fukasawa et a l., 1996; Sherr, 1996; Levine, 1997). Clearly, TP53 is critical in the overall 
preservation of the cell's genomic integrity. In addition, TP53 plays a role in the G0/G1 
transition checkpoint: it  is able to maintain cells in G0 via a growth arrest specific protein, 
Gas1 (Del Sal, 1995). The induction of apoptosis is known to be regulated by 
overexpression of TP53 and its ability to directly activate death genes such as bax, or 
down-regulate survival genes such as bcl-2 (Miyashita et al., 1994; Sherr, 1996).
1 .4 .3  RB1
The retinoblastoma susceptibility gene on 13q14, RB1, was first cloned and 
characterized in detail in 1986 (Cavenee et a l., 1983; Friend, 1986). Both copies of the 
gene are somatically inactivated in many sporadic tumors, including retinoblastomas, 
osteosarcomas, soft tissue sarcomas and carcinomas of the breast, lung and bladder 
(Newsham et a l., 1998). In its unphosphorylated state, the RB1 protein accomplishes a 
G1-arrest via binding to members of the E2F protein family, transcription factors needed 
for S-phase entry and transcription of S-phase genes (Müller, 1995; Weinberg, 1995; 
Sherr, 1996). Through phosphorylation (i.e ., negative regulation) of RB1 by G1/S cyclin 
dependent kinases (CDK4 and CDK6) E2F is released from RB1-mediated repression thus 
enabling progression of the cell into the S-phase.
1 .4 .4  CyclinD and CDK4/6
Passage through the restriction point in G1 and entry into the S phase is controlled by 
cyclin-dependent protein kinases (CDKs) that are sequentially regulated by cyclins.
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Cyclin D proteins act as growth factor sensors and mitogenic stimulation induces their 
synthesis and assembly with their catalytic partners, CDK4 and CDK6. This assembly 
results in the activation of CDK4 and CDK6 which phosphorylate RB1, thereby activating 
E2F and leading the cell to progress through the cell cycle (Sherr, 1994, 1996 and 
references therein). CyclinD1 has been found to be overexpressed in a number of 
cancers, resulting from gene amplification or chromosomal translocations targeting the 
D1 locus on human chromosome 11q13 (Hunter and Pines, 1994; Hall and Peters, 1996; 
Sherr, 1996). CDK4 mutations and gene amplifications have been reported so far in only 
some tumor types, i.e ., malignant gliomas and sarcomas (Reifenberger et a l., 1994; 
Maelandsmo et a l., 1995; Sherr, 1996; Levine, 1997).
1 .4 .5  p16INK4A and p19ARF
The p16 locus on 9p21 encodes a negative regulatory protein, p16INK4A, which induces G1 
arrest through inhibition of the catalytic activity of the CDK4 or CDK6/cyclin D complexes 
and subsequently RB1 phosphorylation (Serrano et a l., 1993; Kamb et a l., 1994). This 
tumor suppressor gene was first found to be interrupted in human melanoma (Kamb et 
al, 1994). Now it is known that multiple mechanisms of p16 inactivation, such as point 
mutation, deletion and hypermethylation, are occurring in different types of tumors, 
including biliary tract, hepatocellular and esophageal carcinomas, gliomas, pancreatic 
carcinomas and acute lymphocytic leukemias (see Sherr, 1996). Besides the above 
mentioned CDK4 inhibitor (INK4A), the p16 locus encodes an alternative transcript, 
known as p19ARF (alternative reading frame; Pomerantz et a l., 1998; Prives, 1998; Zhang 
et a l., 1998). This gene product shares no sequence and functional homology with the 
INK4A protein. p19ARF functions to sense oncogenic mitogenic stimuli, is capable of 
arresting cell proliferation, both at the G1/S and G2/M transition points of the cell cycle, 
and permits TP53-induced apoptosis. The latter two are due to p19ARF 's ability to stabilize 
TP53. This stabilization is accomplished by binding of p19ARF to MDM2 and thus 
preventing MDM2-mediated TP53 degradation (Pomerantz et a l., 1998; Zhang et a l., 
1998; Tao and Levine, 1999). Thus, also p19ARF has tumor suppressor capacity.
1 .4 .6  MDM2
This proto-oncogene, located on 12q13, has been found to be amplified and/or 
overexpressed in 30-40% of human sarcomas (Oliner et a l., 1992). The gene which is 
upregulated by TP53, encodes a protein that can bind and inactivate the transcriptional 
activity of TP53, thereby abolishing TP53's antiproliferative and apoptotic effects 
(Momand et a l., 1992; Oliner et a l., 1993; Chen et al, 1995; Levine, 1997). As mentioned 
above, the inhibitory effect of the MDM2 gene product on TP53 can be neutralized by 
the p19ARF protein (Pomerantz et a l., 1998; Zhang et a l., 1998; Tao and Levine, 1999). 
Two other genes with potential roles in tumor development through amplification 
and/or overexpression and which are also located on 12q13 are SAS (sarcoma amplified 
sequence; Meltzer et a l., 1991; Wunder et a l., 1998) and CHOP (Forus et a l., 1993; 1994; 
Wunder et a l., 1998).
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1.5 Molecular (cyto)genetic techniques
Besides optimization of the cytogenetic procedures for chromosomal identification, 
several new methods for the detection of genetic alterations ((sub)chromosomal, 
subregional or single nucleotide level) have been designed and further refined during 
the past decades. Some of these recently developed molecular (cyto)genetic techniques, 
which have been applied to the analysis of solid tumors with complex chromosomal 
constitutions in this thesis, w ill be introduced in this paragraph.
1 .5 .1  Molecular genetics
The development of novel molecular genetic methodologies has enabled the detection 
of deletions, amplifications, translocations, and (point-) mutations within specific DNA 
sequences using Southern blot-, polymerase chain reaction (PCR)-, single strand 
conformation polymorphism (SSCP)- and direct sequencing analyses (examples in Forus 
et a l., 1993; Chissoe et a l., 1995; Weterman et a l., 1996; Garcia-Sanz et a l., 1998; 
Yokoyama et a l., 1998). Additionally, deletions of specific chromosomal segments in 
tumor cell populations can now be detected via loss of heterozygosity (LOH) of 
polymorphic DNA markers such as naturally occurring restriction fragment length 
polymorphism (RFLPs) and/or microsatellite (e.g. CAn) repeat variations (Lasko et a l., 
1991; Solomon et a l., 1991). Unfortunately, all these techniques require prior knowledge 
of the gene or DNA sequence to be investigated. In many tumors with unknown complex 
genetic rearrangements this information is not available. So, other techniques prefer 
usage when studying tumors with complex anomalies.
1 .5 .2  Fluorescence in situ  hybridization
The sensitive hybridization, detection, and localization of specific complementary 
nucleic acid sequences (probes) in morphologically preserved biological structures (such 
as chromosomes, cells and tissue sections) form the essence of a technique known as in 
situ hybridization (ISH ). Initia lly use was made of radioactively labeled probes. The 
subsequent introduction of non-radioactive labels, such as haptens or fluorochromes and 
the employment of high-affinity reagents that allow immunocytochemical detection and 
amplification of the non-radioactive signal strength released many new technical 
innovations and turned the hybridization technique into a simpler and more accessible 
one. As a result, the application of, in particular, fluorescence in situ hybridization 
(FISH) has expanded enormously. At this moment a wide variety of probes is available 
for FISH analysis of tumor samples, not only via chromosomal preparations, but also via 
monitoring chromosomes in non-dividing (interphase) cells. In some approaches FISH 
is even applicable to archival frozen or paraffin-embedded specimens, making 
retrospective studies possible. The most commonly used probes for FISH detection are 
cosmids, yeast-, bacterial-, and P1-derived artificial chromosomes (YACs, BACs, and 
PACs, respectively), microlibraries and other, PCR-generated, DNA fragments. In 
addition, whole chromosome-specific recombinant libraries are available for so-called
General Introduction 19
"chromosome painting" (Pinkel et a l., 1988). Due to the use of different fluorochromes 
for visualization of different probes it  is possible to detect more than one probe 
simultaneously in one preparation (multicolor-FISH). Elaborating on this, two recently 
developed techniques, known as multiplex FISH (Speicher et a l., 1996) and spectral 
karyotyping (SKY; Schröck et a l., 1996) even make it  possible to use more than twenty- 
four colors for the simultaneous identification of all human chromosomes.
1 .5 .3  Comparative genomic hybridization
The basic idea of the technology called comparative genomic in situ hybridization or CGH 
(Kallioniemi et al., 1992, 1994; du Manoir et a l., 1993) is simple: compare two genomic 
DNA populations, one extracted from normal tissue and one extracted from tumor tissue, 
with each other and search for the differences. The CGH technology is based on earlier 
developed FISH procedures as it  uses differentially labeled test (i.e . tumor) and reference 
(i.e . normal) DNAs to be hybridized simultaneously to normal human metaphase 
chromosomes under in situ suppression hybridization conditions (Figure 3 ). In this 
procedure the two genomic DNA populations are, prior to hybridization, mixed in a 1:1 
ratio. During hybridization the test and reference DNAs compete for the same targets 
(metaphase chromosomes). Subsequently, the hybridized DNAs are detected using two 
different fluorochromes (green and red). The relative amounts of test and reference DNA 
bound to a given chromosomal locus are dependent on the relative abundance of these 
sequences in the two samples. Intensity differences in the fluorescent hybridization 
patterns of test DNA and reference DNA can be interpreted as sequence copy number 
differences between the two genomes. The fluorescent hybridization patterns of test and 
reference DNAs are recorded, digitized, and analyzed using a high-performance cooled 
charge coupled device (CCD) camera, mounted on an epifluorescence microscope that is 
equipped with appropriate filters for visualization of red, green, and blue (for DAPI 
counterstain) fluorescence, and image analysis computer software. Quantitation of the 
results, involving chromosome identification and measurement of fluorescent intensities 
for all fluorochromes along the axis of chromosomes identified, results in a green-versus- 
red intensity ratio profile along the length of that chromosome. Differences in the ratio, 
as they deviate from the balanced situation of 1.0, imply relative copy number 
differences (either gain/overrepresentation or loss/underrepresentation) for that 
particular chromosome and/or its chromosomal (sub)region(s) in the test DNA. There are 
several factors that may hamper the use of CGH in the detection of chromosomal 
abnormalities in tumor genomes. Tumor tissues may be contaminated with infiltrating, 
normal cells and/or exhibit intratumor genetic heterogeneity, leaving several subtle 
abnormalities unrevealed. Furthermore, the detection level of genomic imbalances is 
about 3-20 Mb for deletions (Kallioniemi et a l., 1992; Kirchhoff et a l., 1999) and about 
1 Mb for high-level (5-10 fold) amplification (Forozan et a l., 1997). Finally, the CGH 
technique does neither provide any direct information on the chromosomal constitution 
of under- and/or overrepresentations in the test genome, nor reveal balanced
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Figure 3. Schem atic outline of the comparative genomic hybridization (CGH) technique as described in 
the text ('green' is represented in light-grey, 'red' is  represented in dark-grey).
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chromosomal rearrangements resulting from inversions or translocations. Nevertheless, 
this technique allows, in a single hybridization step, a comprehensive screening of whole 
genomes for (sub)chromosomal imbalances revealing so-called "copy number 
karyotypes". Until now hundreds of studies have been published using CGH to obtain such 
copy number karyotypes for many human neoplasms (reviewed by Knuutila et a l., 1998). 
The test DNAs need not only be derived from fresh tissue. Also archival (including 
formalin-fixed, paraffin-embedded) materials that otherwise were no longer accessible to 
cytogenetic analyses may be used. Interestingly, much effort has been put into the 
improvement of the resolution of CGH, which is directly related to the resolution of the 
target DNA (chromosomes). This has led to CGH analysis on different targets such as 
combed DNA fibers generated from cosmids and YACs (Kraus et a l., 1997), but also on 
arrays of genomic clones spotted on microscopic slides. The last application is known as 
matrix-CGH (Solinas-Toldo et a l., 1997) or aCGH (array-CGH; Pinkel et a l., 1998).
1 .5 .4  Representational difference analysis
The isolation (molecular cloning) of differences between the genomes of normal and 
cancer cells may be difficult, cumbersome or even impractical, particularly if  the cancer 
cells exhibit complex genetic rearrangements and if  there is no clue where and what to 
look for. A novel molecular genetic method, designated representational difference 
analysis (RDA), has been developed to circumvent these limitations and allows for the 
efficient isolation of such differences (Lisitsyn et a l., 1993). The power of the RDA 
method lies within the combined implementation of three elements, i.e . subtractive 
hybridization, representation, and kinetic enrichment (Lisitsyn et a l., 1993; Figure 4 ). 
Representations of complex genomes are generated via restriction enzyme digestion of 
the DNAs, ligation of these fragments to oligonucleotide adaptors and subsequent PCR 
amplification. This results in a preferential amplification of fragments with average 
lengths ranging from 0.5 up to 2 kb, thus leading to DNA samples with reduced 
complexity as compared to the original genomes. This, in turn, causes an increase in the 
efficiency of a subsequent subtractive hybridization. Kinetic enrichment is achieved 
through several rounds of subtractive hybridization and PCR amplification in which target 
DNA sequences are purified (i.e ., enriched). Before each round, the tester DNA fragments 
(containing target sequences) are ligated to new adaptors. Each subtractive round starts 
with mixing the adaptor-ligated tester DNA with an excess of driver DNA (containing 
non-target sequences), followed by denaturation and reassociation. Subsequently, PCR is 
performed using the adaptor sequence as primer. Tester DNA fragments that are absent 
in the driver sample (i.e ., target sequences) are predominantly self-reannealing and, 
thus, form homoduplexes (= double strand tester molecules) with primer sequences at 
both ends. These target sequences are amplified selectively. At the same time, single 
strands of non-target tester fragments form heteroduplexes with driver DNA fragments. 
These duplexes, as well as single stranded tester molecules, have primer sequences at one 
end only. As a consequence they do not participate in the exponential amplification and,
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Figure 4. Schem atic outline of the representational difference analysis (RDA) procedure for genomic 
fragments as described in the text.
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thus, will be subtracted. The selective amplification of homoduplexes results in a kinetic 
enrichment of target sequences in subsequent subtraction hybridization and 
amplification reactions (= difference products, DPs; Figure 4 ). Enriched target sequences 
in second or third round difference products, visible as distinct bands by agarose gel 
electrophoresis, are subsequently cloned into plasmid vectors and analyzed further. The 
combination of subtraction and kinetic enrichment is so powerful that, theoretically, 
even a single short sequence present in one of two highly related genomes can readily 
be isolated, provided that this sequence is included in the starting material (the 
representation DNA). In the application of RDA to cancer there are basically two 
approaches: (i) using tumor DNA as driver and normal DNA as tester, and (ii) using normal 
DNA as driver and tumor DNA as tester. In the first approach DNA fragments may be 
isolated from regions that are deleted in tumors, whereas in the second approach DNA 
sequences may be isolated that are implicated in point mutations, chromosomal 
rearrangements, DNA amplifications or the presence of pathogens.
For the detection of deletions using the first approach, the availability of pure tumor DNA 
is a prerequisite. This DNA can be isolated from tumor cell lines, xenografts or aneuploid 
nuclei that have been sorted from tumor biopsies by flow cytometry. Through the 
application of RDA DNA losses have been detected in a number of neoplasms including 
some kidney cancer cell lines, colon cancer cell lines, tumors of the digestive tract 
(Lisitsyn et a l., 1995) and a pancreatic adenocarcinoma xenograft (Schutte et al., 1995). 
Probes detecting true homozygous deletions have turned out to be extremely useful for 
the mapping and positional cloning of genes that are inactivated in tumors. This was 
demonstrated e.g. for the BRCA2 gene (Schutte et a l., 1995) and, more recently, the 
tumor suppressor gene PTEN (Li et a l., 1997). Due to the usually small nature of 
homozygous deletions, mapping of new tumor suppressor genes through RDA can be 
performed with a precision that is unattainable by any other technique available to date. 
By using the second approach, RDA analysis has led to the isolation of DNA fragments 
that detect high-level amplifications in a human melanoma cell line and a human small­
cell lung cancer cell line (Lisitsyn et a l., 1995). Only in case of amplifications, the 
enrichment and subsequent isolation of target sequences is based on their relative 
abundance in the tester, which leads to kinetic enrichment during the RDA procedure, 
and not on their absence in the driver (Lisitsyn et a l., 1995; Lisitsyn 1995). For this 
reason, there is no absolute need for highly related DNA and, in principle, any normal 
human DNA can be used as a driver (Lisitsyn et a l., 1995).
Recently, new variants of RDA have been developed. First described by Hubank and 
Schatz (1994), but now used by many others, is the variant called "cDNA-RDA". 
Differential gene expression separates differentiated cells from undifferentiated stem 
cells, activated cells from resting cells, and cancer cells from their normal counterparts. 
Many differentially expressed genes have been identified this way, including several 
caffeine up-regulated genes from a pre-B cell line (Hubank and Schatz, 1994), human 
chromosome 17-specific genes from a human-mouse hybrid cell line (Tajima et a l., 
1997), target genes for the Ewing's sarcoma-associated EWS/FLI fusion (onco)protein
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(Braun et a l., 1995) and genes specifically expressed in pancreatic cancer (Gress et a l., 
1997). Another application of RDA is the isolation of differentially methylated genes 
which may play important roles in cellular differentiation and transformation processes. 
This variant has been designated "methylation-sensitive-RDA" (MS-RDA) and was first 
applied by Ushijima and coworkers (1997) in the isolation of hypo- and hypermethylated 
genomic fragments in mouse liver tumors.
1.6 Scope and outline of this thesis
Several hematologic and solid tumors carry relatively simple recurrent chromosomal 
aberrations. These aberrations turned out to be very suitable as specific diagnostic 
markers (reviews by Ladanyi, 1995; Cooper, 1996; Dei Tos and Dal Cin, 1997). In 
addition, they were used often to positionally clone the genes involved (examples in 
Grosveld et a l., 1986; Dauwerse et a l., 1993; Clark et a l., 1994; de Leeuw et a l., 1994; 
Weterman et a l., 1996). However, there are also many tumors that exhibit complex 
cytogenetic constitutions. For most of these latter tumors no recurrent chromosomal 
aberrations are known. The detection, identification and isolation of such aberrations 
appears to be difficult, particularly when the tumors are not amenable to cytogenetic 
analysis and/or when the interpretation of the data remains insufficient. To overcome 
these difficulties, we applied various molecular (cyto)genetic techniques, as outlined in 
paragraph 1.5, to this issue. Tumor types subjected to such analyses were the sarcomas 
malignant mesenchymoma, malignant fibrous histiocytoma of soft tissue and 
osteosarcoma, and the brain tumor glioblastoma. Specific histopathological and 
(cyto)genetic characteristics of these tumors w ill be presented in the introduction 
sections of the different chapters in this thesis. Chapter 2 reports, for the first time, 
the molecular cytogenetics of a rare soft tissue tumor, malignant mesenchymoma. In 
this tumor, supernumerary ring chromosomes were found. Subsequently, these ring 
chromosomes were characterized using FISH and CGH. Chapter 3 describes a 
comprehensive study of a series of malignant fibrous histiocytomas using a combination 
of cytogenetic, CGH, and Southern blot analyses. Novel genomic regions of imbalance 
were detected and the relevance of the TP53- and RB1- cell cycle regulatory pathways 
in the development of this tumor type is discussed. In Chapter 4 the identification and 
isolation of osteosarcoma-associated amplified DNA sequences through CGH and RDA is 
described. This study illustrates the complementarity of these two techniques in the 
search for amplified DNA fragments in tumor samples. In Chapter 5 we report the 
identification of a region of frequent allelic loss on chromosome 4q in osteosarcomas 
which, so far, was not described in this type of tumor. For this study we made use of 
CGH, RDA, FISH and Southern blot analyses. In Chapter 6 an additional region of 
homozygous loss on chromosome 5q, identified by RDA in the same tumor, is shortly 
reported. Chapter 7 describes the isolation and characterization of glioblastoma- 
associated homozygously deleted DNA fragments from chromosomal region 9p21 using
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RDA in conjunction with polymerase chain reaction (PCR) analysis of a series of tumors. 
We postulate that multiple tumor suppressor genes from this chromosomal region may 
play important role(s) in the development of this type of brain tumor. A general 
discussion and some future prospects are provided in Chapter 8. Finally, a summary of 
all the work is presented in Chapter 9.
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Abstract
We report, for the first time, the cytogenetic and molecular genetic constitution of a 
human mesenchymoma. As in several other soft tissue sarcomas, supernumerary ring and 
rod-shaped marker chromosomes were observed next to an otherwise normal diploid 
karyotype. Comparative genomic in situ hybridization and whole chromosome painting 
experiments revealed that chromosome 1q21-q25 and 12q14-q15 sequences were 
amplified, and that these sequences resided on the supernumerary marker chromosomes. 
We assume that, in this malignant mesenchymoma, the observed chromosomal 
anomalies may be associated with its well differentiated liposarcomatous component.
Introduction
Malignant mesenchymoma is a rare soft tissue tumor comprising two or more non-related 
mesenchymal tissue components (Ashley, 1978; Scheel et al., 1990; Campannacci, 1990; 
Fechner and Mills, 1993). Malignant mesenchymomas can be divided in to two groups. 
The main group consists of a specific sarcoma (mostly rhabdomyosarcoma or 
liposarcoma) together with an osteosarcomatous or chondrosarcomatous component. A 
minority of malignant mesenchymomas is characterized by a combination of 
rhabdomyosarcoma and liposarcoma. Other combinations are very rare. We describe a 
case of malignant mesenchymoma with supernumerary ring and rod shaped marker 
chromosomes. This is the first (cyto-)genetic report of a malignant mesenchymoma.
Case report
A 55-year-old obese female presented with a 2-year history of pain and increased swelling 
of the left hip region. Computer tomography (CT) and magnetic resonance imaging (MRI) 
scans revealed a large gluteal soft tissue mass of 20 x 30 x 50 cm extending into the 
pelvis. Open biopsy led to the diagnosis of liposarcoma, with no evidence of metastatic 
spread. The tumor was resected completely by means of hemipelvectomy. The patient 
received no further treatment and is still in remission, 3 years after therapy.
Pathologic findings
The resection specimen revealed an irregular lobulated, soft, partly gelatinous tumor 
mass with a pale-yellow color, and on the cut surface, some areas of chondroid
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consistency. The tumor infiltrated pelvic and gluteal muscles, but there was no bone 
destruction. Microscopic examination showed partly immature adipose tissue with 
connective tissue. Fat cells showed considerable variations in size and form with nuclear 
atypia and some multivacuolar lipoblasts. Myxoid areas were noticed. In many places 
cartilaginous foci were found exhibiting pronounced chondrocytic atypia with nuclear 
polymorphism and hyperchromasia (Figure 1). The tumor was classified as well- 
differentiated liposarcoma, partly of the myxoid type with extensive malignant 
chondromatous component consistent with chondrosarcoma grade I. We conclude that 
this tumor can be best defined as a malignant mesenchymoma (main group).
Figure 1. Histologic picture of the tumor showing liposarcomatous (A) and chondrosarcomatous (B) 
components (H&E staining x 160).
Cytogenetic and molecular analysis
Part of the excised tumor was processed for short-term tissue culture. Cytogenetic 
analysis was performed on G-banded metaphase spreads using standard procedures, and 
revealed a near diploid karyotype [ISCN] with supernumerary ring chromosomes: 48,XX, 
+ r1, + r2 (Figure 2A). Six other cells exhibited near-tetraploidy with, again, 
supernumerary ring chromosomes and, in some cells, large rod-shaped markers (Figure 
2B). Previously, similar ring- and rod-shaped marker chromosomes were frequently 
encountered in well-differentiated liposarcomas, atypical lipomas, and malignant fibrous 
histiocytomas (Sreekantaiah et al., 1991; Mandahl et al., 1988; Sandberg and Bridge, 
1994; Dei Tos and Dal Cin, 1997) and were found to be associated with gene 
amplifications (Sreekantaiah et al., 1992; Pedeutour et al., 1993; Dal Cin et al., 1993; 
Suijkerbuijk et al., 1994; Forus et al., 1995; Nilbert et al., 1994; Nakayama et al., 1995; 
Geurts van Kessel et al., 1997). To test whether, in this case, genomic amplifications 
were manifest and, if so, whether the origin of these amplifications could be traced, we 
performed a comparative genomic in situ hybridization (CGH) experiment (Suijkerbuijk 
et al., 1994; Forus et al., 1995). As shown in Figure 2C, clear amplifications of the
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Figure 2. Tumor-derived karyotype (A) and partial metaphase spread (B) showing supernumerary ring 
chromosomes (arrows) and a rod-shaped marker (arrowhead). (C) Comparative genomic in situ 
hybridization (CGH) using normal human DNA (labeled green) and DNA extracted from the 
mesenchymoma (labeled red); tumor-associated amplified regions 1q21-q25 and 12q14-q15 are marked 
by arrowheads and arrows, respectively. Chromosomes were counterstained using the blue dye DAPI. 
(For color picture see original published paper).
regions 1q21-q25 and 12q14-q15 could be observed after CGH; regions that are typically 
affected in a variety of soft tissue sarcomas, particularly liposarcomas (Pedeutour et al., 
1993; Dal Cin et al., 1993; Suijkerbuijk et al., 1994; Forus et al., 1995; Geurts van Kessel 
et al., 1997). To further confirm these results, whole chromosome 1 and 12 painting 
experiments (Pedeutour et al., 1993) were carried out on tumor-derived metaphase
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Figure 3. Partial tumor-derived metaphase spread after whole chromosome 1 (red) and 12 (green) 
painting. The two ring chromosomes (r) are almost exclusively composed of chromosome 1 and 12 
material. (For color picture see original published paper).
spreads. These experiments clearly showed (Figure 3) that both rings were almost 
exclusively composed of either chromosome 1 (small ring) or chromosome 1 and 12 
(large ring) material, thus confirming the origin of the previously observed amplified 
sequences. Taking these findings together, we assume that the supernumerary ring- and 
rod-shaped marker chromosomes in this malignant mesenchymoma are associated with 
the well differentiated liposarcomatous component.
Malignant mesenchymomas must be distinguished from chondroid lipomas, dedifferen­
tiated chondrosarcomas and dedifferentiated liposarcomas (Johnson et al., 1996; Meis 
and Enzinger, 1993; Ishida et al., 1997). In our case, we found no features of these 
latter tumors. Also, the huge size, the aggressive extension into the pelvis and the 
proximal half of the thigh, and the microscopic appearance were consistent with the 
diagnosis of malignant mesenchymoma. In addition, no areas with characteristics of 
malignant fibrous histiocytoma, fibrosarcoma, or malignant hemangiopericytoma were 
identified. The patient was not irradiated and never experienced any trauma in the 
affected area. The two distinct malignant components, liposarcomatous and chondrosar­
comatous, were rather sharply demarcated from each other without an apparent 
transitional zone. Although scenarios for possible histiogenic pathways must remain 
speculative at this stage, we assume that the tumor has resulted from (re-)growth of a 
primitive mesenchymal cell with a pluripotential capacity rather than from a well-
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differentiated liposarcoma which, subsequently, developed chondroid features.
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Abstract
In order to search for new recurrent genetic aberrations in malignant fibrous 
histiocytoma (MFH), a combination of conventional cytogenetic, comparative genomic 
hybridization (CGH) and Southern blot analyses was applied to a series of 34 tumors. 
Cytogenetic analysis revealed the presence of multiple structural and numerical 
aberrations, including marker chromosomes, telomeric associations, double minutes and 
ring chromosomes. The most frequent genomic imbalances in this series of neoplasms 
as detected by CGH were gains of 1q21-q22 (69% ), 17q23-qter (41% ) and 20q (66%), 
and losses of 9p21-pter (55%), 10q (48%), 11q23-qter (55%), and 13q10-q31 (55%). 
Southern blot analyses with p16INK4A (CDKN2A; 9p21) and RB1 (13q14) probes provided 
clear indications for frequent allelic loss of these tumor suppressor genes and, as such, 
substantiated the CGH results. Additionally, examination of the TP53 and MDM2 genes 
showed frequent allelic loss and amplification, respectively. These data indicate that 
genes involved in the RB1- and TP53-associated cell cycle regulatory pathways may play 
prominent roles in the development of human MFHs.
Introduction
Malignant fibrous histiocytoma (MFH) is the most common malignant soft tissue tumor 
in adults (Weiss and Enzinger, 1978). Histopathologically, MFHs can be subclassified as 
storiform-pleomorphic, myxoid, giant cell and inflammatory (Enzinger and Weiss, 1995). 
Cytogenetic data on MFHs are scarce, but most tumors analyzed thusfar have exhibited 
complex karyotypes with multiple numerical and structural abnormalities (Mandahl et 
al., 1988, 1989; Sandberg and Bridge, 1994; Heim and Mitelman, 1995; Aspberg et al., 
1995; Szymanska et al., 1995; Walter et al., 1997; Schmidt et al., 1998). The structural 
abnormalities have included ring chromosomes, homogeneously staining regions, double 
minutes, telomeric associations and dicentric chromosomes. No specific chromosomal 
anomaly has been reported so far in MFH, but breakpoints in 1p36, 1q11, 1q21, 3p12, 
11p11, 17p11 and 19p13 have been recurrently observed (Mandahl et al., 1989; 
Sandberg and Bridge, 1994; Heim and Mitelman, 1995). Moreover, it has been suggested 
that a 19p+ marker may serve as an indicator for high risk of local recurrence and 
aggressive clinical course (Rydholm et al., 1990; Choong et al., 1996). Recently, Walter 
et al. (1997) observed two solitary rearrangements, t(5;7)(q31;q22) and 
t(13;14)(q10;q10), which were considered as primary changes.
In addition to conventional cytogenetic investigations, five comparative genomic 
hybridization (CGH) studies including data on MFH have been reported (Forus et al., 1995; 
Larramendy et al., 1997; Hinze et al., 1999; Sakabe et al., 1999; Mairal et al., 1999). CGH 
allows for the detection of genomic imbalances (i.e., gains/losses) of whole chromosomes 
or chromosomal regions. Accordingly, this technique may reveal the position and/or
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involvement of genes related to tumor development (Kallioniemi et al., 1992, 1994; 
Knuutila et al., 1998). In the first two studies the regions 1p31 and 7q32 were found to 
be frequently gained (Forus et al., 1995; Larramendy et al., 1997). In addition, 
Larramendy et al. (1997) reported that gain of 1p was significantly associated with a poor 
overall survival and gain of 7q32 with a less favorable metastasis-free/overall survival and 
an increased risk for local recurrences. As such, gain of 7q32 was proposed by these 
authors to serve as a novel prognostic marker. More recently, among other imbalanced 
genomic regions, amplification of 12q12-q15 was detected in more than 3 0 %  of MFHs 
tested (Hinze et al., 1999). In another study an amplicon derived from 8p23.1 was found 
in one MFH from which a candidate gene, designated MASL1, was subsequently isolated 
and characterized (Sakabe et al., 1999). This gene appeared to be overexpressed in 8 of
14 MFHs tested suggesting that overexpression of MASL1 may represent a critical 
oncogenic step in MFH development. Mairal et al. (1999) found loss of 13q14-q21 to be 
the most frequent genomic imbalance (57% ) and, therefore, suggested that the 
retinoblastoma (RB1) tumor suppressor gene (13q14) might serve as a good candidate. 
Molecular genetic studies on MFHs have indicated that the RB1 and TP53 genes, the latter 
located on 17p13, are frequently mutated and/or deleted in MFHs (Ozaki et al., 1993; 
Wadayama et al., 1993; Wunder et al., 1991; Taubert et al., 1995). Additionally, 
amplifications of the genes SAS (sarcoma amplified sequence), MDM2 (human homologue 
of murine double minute 2), CDK4 (cyclin-dependent kinase 4) and HMGIC (high mobility 
group protein IC), all located in the region 12q13-q15, have been reported in MFHs 
(Nilbert et al., 1995 and references therein; Reid et al., 1996; Berner et al., 1997). To 
what extent these tumor suppressor genes and oncogenes are involved in MFH 
development, however, remains to be determined.
In this study we have searched for new recurrent genetic aberrations in MFHs using a 
combination of techniques, i.e., cytogenetics, CGH and Southern blot analysis. Data 
obtained from 34 MFHs revealed many genomic imbalances, including frequent allelic 
loss of 9p21 (p16IM4A).
Materials and methods
Tumor m aterial and DNA iso lation
Thirty-four MFHs were available for this study. Of these, 15 were analyzed cytogenet­
ically, 29 were analyzed by CGH and 28 were analyzed by Southern blot analysis (Table 
1). The tumors were derived from patients from four different hospitals. 
Histopathological data of the tumors are listed in Table 1. Fresh frozen samples from all 
tumors were used for the isolation of high molecular weight genomic DNAs as described 
by Forus et al. (1993) and Simons et al. (1997). Genomic DNA from peripheral blood 
cells of unrelated human controls was isolated using standard SDS/proteinase K lysis, 
phenol/chloroform extraction and ethanol precipitation.
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Table 1. Tumor characteristics and types of analyses performed in this study.
tumor sex type grade site karyotype analysis
MFH 2 M s/p IV back nd CGH nd
MFH9 F u u u nd CGH nd
MFH11 F s III thigh nd CGH nd
MFH17(a) u u u u nd CGH SB
MFH19(a) F s/p IV thigh nd CGH nd
MFH25(a)(b) F s + m IV thigh nd CGH SB
MFH42 M P + g IV arm nd nd SB
MFH44 F s/p IV thigh nd CGH SB
MFH45 F s/p + m IV arm nd CGH SB
MFH46 F s/p + m III thigh nd CGH SB
MFH47 M s/p + m IV femur nd CGH SB
MFH48 M s IV tibia nd CGH SB
MFH49 M m III knee nd CGH SB
MFH52 M s/p + m IV abdomen nd CGH SB
MFH56 F P IV arm nd CGH SB
T80 F g u knee abnormal* CGH SB
T83a M s u thigh nd nd SB
T84a F m u thigh nd nd SB
T100 M s/p u thigh abnormal* CGH SB
T101 F s/p + g u thigh abnormal* CGH SB
T102 M s/p IV hand abnormal* CGH nd
T103 M m II lower leg abnormal* CGH nd
T104 F s/p + g u calf abnormal* CGH SB
T105 M m + p III/IV arm normal (46,XY) CGH SB
T106 M m u arm normal (46,XY) nd SB
T107 F m III/IV arm normal (46,XX) CGH SB
T108 F m IV femur abnormal* CGH SB
T109 M s/p + g IV arm abnormal* CGH SB
T120 M u u u abnormal* CGH SB
T126 F s/p III/IV thigh no metaphases CGH SB
T128 M m II buttocks abnormal* CGH SB
T129 F u u u abnormal* CGH SB
V I9 u u u u nd CGH SB
V34 u u u u nd nd SB
(a) previously studied by Forus et al. (1995)
(b) this tumor was designated MFH43 in the study by Forus et al. (1995)
M male patient, F female patient
m  myxoid, g giant cell, s storiform, p pleomorphic, s/p storiform/pleomorphic
u unknown, nd  not done
* see Table 2 for detailed cytogenetic data
CGH comparative genomic hybridization performed
SB Southern blot hybridization performed
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Cytogenetic analysis
Tumor tissues were mechanically minced and incubated for 24 hours in 5 ml medium 
(see below) containing 40 U/ml collagenase (Worthington Biochemicals Corporation). 
Subsequently, the cells were cultured for 2-8 days in RPMI-1640 medium plus glutamax-
1 (Life Technologies) supplemented with 1 5 %  fetal calf serum (Seratech) and 
antibiotics. Dividing cells were harvested according to standard procedures following 
colcemid treatment (5 pl karyoMAX Colcemid solution / ml medium, 5 hours; Life 
Technologies). After methanol/acetic acid fixation, metaphase spreads were prepared for 
GTG banding. Resulting karyotypes were described according to the International System 
for Human Cytogenetic Nomenclature (ISCN, 1995).
Comparative genom ic hybridization (CGH)
CGH analysis was performed as described by Simons et al. (1999b) and Jeuken et al. 
(1999) with some minor modifications. Briefly, tumor DNA was labeled with digoxigenin- 
11-dUTP (Roche Molecular Biochemicals) and normal (reference) DNA with biotin-16- 
dUTP (Roche Molecular Biochemicals). Three-hundred-sixty ng of each of the labeled 
probes, 100-fold excess human Cot-1 DNA (Life Technologies), and 50-fold excess of 
herring sperm DNA (Life Technologies) were co-precipitated and dissolved in 15 pl of 
hybridization buffer. Metaphase spreads were treated with pepsin (400 U/ml in 0.01 N 
HCl) for 10 minutes at 37 °C, followed by formaldehyde treatment (1 %  formaldehyde in 
PBS) for 5 minutes at room temperature. Subsequently, the probe-mix was added onto 
the slide and, after sealing of the coverslip, codenaturation of the probe-mix and the 
target chromosomes was achieved through incubation of the slide at 74 °C for 4 minutes. 
Hybridization was carried out at 37 °C for 3 days. Following washing, immunocyto- 
chemical detection of the probes was achieved with rhodamin-conjugated sheep anti- 
digoxigenin (Roche Molecular Biochemicals) and fluorescein isothiocyanate (FITC)- 
conjugated streptavidine (Roche Molecular Biochemicals). Afterwards, the slides were 
mounted in anti-fade medium containing DAPI for counterstaining of the chromosomes. 
Image acquisition was performed using a Zeiss Axiophot epi-fluorescence microscope 
equipped with a cooled CCD-camera (Sensys, Photometrics) and dedicated image 
acquisition software. Examination of CGH images was carried out using the QuipsTM CGH 
analysis software (Vysis). Based on results of preparatory CGH control experiments 
(normal versus normal DNA), using a 9 5 %  confidence interval (= mean ± 2 times standard 
deviation; see Vysis user guide, 1996) to achieve statistical justification, fluorescence 
ratios below 0.90 (lower threshold) were interpreted as losses and fluorescence ratios 
above 1.10 (upper threshold) were interpreted as gains. In  addition, normal versus 
normal control experiments were performed simultaneously with the normal versus tumor 
experiments to serve as a quality control of the CGH results (validation of the previously 
established thresholds). Also, care was taken in the interpretation of imbalances for 
regions prone to CGH artefacts, i.e., 1p32-pter, 16p, 19, 22, heterochromatic, telomeric 
and centromeric regions, and p-arms of acrocentric chromosomes (Kallioniemi et al., 
1994; Karhu et al., 1997). Ratios above 1.75 were scored as high copy number gains.
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Southern blot analysis and densitom etric scanning
Southern blot hybridizations were carried out as described by Forus et al. (1993) and 
Simons et al. (1999a,b). Quantitation of signal intensities was achieved by 
densitometric analysis using a type GS690 Imaging Densitometer (BioRad) and Multi­
Analyst software (BioRad). The net signals from specific bands were corrected for 
unequal sample loading by calibration relative to the signal obtained by a control probe 
(SYT, see below). Subsequently, the signals were compared to signals from normal 
control samples and interpreted as follows: samples with signal values below 0.75 were 
considered to exhibit allelic losses (i.e., deletions), samples with signal values between 
0.75 and 2.25 were considered to be normal, and samples with signal values above 2.25 
were considered to exhibit overrepresentations (amplifications).
Probes
An arbitrarily chosen control probe, a fragment of the human SYT cDNA originating from 
18q11.2, was generated in the department of Human Genetics (Nijmegen, The 
Netherlands; dos Santos et al., 1997). The p16IM4A probe (partial cDNA clone) and RB1 
probe (3.8 kb subclone of RB1 cDNA; PG 3.8M, Fung et al., 1987) were generously 
provided by Dr. A. de Klein (Erasmus University Rotterdam, The Netherlands). A 618 bp 
TP53 probe (exon 8) was generated by PCR using the TP53 P7L/P8R primer pair (GDB 
accession number 605513) and standard PCR conditions. The MDM2 probe (MDM2-3 
cDNA, Oliner et al., 1992) was kindly provided by Dr. B. Vogelstein.
Results
Cytogenetic f ind ing s in MFH
Fifteen of the 34 MFHs used in this study (listed in Table 1) were processed for 
cytogenetic analysis. One sample did not yield any metaphases (T126), 3 samples (20% ) 
showed normal karyotypes (T105, T106, T107; not shown), 9 samples (60% ) exhibited 
highly abnormal karyotypes (T100, T101, T104, T108, T109, T120, T128, T129, T80), and 
in 2 samples (13% ) only single abnormal cells were found (T102, T103) (Table 2). The 
modal chromosome numbers differed widely among the different samples analyzed. 
Chromosomal aberrations occurring in more than one sample were del(1)(q11) in T104 
and T109, add(1)(p11) in T120 and T80, add(4)(p15-16) in T100, T101, T108 and T109, 
del(6)(q14) in T101 and T109, del(6)(q21) in T108 and T109, and add(19)(q13) in T100, 
T104, T108 and T109. Besides various other structural and numerical aberrations, several 
marker chromosomes were found to be present in all abnormal tumors (Table 2), except 
T102 and T103. In 2 cases (T101, T80) ring chromosomes were encountered. Telomeric 
associations (tas) were seen in case T129, but in 4 distinct metaphases each 
representing different clones within the same tumor sample. The tas were observed
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Table 2. Composite karyotypes of cytogenetically abnormal tumors.
tumor karyotype
T80 60-73, X X , +X, add(l)(p?35), add(l)(pl 1), add(l)(pl 1), +2, +4, +5, +5,-6, -6, del(7)(p21), 
add(7)(pl5), +10, add(12)(pl 1), -13, -14, +16, +19, -22, +12-18mar, +2r [cp3],
T100 119-140, -X,-X,-X, add(X)(p22.3), -1, del(l)(q22), der(l)add(l)(p36.3)del(l)(ql lq32), -2, 
-3, -3, del(3)(pl2p25)x2, add(4)(pl5)x2, add(4)(pl6), -5, add(5)(pl5.3)x2, -6, add(6)(p25), 
del(6)(q25), del(7)(pl5), -8, -8, -9, del(9)(q31), fra(9)(q33), -10, -10, -11, -11, add(l l)(pl5), 
+ 12, add(12)(pl3), -13, -13, -13, -14, -15, -15, -16, -16, -17, -17, -18, -19, 
add(19)(ql3.4), add(20)(ql3.3)x2, +21, +21, +21, +21, del(22)(ql2), +marl, +mar2, +mar3, 
+mar4, +31-34mars, dmin, inc[cp20].
T101 59-78<3n>, X X , der(X)t(X;?)(p22;?), add(l)(p36.3), der(l)add(l)(p36.3)del(l)(q25), 
der( 1 )add( 1 )(p36.3)add( 1 )(q31 ), add(3)(p25), add(4)(pl6), add(5)(pl5.3), add(5)(pl5.3), 
add(5)(q35), del(6)(ql4), del(6)(q23), add(7)(q36), del(7)(q32), add(8)(q24.3), i(9)(ql0), 
add(10)(pl5), add(12)(pl3), add(13)(q22), add(21)(q22.3), +marl, +raar2, +mar3, +mar4, 
+r, inc[cpl7] / 144-148<6n>, idemx2, inc[cp3] / 312<12n>, idemx4, inc[l] /46,XX[1],
T102 46, X Y , t(9;22)(q34 ;q 11), del(14)(q21-24) [1] / 46, X Y  [18]
T103 46, X Y , add(19)(ql3.4) [1] / 46, X Y  [18]
T104 87-97,X X X X ,  del(l)(qll), i(l)(pl0), -4, +5, add(6)(p25), del(6)(q31), +7, -9, -9, 
der(10)t(5;10)(ql 1.2;q26), -11, -11, -12, -12, -13, t(13;14)(pll;qll)x2, -14, -15, 
add(15)(q26)x2, -16, -17, add( 19)(q 13.4), der( 19)t( 12; 19)(q 14;q 13.1 )x2, add(20)(ql3.3)x2, 
+21, -22, -22, -22, +marl, +mar2, +4-10mars [cpl5] / 46,X X  [4].
T108 68-75,X X , add(X)(p22.3), del(l)(pl3), del(l)(p33), der( 1 )t( 1 ;5)(q21 ;q 13 ), 
der( 1 )t( 1 ;5)(q21 ;q 13), del(2)(pl4), -3, -3, del(3)(q21), -4, -4, add(4)(pl5), -5, -5, 
del(6)(q21), +7, -9, del(9)(pl3), add(9)(p22), -10, -10, add(l l)(q23), del(17)(pl3), 
add(19)(ql3.3), add(19)(ql3.3), +20, del(20)(ql3.1), add(22)(pl3), +marl, +mar2, +2- 
9mars [cpl5].
T109 85-95, X X Y Y ,  del(l)(qll), del(l)(q24), del (l)(q32), del(l)(q41), 
der( 1 )t( 1 ; I I;?)(q21;ql3q23;?), der( 1 )t( 1 ; 11 ;?)(q21 ;q 13q23 ;?), -2, -2, -2, -2, -3, -3, 
del(3)(ql 1), -4, der(4)t(4;?;l I)(pl6;?;ql3q25), del(5)(ql4), del(5)(ql4), 
der(5)t(5 ;8)(p 11 ;p 11), del(6)(ql4), del(6)(q21), -8, -9, -10, -10, -11, -11, -11,-11, 
del(12)(pII), del(12)(ql2), add( 12)(p 11 ), der(12)t(l l;12)(qll;pl 1), del(13)(q22), -14,-14, 
-14, -15, add( 16)(p 13), add(16)(pl3), -17, add(17)(pl3), add(17)(pl3), -18, -18, 
add(19)(ql3), add(19)(ql3), del(20)(ql2), add(20)(pl3), der(20)t( 1 ;20)(q 12 ;p 13 ), 
der(20)t( 1 ;20)(q 12;p 13), +22, +22, +6-16mars [cpl5] /46,XY [5],
T120 62-71, Y, ?del(X)(p22), add(l)(pll), add(l)(pll), del(3)(q24), +5, +5, +6, +11, 
add(12)(q?22), +13, ?14, -15, -17, +16-18mar [cp3],
T128 46,XY[29] / 46,X Y , t(2;4)(q37;q26), -22, +mar [1]
T129 46,X X  [23] / 46,X X , t(5;21)(ql5;pl 1), tas(8;9)(p23;ql3.4) [1] / 46,X X , tas(7;15)(q36;q26), 
-18 [1] / 46,X X , -11, -18, +mar, +mar [1] / 46,X X , tas(21;?)(pl2;?) [1] / 46,X X , 
tas(3;12)(p26;q24.3) [1].
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Table 3. Specified chromosomal/(sub)region imbalances per tumor detected by C G H  (1)
Tumor C G H  losses
MFH2 A lq25-qter, 2p, 2q21-qter, 3ql l-qI3.1, 3q24-qter, 4q, 6q, 7q31-qter, 8, 9p, 11, 13ql0-q31, 21q
MFH9 A lq31-qter, 2p23-pter, 2q22-qter, 4, 6ql0-q22, 8pl2-pter, 9pl3-pter, 10pl3-pter, 
Ï2ql5-q21, 13ql4-qter, 14ql3-q21, Y
MFH11 A lq25-qter, 2p22-pter, 2q22-q32,4q21-qter, 5ql3-qter, 6p22-pter, 6q; 7pl0-pter, 9pl3-pter, 
Î Oql 1.2-q23s l ip , 13q, 16q, 18pl 1.2-pter, 21q, Y
MFH 17 A 4, 6q, 8p2I-pter, 9, 10, 11, 12p, 13q, 14q, 15q, 18q, 20p, Y
MFH19 A Ipl0-p31, 4q, 6q, 9p, 10, 12ql5-q21, 14, Y
MFH25 A lq22-qter, 3q, 4q l0 -q l3 , 6ql0-q23, 8pter-q22, 9pl3-pter, 10pter-q22, 1 lq, 13q, 14q21-qter, 
20p, Y
MFH44 B 2q31-2q37, 9q32-qter, 22ql3-qter, Xp21-pter
MFH45 B lq24-qter, 3p22-3qter, 10q22-qter, 1 lq23-qter, 15ql0-qI5, 16ql0-qter, 17qil-q21,X
MFH46 B lp31-pter, lq32-qter, 2p22-pter, 2q31-qter, 7q22-q35, 10pl3-qter, l lq , 13ql0-ql3, 17p, 
I8q, 19, 21q22, Xp21-p22, Xq
MFH47 B IplO-pter, 5ql0-q31, 6q22-q24, 7q l0 -q3 i,8p , 9p, 10q21-q24, I lp l0 -p l5 , 13qlO-q31, 18q, X
MFH48 B lp36.1-pter, lq32-qter, 4q22-q27, 5ql3-q21,8p, 9pter-q22, 10pl0-pl3, 11 q 14-qter, 12q, 
13q, 19, Xpter-qlO, Xq23-qter
MFH49 B lp35-pter, 3pter-q21, 5ql3-qter, 6p, 6q22-qter, 10, 1 lq, I4q, 15q, 17p, 22qter
MFH 5 2 B 4pl4-pter, 8p, 10, 16, X
MFH56 B 9p21-pter
T80 B Ipl0-p22,3p , 6p23-6q22, 9p, 10q21-q23, 11, 12pl0-pl2, 13q, 14q, 15q, 17pter-ql2, 
18pter-ql2, 20p, X
TI00 B lq25-qter, 2p24-qter, 3q21-q26, 6ql0-q l6 , 8q21-qter, 10pl0-pl3, 10q22-qter, l lq , 12, 
13ql4-q22, 15q21-qter, Xp22.1-qter
T10I B 2, 3p l4 , 9p21, 10q22-qter, Ilq l4 -q24 , 18q21-q22
T102 A 2ql4-qter, 4, 5p, 6pter-q22, 8p, 9p, 10, I lq23-qter, 13q, 18q, 21q
T103 A Ipl0-p21, 2q32-qter, 3, 5q, 6 q l0 -q I6 ,9p, 10p, 20p, X
T104 A 2q32-q34, 3, 4p, 6q22-q24; 9pter-q21, 11, 12p 10-p11, 12ql5-q21, 13q, 14q, Y
TÍ05 B lp32-pter, lq31-qter, 3pl4-p21, 4q, 6q, 9pl0-p21, lOq, l lp l l .2 -p l4 ,  llq22-qter, 
13ql0-q21, 14q, 15ql0-q21, 16qll-q21, 18q, Xpter-q24
T107 B 3, I Op, 12p, 18q
T108 B lq25-qter, 3pter-ql3.3, 4pl0-pl5,4q22-q28, 5q21, 6p, 8pl0-pl2, 9p, 1 lq22-qter, 13q, 
14ql0-q21, 18q,21q,X
T109 B lq3I-Iq ter, 2q21-qter, 4q31.3-qter, 5ql4-q23, 8, lOpl 1.2-pter, 1 lql3-qter, 15ql0-q21
T120 B Ipl0-p31,16q, X
T126 B lq25-qter, 2q35-qter, 3pl3-qter, 4ql3-qter, 7q, 8ql3-qter, 10, 11, 12q, 13ql0-q31, 14q, 
15ql0-q22, 16q, Xq
T128 B lq, 2q21-qter, 3pter-q24, 8q22-qter, 9p ll-p ter, Ilq l4-q ter, 12p, I3ql0-q31, 16q, Xq21-qter
T129 B 13q21-q22, X
V Í9 A 13q, 14q, 15q, I7p
A  tumors analyzed versus normal male reference D N A  on male metaphase spreads 
B  tumors analyzed versus normal female reference D N A  on female metaphase spreads.
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Table 3. Specified chromosomal/(sub)region imbalances per tumor detected by C G H  (2)
Tum or C G H  gains
MFH2 lp3 l-p36, Iq21-q23,4p, 5p, 6p, 9q32-qter, 13q32-qter, 15q, 16, 18p, 19, 20pl 1.2-qter, 22q, X
MFH9 Iq21-q22, 7, 9q, 16, 17p-ql2, 19, 20q, 22q,X
M FH ll Ip l3-lq23, 4pl5.3-pter, 5p, 6pl0-p21.2, lOp, 12q23-qter, 14q, 15q, 19, 20q, X
MFH17 1. 3a. 6d. 8Dl2-ater ( '8 p ll.2 Hi'), 16p, Xq21-qter*
MFH 19 Ial0-a21. 6d, 19.20,X
MFH25 ln34.3-n ter.2a32-ater.4D . 9a31-ater. 12a22-ater. 15a. 16. 18t> H 8pl 1.1*), 19, 20q, 22q, X
MFH44 Ip31-q25, 7pter-q21, 8ql3-q23
MFH45 lp21-pter, 3p22-pter, 6ql6-qter, 7pl4-p22, 9pl3-pter, llpter-ql3, 17p 10-11.2, 18pl0-pter, 20
MFH46 Ip22-q25, 2ql0-q23, 3pter-ql3.3, 4, 6q, 7pter-7q21, 12p, 12ql5-q21, 13ql4-qter, 20p
MFH47 3pl4-qter, 4, 5q32-qter, 6p21.3-pter, 7pl5-pter, 8q, 9q22-q33, lOp, 12p, 14q, 15q22-qter, 20ql2-20qter
MFH48 Ip22-lq21, 2ql0-q22, 3pl0-pl4, 4ql0-ql3, 5p, 6q, 7p21-pter, 7ql0-q31, 8ql0-ql3, 12p, 14q22-qter, 20, 22q
MFH49 lp31-qter, 3q26-qter,4pter-q32,7, 9q, 12, 17q, 18
MFH52 Ip31-q25, 3p21-pter, 3ql0-q26, 4ql0-q32, 5pl0-pl4, 5ql4-q23, 6ql0-q24, 8q, llplO-14, 
Ilq l4-q22, 17q22-qter, 18pll-pter
MFH56 Iql0-q23, 3pl0-pl3
T80 lp31-pter, lql2-qter, 2pl5-qter, 4p, 7p*, 7q, 8q*, 12ql3-ql5*,I7q23-qter, 20q, 2 lq
T100 lp31-pter, Iq21-q23, 3p22-pter, 4p, 4q25-q28, 6p, 6q21-qter*, 7p, 9q32-qter, 13q31-qter, 14ql3, 
14q24-qter, I6p, 16q23-qter, 17, 18, 19p, 20q, 2!q, 22q*, Xp22.2-pter
T101 lp32-pter, Iql0>q22, 4p, 5p, 6p, 13q21-qter, 14q23-qter, 17q22*qter, 20ql2-qter, 21q, 22ql3
T102 lp31-pter, 7pl4-qter, 14q22-qter, 15q, 16, 19, 20q, 22q, X, Y
T103 Ip31-p22, lq, 5pl4-pter, 6q21-22, 6q23-qter, 8q21-qter, 9q32-qter, 16, 17p, 20q, 22q, Y
T1Ö4 lpter-q21, Iq41-qter, 5pl4-pter, 6p, 18p, 19, 20q, X
T1Ö5 Ip31-q24, 7, 12p, 13q22-qter; 17p, 18p, 19, 20q, Xq26-qter
T107 17q21-qter, 19, 20q
TI08 Ip32-p34.3, lq 2 1-24, 3q22-qter, 4pl5.3-pter, 4q31.2-qter, 5pter-5ql3, 7, 8q23-qter, 9q21-qter, I lq l0 -q l4 , 
12, 14q22-qter, 16pl2-pter, 17, 19p, 20
T109 lp31-pter, Iq21-q24, 4pl5.3-pter, 5pter-qI2, 6p22-pter, 6q22-qter, 7pter-qll.2, 16p, 17, 19q
T120 lq31-32*, 2pter-ql3, 4, 5, 8q, 12pl2-pter, 12ql4-I5*, 17q22-qter, 20p
T126 lp21-pter, 2pl0-pl2, 5p (5pll-pl3*), 6p, 7p (7pl4-pl5*), 8pter-ql2, 12p, 13q31-qter, 
15q22-qter, 16p, 17, 18p, 19, 20q, 21q, 22q
T128 lp2I-pter, 3p24-pter, 3q26.3-qter, 5p, 6p22-pter, 8ql0-q21.3, 14q(14q31-32*), 17p, 17q23-qter, 18, 20q, Xp
T129 lp31-pter, 1 q21 -q22, 3p22-pter, 5pl4-pter, 8q23-qter, 9q31-qter, 17, 18p, 19, 20, 22q
V19 1 ,3 ,8 , Y
* high level amplification; underlined: also found by Forus e t  al. (1995)
48
 
Ch
ap
te
r 
3
Figure 1. Summary of CGH imbalances from 29 MFHs. A horizontal bar depicted above each ideogram represents imbalance of the corresponding 
chromosome arms/(sub)regions found in one tumor. Each green bar represents one gain, each red bar represents one loss, and each yellow bar (= 
overlay of green and red) represents one gain and one loss. The numbers of gains and losses (vertical axis) are representative for the number of tumors 
showing gains or losses for that particular region. For example, chromosome band 4p16 (arrow) shows 7 green bars and 5 yellow bars, meaning that 
this chromosomal region was found to be gained in 12 tumors (= 7 green plus 5 yellow bars) and to be lost in 5 tumors (yellow bars). (For color 
pictures see original published paper).
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Table 4. Most frequent gains and losses detected by CGH in 29 MFHs and 
involvement of these regions found by others (a,b,c,d,e).
gain/ region* this study Forus3 Larramendyb Hinzec Sakabed Mairale
loss n =  29 n =  16 n =  58 n =  20 n =  19 n =  30
i gain lq21-22 20 (69%) 4 (25%) 12 (40%)
gain 17q23-qter 12(41%) - - - - 6 (20%)
gain 20q 19(66%) 1 (6%) - 6 (30%) - 7 (23%)
loss 9p21-pter 16(55%) 6 (10%) 4 (20%) - 8 (27%)
loss lOq 14 (48%) - - - 7 (23%)
loss llq23-qter 16 (55%) 7 (12%) - - 12 (40%)
loss 13ql0-q31 16(55%) 12(21%) - 2 (1 1 % ) 17 (57%)
ii gain 5p 12(41%) - 15(26%) 9 (45%) 5 (26%) 10(33%)
gain 7p21 13 (45%) 2 (13 % ) 13 (22%) 8 (40%) - 4 (13%)
gain 16p 10(34%) - - 6 (30%) - 3 (10%)
gain 18p 11 (38%) 2 (13%) 18pl 1.3** (3% )- - 9 (30%)
gain 19p 13 (45%) - - - - 12 (40%)
gain 19q 12(41%) - - - - 13 (43%)
loss lOp 13 (45%) 4 (7%) 2 (10%) 2 (1 1 % ) 9 (30%)
iii gain lp21-pter 14 (48%) 3 (18 % ) 8 (14% ) 3 (15%) - 6 (20%)
gain 22q 10 (34%) - 5 (9%) 2 (1 0 % ) - 6 (20%)
loss lq31-qter 13 (45%) 3 (5%) 1 (5% ) - 9 (30%)
loss 2q21-qter 11 (38%) 3 (5%) 1 (5% ) - 5 (17%)
loss 8p 9 (31% ) 4 (7%) 4 (20%) - 4 (1 3 % )
i, ii, iii three different groups of involvement (see text); * minimal common region of gain 
or loss; n total number of tumors analyzed; a Forus et al., 1995 (only screened for gains); 
b Larramendy et al., 1997; c Hinze et al., 1999; d Sakabe et al., 1999; e Mairal et al, 1999; 
* *  amplification; - no imbalance found
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Table 5. Southern blot hybridization results withp l 6 INK4A, RBI, TP53 and 
MDM2 probes and gene corresponding region-specific CGH results.
R B I  pathway T P53  pathway
1
'O
On 9
p2
1
R
B
I
13
ql
4
TP
53 Cnt- M
D
M
2
a*
tumor SB CGH SB CGH SB CGH SB CGH
MFH17 . _
MFH25 - - -
MFH42 nd nd - nd nd nd
MFH44
MFH45
MFH46 - - nd +
MFH47 - - - - -
MFH48 - - - ' - nd
MFH49 - nd - nd +
MFH52
MFH56
T100 - nd -
T101 - - nd
T104 +
T105 - +
T106 nd nd nd nd nd nd
T107 +
T108 - - - - + +
T109 -
T120 - „ + +
T126 - nd nd +
T128 - - - nd
T129 - -
T80 - - - + +
T83a nd nd nd nd + nd
T84a nd - nd nd nd nd
V19 - -
V34 nd nd nd nd nd nd
SB Southern blot hybridization (as compared to control probe SYT  at 18ql 1.2); 
CGH comparative genomic hybridization;
• neutral (normal); - deleted/underrepresented; + overrepresented; nd not done
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between chromosomes 8 and 9, 7 and 15, 3 and 12, and 21 and a marker chromosome. 
In tumor T100 double minutes (dmins) were encountered.
Regions of genom ic imbalance revealed by CGH
All 29 MFH samples (100% ) analyzed by CGH (Table 1) showed copy number changes 
which are specified in Table 3. In order to obtain information on minimal imbalanced 
regions of overlap, a summary of all detected imbalances per chromosomal (sub)band is 
provided in Figure 1. Careful examination of all chromosomes as displayed in this figure 
revealed 3 groups of involvement for specific chromosomal regions in our MFH series 
(Table 4): (i) regions which show virtually exclusive over- or underrepresentations in a 
high percentage of the tumors: gains of 1q21-22 (20/29, 69%), 17q23-qter (12/29, 
41% ) and 20q (19/29, 66%), and losses of 9p21-pter (16/29, 55% ), 10q (14/29, 48% ), 
11q23-qter (16/29, 55%), 13q10-q31 (16/29, 55% ); (ii) regions with less prominent 
imbalances but which are still primarily gained or lost: gains of 5p (12/29, 41% ), 7p 
(in particular 7p21: 13/29, 45% ), 16p (10/29, 34%), 18p (11/29, 38% ) and 19 (19p: 
13/29, 45% ; 19q: 12/29, 41% ), and loss of 10p (13/29, 45% ); (iii) regions that are 
showing an imbalance in a relatively high percentage of the tumors, but for which the 
opposite imbalanced state is also observed in a considerable number of tumors: gains 
of 1p21-pter (14/29, 4 8 %  versus 4/29, 14%  loss) and 22q (10/29, 3 4 %  versus 2/29, 
7 %  loss), and losses of 1q31-qter (13/29, 4 5 %  versus 5/29, 17%  gain), 2q21-qter 
(11/29, 3 8 %  versus 2/29, 7 %  gain) and 8p (9/29, 3 1 %  versus 2/29, 7 %  gain). 
Chromosomes X and Y were omitted from this analysis, because tumor DNAs from male 
and female patients were randomly hybridized with normal male or female reference 
DNAs onto metaphase spreads of normal healthy male or female donors (see Table 3). 
However, CGH data of the X and/or Y chromosomes per case corresponded well to the 
sex of the patient.
High copy number gains (amplicons) were observed in several tumors, but were mostly 
sporadic: 1q31-32, 5p11-p13, 6q21-qter, 7p14-p15, 7p, 8p11.2, 8q, 12q13-q15, 12q14- 
q15, 14q31-32, 18p11.1, 22q (Table 3).
Confirm ation of allelic im balances by Southern blot analysis: clues for involvem ent 
of cell cycle regulatory genes
Since loss of 9p21-pter was a prominent finding in our CGH analysis and since this 
region harbors the p16INK4A tumor suppressor gene (also known as CDKN2A; 9p21) we 
decided to study this loss in more detail using Southern blot analysis with a p16INK4A cDNA 
as probe. Allelic loss of p16INK4A was observed in 9 of 28 (32 % )  tumors tested (Table 5). 
Because the p16INK4A protein acts as an indirect inhibitor of the cell cycle control 
protein RB1 (Kamb et al., 1994; Sherr, 1996) and since 13q14 (the region where RB1 is 
located) was frequently found to be lost by CGH (this study; Mairal et al., 1999), the 
deletion status of the RB1 gene was assayed in 25 samples using Southern blot analysis. 
Allelic loss of RB1 was found in 8 of 25 (32 % )  tumors tested (Table 5).
For comparison between the Southern blot results and the CGH findings, the CGH results
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of the p16INK4A- and RBI-corresponding chromosomal regions are also listed in Table 5. 
Through CGH analysis losses of the 9p21 and 13q14 regions were found in 10/23 (43% ) 
and 13/23 (57% ) cases that were also tested by Southern blot analysis, respectively. 
The percentages of similarity between Southern blot and CGH results [(number of tumors 
analyzed with both techniques showing identical results / total number of tumors 
analyzed with both techniques) x 100%] for p16INK4A/9p21 and RB1/13q14 were 7 8 %  
(18/23) and 5 7 %  (12/21), respectively.
In addition to the p16INK4A and RB1 genes, TP53 and MDM2, known to be involved in cell 
cycle regulation and to play a role in soft tissue sarcomas including MFHs, were 
examined (Taubert et al., 1995; Wadayama et al., 1993; Nilbert et al., 1995 and 
references therein; Reid et al., 1996). Allelic loss of TP53 was observed in 5 of 22 (23% ) 
tumors tested and amplification of MDM2 was observed in 8 of 22 (36% ) tumors tested 
(Table 5). For these two genes/regions CGH/Southern blot similarity scores of 7 5 %  
(15/20) and 8 0 %  (16/20) were obtained, respectively.
Discussion
Of a total of 34 MFHs, 15 cytogenetically analyzed specimens exhibited a variety of 
numerical and structural abnormalities, including marker chromosomes, tas, dmins and 
ring chromosomes. These findings have been similarly described by other authors 
(Mandahl et al., 1989; Sandberg and Bridge, 1994; Heim and Mitelman, 1995; Mitelman 
et al., 1998). Notably, abnormalities in chromosome bands 1q11 and 1p36 and 
del(6)(q21) were also prominent in the current series, analogous to previous reports 
(Mandahl et al., 1989; Heim and Mitelman, 1995; Schmidt et al., 1998). To what extent 
these and/or other chromosomal regions are specifically implicated in MFH 
development, however, remains to be established. A 19p+ marker which has been 
postulated as a marker for poor prognosis, was not found in our study (Rydholm et al., 
1990; Choong et al., 1996).
As it appears to be difficult to decipher cytogenetic data in the search for MFH- 
associated genomic alterations (Sandberg and Bridge, 1994; Heim and Mitelman 1995; 
this study), the CGH technique was used to further approach this objective. Among a 
wide spectrum of genomic imbalances detected in 29 MFHs, prominent regions of over- 
and under-representation were observed: gains of 1q21-q22, 17q23-qter and 20q, and 
to a lesser extent of 5p, 7p, 16p, 18p and 19, and losses of 9p21-pter, 10q, 11q23-qter, 
13q10-q31, and to a lesser extent of 10p (Table 4). As CGH does not provide any 
information on how genomic imbalances are organized in chromosomal complements, it 
is difficult to compare our cytogenetic data with the CGH results. Some findings, 
however, may be related: the high level amplifications found for 22q in T100, and 7p, 
8q and 12q13-15 in T80 probably correspond to the observed dmins and rings in these 
two tumors, respectively. Additionally, the prominently imbalanced regions mentioned
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above were all found to display cytogenetic aberrations, except for 17q23-qter and 18p. 
These cytogenetic aberrations and imbalanced regions may, therefore, be related. The 
regions 9p21-pter, 11q23-qter and 13q10-q31 were also reported by other investigators 
to exhibit cytogenetic anomalies, including breakpoints and deletions (see Mitelman et 
al., 1998). Tumors T105 and T107 showed many chromosomal imbalances as detected by 
CGH while cytogenetically these tumors were found to be normal. This discrepancy may 
be explained by tumor tissue culture artefacts, i.e., infiltrating normal fibroblasts or, 
alternatively, intratumor heterogeneity which is known to occur in sarcomas, including 
MFHs (Orndal et al., 1994; Simons et al., 1999a). Indeed, we could confirm such 
heterogeneity in several of the MFHs used in this study by cytogenetic analysis (T101, 
T129) and spectral karyotyping (SKY; data not shown).
Comparing our CGH findings with those reported by others (Forus et al., 1995; 
Larramendy et al., 1997; Hinze et al., 1999; Sakabe et al., 1999; Mai ral et al., 1999) 
several similarities were noted (listed in Table 4). All prominent regions identified by us 
were also described in the other studies, although most of them at a lower incidence. 
Particularly, in contrast to Larramendy et al. (1997), Hinze et al. (1999) and Mairal et 
al., (1999), we observed loss of the 9p21-pter region in a high percentage (55% ) of the 
tumors tested. Special care should be taken, however, when comparing CGH results of 
different studies at the quantitative level: different image acquisition and analysis 
programs and criteria (thresholds) for gains and losses may have been used in the 
different studies and, thus, may have a significant influence on the interpretation of the 
CGH results. Nevertheless and in contrast to others, loss of 9p was found to be one of 
the most noticable genomic imbalances in our series of MFHs. A similar conclusion may 
be drawn for the 13q10-q31 region. Interestingly, Mairal et al. (1999) also pointed at 
this latter region as being critical in the development of MFHs. Candidate genes for 9p21 
and 13q10-q31 are p16INK4A and RB1, respectively (Kamb et al., 1994; Wunder et al., 
1991). Other notable regions of imbalance were 1q21-q22 (gain), 10q (loss), 11q23-qter 
(loss), 17q23-qter (gain) and 20q (gain). Region 1q21-q22 has previously been found 
to be frequently amplified in human sarcomas including MFHs (Forus et al., 1995; 
Szymanska et al., 1997). Several genes in this region showed increased copy numbers, 
but so far the highest and most frequently amplified region is contained within a YAC 
located proximal to FLG (Forus et al., 1998). Chromosome arm 10q is thought to contain 
multiple tumor suppressor genes including PTEN at 10q23 (Maier et al., 1997 and 
references therein; Li et al., 1997). Although this gene is known to be deleted/mutated 
in several neoplasms, including brain tumors, prostate carcinomas and endometrial 
carcinomas (Li et al., 1997; Maier et al., 1997; Cairns et al., 1997; Maxwell et al., 1998), 
to our knowledge it has not been reported to be involved in sarcomas. Furthermore, it 
remains to be investigated which genes may be related to the imbalanced regions 
11q23-qter, 17q23-qter and 20q.
The high level amplifications on 7p and 12q13-15, which we both found twice (T80 and 
T120), were also noted by other groups (Forus et al. 1995; Larramendy et al. 1997; 
Hinze et al. 1999; Mairal et al., 1999), suggesting a role also for these regions in MFH
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development. The 12q13-15 region is known to contain the MDM2, SAS, HMGICand CDK4 
genes, all four found to be overexpressed in soft tissue sarcomas including MFHs (Nilbert 
et al., 1995; Reid et al., 1996; Berner et al., 1997; Forus et al., 1998). The frequent 
involvement (gain) of 7q32 as observed by Larramendy et al., (1997) could not be 
confirmed in our study: gain of 7q (including 7q32) was found in only a minor portion 
(6/29, 21% ) of the tumors tested. Additionally, Southern blot analysis using a CFTR 
probe (7q31; Zielenski et al., 1991) showed overrepresentation in only 2 of the tumors 
tested (not shown).
In order to test whether the histological sub-classification of the MFHs used in our study 
correlated with specific CGH findings, data from tumors with myxoid characteristics (13 
tumors; see Table 1) and from tumors with storiform and/or pleomorphic components 
(19 tumors) were collected in the same manner as described above for Figure 1. This 
survey, however, did not reveal obvious subtype specific CGH profiles (not shown). This 
finding is most likely due to the fact that many tumors consisted of more than one 
subtype (see Table 1). An additional problem could be that the tumors were often large 
in size and heterogeneous in composition, thereby introducing sample biases. 
Nevertheless, if we focused on pure myxoid tumors (7 tumors) and compared them with 
the pure storiform/pleomorphic tumors (9 tumors) some putative differences were 
found: no involvement of 2q in myxoid tumors versus mainly loss of 2q in 
storiform/pleomorphic tumors; loss of 6p in myxoid tumors versus gain of 6p in 
storiform/pleomorphic tumors; gain of 12q in myxoid tumors versus loss of 12q in 
storiform/pleomorphic tumors; and, to a lesser extent, gain of 9q in myxoid tumors 
versus no imbalance of 9q in storiform/pleomorphic tumors. To embody these 
speculations larger series of tumors, preferably consisting of single histological 
subtypes, have to be tested. Interestingly, the most prominent CGH imbalances found 
in the total series of MFHs (Figure 1 and Table 4) were all found in both the myxoid and 
storiform/pleomorphic tumors. This suggests that these copy number aberrations are 
generally occuring and not characteristic for any MFH subtype.
Through Southern blot analysis with a p16INK4A probe the above mentioned frequent 
allelic loss of 9p21-pter was confirmed. We propose that the p16INK4A gene may play a 
prominent role in the development of MFH. Within the 9p21 region additional tumor 
suppressor genes are thought to be located (Simons et al., 1999b and references 
therein). Obviously, also one or more of these genes may be involved. We, as well as 
others, further suggest that loss of 13q10-q31 and the RB1 gene (13q14) may play a 
critical role in MFH development (Wunder et al., 1991; Ozaki et al., 1993; Mairal et al., 
1999). Comparison of the Southern blot results with the corresponding regional CGH 
data (Table 5) revealed that most findings were in agreement with each other, but some 
discrepancies could also be observed. These inconsistencies may be explained by (i) 
differences in sensitivity of the two techniques, (ii) contamination of normal DNA 
within the tumor samples, or (iii) the arbitrarily chosen probe from chromosome 18q for 
quantification of the Southern blot data. After the analyses were completed we found 
that the corresponding 18q region was also affected in some of the tumors examined by
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CGH (Figure 1), which might disturb the actual interpretation of the results.
Analysis of the RB1, p16INK4A, TP53 and MDM2 genes, all participating in known RB1- and 
TP53-associated cell cycle regulatory pathways (Sherr, 1996 and references therein), 
revealed that these genes were affected in many MFHs. More than one gene or 
corresponding chromosomal region was affected in 16/28 (57% ) tumors (Table 5). More 
interestingly, in 22/28 (79% ) of the tumors tested at least one of the two pathways was 
affected: either the RB1 pathway (due to RB1/13q14 and/or p16INK4A/9p21 involvement) 
or the TP53 pathway (due to TP53/17p13 and/or MDM2/12q14 involvement). This 
percentage may become considerably higher after mutation analysis, since minor 
(point)mutations have frequently been observed in these genes. In about one-third of 
the tumors both pathways seemed to be affected. These results indicate that 
disturbance of either one or both of the RB1- and TP53-associated cell cycle regulatory 
pathways may play a critical role(s) in MFH development.
In conclusion, using a combination of techniques, prominent MFH-related genomic 
imbalances were found: gains of 1q21-q22, 17q23-qter and 20q, and losses of 9p21-pter, 
10q, 11q23-qter, and 13q10-q31. Additionally, we postulate that genes involved in the 
RB1- and TP53-associated cell cycle regulatory pathways, in particular the p16INK4A gene, 
may play critical roles in MFH development.
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Abstract
Comparative genomic hybridization (CGH) analysis of a primary osteosarcoma and its 
metastasis revealed two regions of DNA amplification, one at chromosome 17p11.2-12 
and one at chromosome 19q12-13. Subsequent representational difference analysis 
(RDA) of the primary tumor resulted in the isolation of two distinct tumor-amplified DNA 
fragments originating from chromosome 19. A YAC clone corresponding to one of the 
two isolated DNA fragments was used for fluorescence in situ hybridization (FISH) on 
normal human lymphocyte metaphases and tumor-derived nuclei. This resulted in the 
chromosomal localization of this YAC to 19q12-13.1 and proved the amplification status 
of the isolated fragment in the tumors. Our findings indicate that a combination of both 
the CGH and RDA techniques is suitable for the detection and isolation of novel 
osteosarcoma-associated amplified DNA sequences. The availability of such RDA-isolated 
sequences may be instrumental in the search for genes relevant for the development of 
these tumors.
Introduction
Cytogenetic studies of osteosarcomas have revealed highly aneuploid and extremely 
complex karyotypes with numerous abnormalities, including homogeneously staining 
regions, double minutes and supernumerary ring chromosomes (Biegel et al., 1989; 
Mertens et al., 1993; Tarkkanen et al., 1993; Fletcher et al., 1994; Hoogerwerf et al., 
1994; Sandberg and Bridge, 1994; Heim and Mitelman, 1995). These latter anomalies 
appear to be associated with gene amplification, as has for instance been shown for 
the MYC oncogene on chromosome 8 (Ozaki et al., 1993). Amplification of the MDM2 
gene on chromosome 12 has been observed specifically in recurrent and metastatic 
lesions and it has been suggested that such an amplification may be associated with 
poor prognosis (Ladanyi et al., 1993). Other osteosarcoma-associated alterations 
include loss or rearrangement of the chromosome 13q14 and 17p13 subregions, 
harboring the RB1 and TP53 tumor suppressor genes, respectively (Toguschida et al., 
1988; Miller et al., 1990; Mulligan et al., 1990; Andreassen et al., 1993; Hoogerwerf 
et al., 1994). It has been suggested by Wadayama et al. (1994) that alterations at 
the RB1 locus in primary osteosarcomas may serve as indicators for poor clinical 
outcome. In  order to get further insight into the molecular genetic changes that are 
relevant for the initiation and progression of osteosarcomas, we have employed the 
recently developed techniques of comparative genomic hybridization (CGH; 
Kallioniemi et al., 1992, 1994; Du Manoir et al., 1993; Suijkerbuijk et al., 1994a) and 
representational difference analysis (RDA; Lisitsyn et al., 1993, 1995a,b) for the 
analysis of a primary osteosarcoma and its metastasis. Previously, it has been shown 
that the CGH technique is suitable for the detection and mapping of
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(sub)chromosomal DNA losses, gains, and amplifications in tumors, including 
osteosarcomas (Kallioniemi et al., 1992, 1994; Forus et al., 1995a,b; Tarkkanen et 
al., 1995; Geurts van Kessel et al., 1997). In addition, it has been demonstrated that 
the RDA technique can be used for the direct isolation of DNA fragments that are 
deleted, rearranged or amplified in tumors and, as such, may be a valuable tool in 
the search for tumor suppressor genes and oncogenes (Lisitsyn et al., 1993, 
1995a,b). This novel technique is based on subtractive hybridization followed by 
PCR. Subtraction is carried out with representations of two DNA populations (tester 
and driver) of which the differences are the targets (present in the tester) to be 
isolated. Representations are made by restriction enzyme cleavage of genomic DNA, 
followed by adaptor ligation and adaptor-primed PCR amplification. In the 
application of RDA to cancer there are basically two approaches: (i) using tumor DNA 
as driver and normal DNA as tester, and (ii) using normal DNA as driver and tumor 
DNA as tester. In  the first approach DNA fragments may be isolated from regions that 
are deleted in tumors, whereas in the second approach DNA fragments may be 
isolated that are implicated in point mutations, chromosomal rearrangements, 
amplifications, or the presence of pathogens. Only in case of amplifications, the 
enrichment and subsequent isolation of target sequences is based on their relative 
abundance in the tester which leads to kinetic enrichment during the RDA procedure 
and not on their absence in the driver (Lisitsyn et al., 1995a,b). Here, we report the 
detection of two regions of amplification in a primary osteosarcoma and its 
metastasis, followed by the isolation of two DNA fragments from one of these 
regions. Finally, we confirm the origin of these fragments and their amplification in 
the two tumors by molecular studies and fluorescence in situ hybridization (FISH) 
analyses.
Materials and methods
Tissue sam ples and culturing
Primary tumor (T87) and metastasis (T95) tissue samples were obtained after surgical 
removal. Part of the tumor samples was used for cytogenetic analysis and part was 
stored at -70 °C until further analyses. For cytogenetic analysis the cells were cultured 
in RPMI-1640 medium plus glutamax-1 (Gibco BRL) supplemented with 15%  fetal calf 
serum (Seratech) and antibiotics. Tumor cell metaphases were harvested according to 
standard procedures after colcemid treatment (5 pl karyoMAX Colcemid solution (Gibco 
BRL)/ml medium, 5 hours). After methanol/acetic acid fixation, metaphase spreads were 
prepared for GTG banding and analyses. Resulting karyotypes were described according 
to the International System for Human Cytogenetic Nomenclature (ISCN, 1995). 
Similarly, metaphase spreads for CGH and FISH analyses were prepared from cultured 
normal human peripheral blood lymphocytes.
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DNA preparation and Southern blot analysis
High molecular weight genomic DNAs from both primary and metastatic tumor tissues 
(frozen material) and from peripheral blood cells of control persons were isolated using 
standard methods, including SDS/proteinase K lysis, phenol/chloroform extraction, and 
ethanol precipitation. These DNAs were used for CGH, RDA, and Southern blot 
experiments. BglII-representation DNAs and BgflI-cleaved genomic DNAs were size- 
selected on agarose gels and blotted onto Genescreen Plus membranes (Dupont). 
Selected probes were labeled by random priming and, after pre-annealing with hybridime 
DNA (HT Biotechnology) for 5 hours, hybridized overnight at 65 °C in 0.5 M sodium 
phosphate buffer, 1 mM EDTA, 7 %  SDS. Subsequently, blots were washed in 40 mM sodium 
phosphate, 0.1%  SDS, and exposed to X-ray films at -80 °C using intensifier screens.
Comparative genom ic in s itu  hybridization (CGH)
CGH experiments were based on the procedures described by Kallioniemi et al. (1992, 
1994) and Suijkerbuijk et al., (1994a,b) and performed as follows: One microgram of tumor 
DNA was labeled with digoxigenin-11-dUTP (Boehringer Mannheim) and 1 pg of normal 
(reference) DNA was labeled with biotin-14-dATP (Gibco BRL) using a commercially 
available nick-translation system (Gibco BRL). Six extra units of DNA polymerase I large 
fragment (Klenow, Gibco BRL) were added in each reaction mixture to increase DNA 
fragment lengths as was described by Forus et al. (1995a). Two hundred ng of each of the 
labeled probes, a 75-fold excess of Cot-1 DNA (Gibco BRL), and 20 pg of herring sperm 
DNA (Gibco BRL) were coprecipitated and dissolved in 12 pl of hybridization buffer (50%  
v/v deionized formamide, 10%  w/v dextran sulphate, 2 x SSC, 1 %  v/v Tween-20, pH 7). 
Subsequently, this mixture was denatured at 80 °C for 10 minutes, and allowed to 
preanneal at 37 °C for 30 minutes. Finally, the probe-mix was used for hybridization to 
denatured normal metaphase spreads. Denaturation of the metaphase spreads was 
accomplished by immersing the slides for 3 minutes at 74 °C in 7 0 %  formamide, 2 x SSC, 
followed by proteinase K (Gibco BRL) digestion for 7.5 minutes at room temperature (0.1 
pg/ml proteinase K in 20 mM Tris-HCl, 2 mM CaCl2), and dehydration through an ethanol 
series (70%, 80%, 90%, 100%). Hybridization was carried out under a coverslip (18 mm2) 
at 37 °C over 3 nights. After hybridization, the slides were washed with 5 0 %  formamide, 
2 x SSC, and 2 x SSC at 42 °C, followed by immunocytochemical detection of the 
hybridizing probes using standard incubation conditions. For detection of biotinylated 
normal DNA and digoxigenin labeled tumor DNA, Cy3-conjugated avidine (1:100; 
Amersham) and fluorescein isothiocyanate (FITC)-conjugated sheep anti-digoxigenin 
(1:20; Boehringer Mannheim) were used, respectively. Afterwards, the slides were mounted 
in anti-fade medium (1.4%  w/v di-azobicyclo-(2,2,2)-octane (DABCO, Merck), containing 
0.5 pg/ml 4,6-di-amino-2-phenylindole (DAPI, Sigma) for counterstaining of the 
chromosomes. Examination of chromosome preparations was carried out using a Zeiss 
Axiophot epifluorescence microscope, equipped with appropriate filters for visualization of 
FITC, Cy3, and DAPI fluorescence. Digital images of metaphases were recorded and 
analyzed using the CGH software described by du Manoir et al. (1993, 1995).
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Representational difference analysis (RDA)
RDA was performed essentially as described by Lisitsyn et al. (1993, 1995a,b). 
Representations were made from primary tumor DNA (the tester) and from a DNA pool 
of 5 unrelated control persons (the driver) after Bg lII cleavage and subsequent PCR 
amplification using its corresponding anchor primers (Lisitsyn et al., 1993). A few 
modifications were made in the original protocol for our use: (i) Commercially purified 
oligonucleotides (Eurogentec and Isogen) were used; (ii) Beta-mercaptoethanol and 
bovine serum albumin were omitted from the PCR buffer; (iii) The Centricon-100 ultrafil­
tration device (Amicon) was used to remove the digested R-adaptors from the tester 
representation.
Cloning and characterization of RDA-difference products
DNA bands were isolated from agarose gels and after digestion with BglII ligated into a 
BamHI-digested dephosphorylated pBluescript KS+ I I  plasmid vector (Stratagene). The 
ligation products were used to transform DH5alpha Escherichia coli cells. Plasmid DNA 
from transformants was isolated using standard protocols (Sambrook et al., 1989). 
Selected clones were sequenced with an AB I Dyedeoxy Terminator Cycle Sequencing kit 
and a 370A DNA sequencer apparatus (Applied Biosystems), and sequences were 
compared to known sequences using the Genbank and EMBL databases. From the 
analyzed sequences, the following primer sets were designed for PCR analysis:
Clone 18: 18FOR: 5'AGTGTGTACCTGGCAGCGGC 3' and 
18REV: 5'TCTCATATGCCTGGGTGATGGA 3';
Clone 38: 38FOR: 5'TTCAGCATGATCCCAATCAAAA 3' and 
38REV: 5'ATAAACCCCAGCACAATTAGCC 3'.
PCR analysis of monochromosomal somatic cell hybrids was carried out as follows: One 
hundred ng of hybrid DNA was used as a template in 100 pl reaction volume containing 
10 mM Tris-HCl pH 8.4, 50 mM KCl, 0 .01%  v/v gelatine, 0.1 %  v/v TritonX-100, 1.5 or
2 mM MgCl2, 100 ng FOR-primer, 100 ng REV-primer, 200 pM dNTPs, and 1 U Amplitaq 
DNA polymerase (Perkin Elmer). Thirty-five cycles of 30 sec 94 °C, 1 min annealing 
temperature (62 °C for 18 FOR/REV primer set and 59 °C for 38FOR/REV primer set), and 
1 min 72 °C were performed, followed by a final extension of 5 min 72 °C in a DNA 
thermal cycler apparatus (Perkin-Elmer). After PCR, 10 pl of each reaction mixture were 
loaded on a 2 %  agarose gel and electrophoresis was performed.
Screening of a human YAC library
A human YAC library (Anand et al., 1990) was screened by PCR using 1 pl of the YAC-plugs 
(UK HGMP Resource Centre) as templates in 25 pl reaction volume containing 10 mM Tris- 
HCl pH 8.4, 50 mM KCl, 0.01%  v/v gelatine, 0.1 %  v/v TritonX-100, 1.5 or 2 mM MgCl2, 
100 ng FOR-primer, 100 ng REV-primer, 480 pM dNTPs, and 1 U Amplitaq DNA polymerase. 
Thirty-five cycles of 30 sec 94 °C, 1 min annealing temperature (see above), and 1 min 
72 °C were performed, followed by a final extension of 5 min 72 °C. Subsequently, 10 pl 
of each reaction mixture were analyzed by agarose gel electrophoresis (2%).
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Fluorescence in situ  hybridization
FISH experiments were carried out basically as described before (Suijkerbuijk et al., 
1994a,b). Whole chromosome paint probes were generated from flow sorted chromosomes 
by degenerate oligonucleotide primed PCR (DOP-PCR) according to Telenius et al. (1992). 
YAC DNA was labeled with digoxigenin-11-dUTP using a nick-translation kit (Boehringer 
Mannheim). The whole chromosome 17 paint probe was labeled with biotin-14-dATP using 
a nick-translation kit (Gibco BRL), whereas the whole chromosome 19 paint probe was 
labeled with digoxigenin-11-dUTP using DOP-PCR incorporation. The labeled DNAs were co­
precipitated with an excess of Cot-1 DNA (50-fold for the YAC, 100-fold for the chromosome
17 paint, and 40-fold for the chromosome 19 paint) and, prior to hybridization, 
preannealed at 37 °C for 30 minutes. All target slides for FISH were pre-treated with acetic- 
acid and RNaseA according to standard procedures, followed by denaturation in 70%  
formamide, 2 x SSC, at 70 °C for 2 minutes. Target slides for metaphase- and interphase 
with the YAC probe were, prior to denaturation, subjected to a pepsin-treatment: 10 
minutes at 37 °C in 800 pg pepsin/ml 0.01 N HCl (porcine pepsin, Serva), followed by post­
fixation in 1 %  formaldehyde for 10 minutes at 37 °C. Hybridizations were carried out at 37 
°C over 2-3 nights and post-hybridization washes as well as immunocytochemical 
detections were performed using standard procedures. Detection of the probes was 
acchieved by using the following fluorochrome conjugates and antibodies: For paint 19: 
sheep-anti-digoxigenin-Rhodamin (Boehringer Mannheim), donkey-anti-sheep-TexasRed 
(Jackson Immuno Research Laboratories); for paint 17: avidin-FITC (Vector Laboratories), 
rabbit-anti-FITC (Dakopatts), mouse-anti-rabbit-FITC (Jackson Immuno Research 
Laboratories), rabbit-anti-FITC, mouse-anti-rabbit-FITC; for YAC 19B-A6: sheep-anti- 
digoxigenin-FITC (Boehringer Mannheim), donkey-anti-sheep-FITC (Jackson Immuno 
Research Laboratories), rabbit-anti-FITC, mouse-anti-rabbit-FITC. Afterwards, slides were 
mounted, analyzed, and pseudocolored with the Oncor-image software (Gaithersburgh MD).
Results
Case report and cytogenetic analysis
An osteosarcoma sample (T87) was obtained from a 15 year-old female patient after 
chemotherapy and surgery. The tumor was located in the right distal femur. 
Histopathological examination showed an osteoblastic and fibroblastic type of 
osteosarcoma with hyalinization and abundant osteoid formation. Since at that time the 
tumor cells failed to grow in culture, no cytogenetic data could be obtained. Two years 
later the same patient developed a metastasis (T95) in the right ilium. 
Histopathologically, this metastasis showed the same characteristics as the primary 
tumor (T87). After chemotherapy and surgical removal, the tumor cells were grown 
successfully in culture and cytogenetic analysis was carried out on cells harvested after 
6 days. Twenty metaphases were analyzed that showed chromosomal counts ranging
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from 65 to 67. In addition, several clonal structural abnormalities, including marker 
chromosomes, were observed. One representative karyotype was interpreted as follows: 
65, X, -X, del(1)(p31), add(1)(p36), -2, -2, add(3)(p26), del(4)(p15) x2, +add(4)(p16), 
add(6)(p25), del(10)(p11), -16, +17, del(18)(p12), +21mar.
Detection of osteosarcom a-associated genom ic im balances using  CGH
In order to characterize the genomic alterations in more detail we performed CGH with 
DNAs extracted from the primary tumor or its metastasis compared with normal 
(reference) DNA. As a result, two sites of overt amplifications could easily be recognized 
in both the tumor and its metastasis: one on 17p11.2-12 and one on 19q12-13 (Figure 
1A). For CGH analysis, a minimum of 8 target chromosome homologues was analyzed for 
imbalances by measuring the average fluorescence ratio profiles for each individual 
chromosome. Chromosomes were identified using DAPI-banding. Thresholds for overrep­
resentation (gain) and underrepresentation (loss) of chromosomal (sub)regions were 
arbitrarily set at 1.25 and 0.75, respectively, as described elsewhere (du Manoir et al., 
1993, 1995). Again, two regions of overrepresentation were detected in both tumors (T87 
and T95): one on 17p, with the highest ratio value at p12, and one on 19q, with the 
highest ratio value at 19q12-13 (Figure 1B). Complete suppression of heterochromatic 
regions of critical chromosomes (chromosomes 1,9,16, and 19; Du Manoir et al. (1995)) 
was observed, proving the signal of overrepresentation on 19q12-13 to be a true signal. 
A statistical threshold defined as the 95 %  (central value ± 1.96 S.D.) confidential 
interval (see du Manoir et al., 1995) was also applied and gave the same chromosomal 
imbalances (not shown). Other copy number alterations could not be detected in the 
tumor DNAs with this technique under the stringency conditions applied.
•  / -0 £ 
% ' •  j  \
t
V
f M I  
* **** & 4 ^  * 
i  #
\  *
%  4 k
J ,
% A a  * è  *«*
Figure 1. A. CGH result showing overt amplifications on chromosomes 17p11.2-12 (arrow heads) and 
19q12-13 (arrows) as encountered in both the primary tumor (T87) and the metastasis (T95). Shown is 
a partial normal male metaphase spread after cohybridization with reference (normal, red) and test 
(tumor T87, green) DNAs as probes. The chromosomes are counterstained in blue. B. Schematic 
representation of the average fluorescence ratio profiles of chromosomes 17 and 19 after CGH with T87 
DNA as test probe. Profiles are plotted on the right side of the chromosomes. The vertical red and green 
lines reflect the lower and upper thresholds, respectively, and the black lines in the middle represent 
fluorescence ratios of 1. Clearly two peaks of overrepresentation can be seen at 17p and 19q. (For color 
picture see original published paper).
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Localization of chromosome 17 and 19 sequences by FISH in tum or-derived 
metaphase spreads
Since the CGH analyses showed amplifications on chromosomes 17p and 19q, we decided 
to perform FISH with whole chromosome 17 and 19 painting probes on metaphase 
spreads derived from the metastasis (T95) to localize these sequences within the tumor 
genome. The paints, detected in two different colors, showed hybridization to at least 
5 marker chromosomes, next to the normal copies of chromosomes 17 and 19 in the 
metaphases (not shown). This indicates that indeed extra chromosome 17 and 19 
sequences are present in the tumor genome.
Iso lation  of tum or-associated am plified DNA fragm ents using  RDA
Based on the observed highly abnormal karyotype and the DNA amplifications detected 
by CGH, we set out to isolate aberrant (in particular amplified) DNA fragments from the 
primary tumor via the recently developed RDA technique. Therefore, BglII represen­
tations of the primary tumor DNA (T87; the tester) and a pool of five normal unrelated 
DNAs (the driver) were generated. For the isolation of highly amplified sequences in 
tumor DNA, any normal human DNA can be used as driver, avoiding the need for 
matching normal DNA of the same patient (Lisitsyn et al., 1995a). Difference products 
after one, two and three rounds of subtractive hybridization and PCR amplification are 
shown in Figure 2. After agarose gel electrophoresis five clear bands, varying in size 
from 300 bp to 500 bp, could be observed in the round 3 difference product while 
background levels were reduced considerably. All five bands from the round 3 difference 
product (Figure 2) were isolated and cloned into pBluescript KS+ I I  plasmids. The clone
Figure 2. RDA results of tumor T87 as tester and a pool of 5 normal DNAs as driver. Tester: B g l I I  
representation of tumor DNA. DP1, DP2, and DP3: difference products after first, second, and third round 
of hybridization/amplification. In  DP3 five bands appear (1 to 5) which represent target sequences 
enriched from the tumor DNA.
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inserts were analyzed by using them as probes on Southern blots containing tester and 
driver DNAs, both representation and total genomic DNAs. Two distinct clones (clone 18 
of 471 bp and clone 38 of 330 bp, derived from bands 5 and 2, respectively) showed 
more intense hybridization signals in the tester lanes than in the driver lanes, indicating 
that these fragments represent amplified sequences as present in the original tumor. An 
example of such a Southern blot analysis is shown in Figure 3. Other clones, derived 
from all 5 bands, showed similar intensities in tester and driver lanes on Southern blots, 
indicating that they represent sequences that have escaped the RDA subtraction. Clones
18 and 38 were sequenced and, subsequently, compared with known sequences in 
databases. No homologies could be found for either one of them. Neither could we 
detect any overlap or similarity between the sequences of the two clones. To establish 
the chromosomal localization of these clones via PCR analysis of monochromosomal 
somatic cell hybrid lines, primer sets (FOR and REV primers) designed from the clone 18 
and clone 38 sequences were used (see Materials and Methods). PCR products of 
expected sizes (355 bp with 18FOR/REV primer set and 205 bp with 38FOR/REV primer 
set) were observed in the positive controls and, in addition, only in the chromosome 19 
containing somatic cell hybrid, indicating that both clones map to this human 
chromosome. The chromosomal localization of clone 38 is illustrated in Figure 4.
Figure 3. Hybridization of clone 38 to Southern 
blots containing ßg/II-representation DNAs and 
ßg/II-cleaved total genomic DNAs of driver 
(normal) and tester (tumor T87). Clone 38 
sequences are overrepresented in the tester 
DNA as compared to the driver DNA.
Figure 4. Chromosomal localization of clone 38. 
Two clone 38-specific primers were used for PCR 
analysis of monochromosomal somatic cell 
hybrid lines (1 to 22, X, and Y). Mouse (m), 
hamster (h), and no (-) DNAs were used as 
negative controls, whereas tester (T), driver (D), 
and clone 38 (38) DNAs were used as positive 
controls. A PCR product of expected size (205 
bp) was revealed only in the chromosome 19 
containing cell hybrid, demonstrating that clone 
38 maps to this chromosome.
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YAC iso la tion  and FISH analysis
To reconfirm the chromosomal origin of clones 18 and 38 by visualization with FISH, a YAC 
library was screened by PCR with the FOR/REV primer sets. One clone 38-positive YAC (19B- 
A6) of approximately 400 kb was isolated using the 38FOR/38REV primer set, whereas 
screening with the 18FOR and 18REV primers did not result in the isolation of a clone 18- 
positive YAC. FISH analysis with YAC 19B-A6 on high resolution normal human metaphase 
spreads revealed positive signals on chromosome 19 only, thereby reconfirming the 
localization of the corresponding DNA fragment (clone 38) on chromosome 19. In 
addition, the hybridization signal maps to 19q12-13.1, a region exactly coinciding with 
the region of amplification as observed by CGH (Figure 5). Subsequently, YAC 19B-A6 was 
used for interphase FISH analysis of tumor T95. In all nuclei examined (over 50), four 
separate clusters of multiple copy signals could be observed. Examples of tumor nuclei 
exhibiting these clusters of amplification are shown in Figure 6. For comparison, the two 
normal YAC signals on a normal lymphocyte nucleus are also shown. These results confirm 
that the corresponding sequences are amplified in the osteosarcoma studied.
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Figure 5. Chromosomal localization of YAC clone 19B-A6 by FISH on normal high resolution metaphase 
chromosomes. A specific hybridization signal (green) can be seen on chromosome 19q12-q13.1 (arrow 
heads, left). Chromosomes are pseudocolored in red (left) for optimal counterstaining. Chromosomal 
identification is performed using DAPI-banding (right). (For color picture see original published paper).
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Figure 6. FISH analysis of normal lymphocyte and tumor T95-derived nuclei using YAC 19B-A6 as a probe 
(green). Multiple signals can be seen in the tumor nuclei (B) as compared to the two signals (arrow 
heads) in the normal situation (A). Nuclei are counterstained in red (pseudocolor). (For color picture 
see published paper).
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Discussion
In this study, we successfully combined the two techniques of comparative genomic 
hybridization and representational difference analysis for the detection and isolation of 
osteosarcoma-associated amplified sequences. Both a primary and a metastatic 
osteosarcoma lesion from the same female patient were used in this study. Cytogenetic 
analysis of the metastatic tumor revealed a very complex karyotype with many marker 
chromosomes, which is often seen in osteosarcomas (Sandberg and Bridge, 1994; Heim 
and Mitelman, 1995). Since the primary tumor failed to grow in culture we could not 
compare cytogenetic data of the primary tumor with the metastatic tumor. However, CGH 
analysis allowed a genetic comparison the two tumors. Both showed the same overt 
regions of amplification on chromosome 17p11.2-12 and 19q12-13. No CGH-detectable 
changes seemed to have occurred during metastasis of the primary tumor. FISH analysis 
with whole chromosome 17 and whole chromosome 19 paints on tumor-derived 
metaphases indicated that extra material of chromosomes 17 and 19 was cryptically 
present in several of the cytogenetically defined marker chromosomes, which is in 
agreement with the CGH findings. The observed marker chromosomes and regions of 
amplification (CGH results) made these tumors suitable for RDA analysis. We chose to 
perform RDA on the primary tumor. After three rounds of subtractive hybridization (with 
tumor DNA as tester and normal DNA as driver) and PCR, five bands were observed in 
the difference product. Two cloned DNA bands from the round 3 difference product (18 
and 38) showed more intense hybridization signals in the tumor DNA compared with 
normal DNA on genomic Southern blots. Also in the metastatic tumor, these sequences 
appeared to be highly amplified as determined by Southern blot analysis (not shown), 
as was expected from the CGH results. The other bands did not appear to represent 
amplified or altered DNA fragments. This suggests that these fragments were not caught 
by the driver during the subtractive hybridization steps in the RDA procedure, 
demonstrating that the RDA technique is not completely watertight.
The two isolated amplified sequences are both derived from chromosome 19 as was 
determined by PCR analysis of a monochromosomal somatic cell hybrid panel. The use 
of a clone 38-positive YAC (19B-A6) for FISH analysis revealed its localization to 19q12- 
13.1, whereas clone 18 could not be mapped to a specific chromosome 19 region with 
FISH, since no YAC was isolated with this clone. In addition, four clusters of multiple 
copy signals could be observed in tumor nuclei with FISH using this YAC. From this, we 
conclude that the clone 38 fragment is indeed amplified in both the primary and 
metastatic osteosarcoma lesions. Although it has not been reported before that the 
19q12-13 region is frequently amplified in osteosarcomas, it has occasionally been 
shown to be amplified in ovarian cancer (Thompson et al., 1996). At least two candidate 
genes are located in this region of which AKT2, a gene encoding a ser/thr kinase, has 
been found to be amplified in ovarian cancer. The second gene, the DNA repair gene 
ERCC2, has not yet been implicated in these amplifications (Thompson et al., 1996). The 
role of these genes in pathogenesis of osteosarcomas, however, remains to be
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established and it should be considered that other (yet-unidentified) candidate genes 
may be located within the 19q12-13 region as well. Although the clone 18 and 38 
sequences did not exhibit open reading frames or homologies with known sequences, 
they may be located close to a relevant gene(s).
In general, genomic rearrangements create bridging breakpoint fragments which are not 
present in normal DNA. Such fragments are also likely to be present in the tumors studied 
here. However, we were not able to isolate this type of difference products via RDA. This 
might be due to the fact that there is a very low chance, about 10 % , that such a 
fragment will be present in the tester representation as a consequence of PCR-based size 
selection of fragments during preparation of the representation (Lisitsyn et al., 1993, 
1995a). To increase the probability to isolate bridging fragments several different 
representations should be used (Lisitsyn et al., 1993, 1995a). It is also possible that 
fragments that are amplified in the tumor have an advantage over single copy bridging 
fragments for becoming enriched in the tester representation. Subsequently, these 
fragments will have a higher chance to escape subtraction and to compete in the RDA- 
PCR reactions and, thus, to become even more enriched during the RDA cycles. In this 
way, bridging fragments might be more difficult to isolate from samples where also DNA 
amplifications are present. Also, Lisitsyn et al. (1995a) were not able to isolate this type 
of bridging fragments from samples with DNA amplifications.
No fragments from the chromosome 17 amplification region were isolated with RDA. This 
may be due to several reasons. (i) The restriction enzyme used for preparation of the 
representations may not have generated efficiently PCR-amplifiable chromosome 17 
target fragments. (ii) I f  the amplification region was composed of relatively large 
fragments that were not abundantly amplified, it is possible that PCR-amplifiable 
fragments from this region were subtracted by the driver. If  the amplification in the 
tumor consists of relatively small regions that are amplified many times, it may be easier 
to isolate such fragments. In either case, however, success depends on the presence of 
suitable restriction sites within the amplified segment. The chromosome 17p11.2-p12 
region may harbor genes that are particularly relevant for osteosarcoma development. 
This suggestion is based on our present and other CGH studies, indicating a frequent 
high copy amplification of this region in osteosarcomas (Forus et al., 1995b, Tarkkanen 
et al., 1995). Interestingly, this region has also been shown to be amplified in 
osteosarcoma-derived metastases and xenografts (Forus et al., 1995b), suggesting a role 
for 17p in tumor progression and possibly metastasis. The case reported here supports 
this suggestion. Particularly, since the 17p11.2-p12 amplification was first detected in 
the primary tumor which shortly thereafter metastasized and no CGH-detectable 
differences were observed between the two lesions. Also, in several other tumor types 
e.g. gliomas (Mohapatra et al., 1995), malignant astrocytomas (Bijlsma et al., 1994), 
and malignant fibrous histiocytomas (Forus et al., 1995a), this region has been found 
to be amplified. Currently, we are isolating DNA fragments from the 17p11.2-p12 region. 
These fragments and the chromosome 19 sequences reported here may be instrumental 
in the identification and isolation of the relevant (onco)genes.
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Abstract
Representational difference analysis (RDA) of a human osteosarcoma xenograft resulted 
in the isolation of four tumor-associated homozygously deleted DNA fragments, all 
originating from chromosome 4, region q32-q34. Southern blot analysis using the RDA 
fragments and interphase FISH analysis using PACs corresponding to these RDA 
fragments revealed allelic loss of the 4q32-q34 region in 17 of 27 (63% ) osteosarcomas 
tested. These results suggest the involvement of a tumor suppressor gene(s) within this 
chromosomal region in osteosarcoma development. The RDA fragments and 
corresponding PAC clones will be instrumental in the isolation of such a gene(s).
Introduction
Osteosarcomas commonly display highly aneuploid and extremely complex karyotypes 
with many abnormalities, including marker chromosomes, homogeneously staining 
regions, double minutes and supernumerary ring chromosomes (Biegel et al., 1989; 
Mertens et al., 1993; Tarkkanen et al., 1993; Fletcher et al., 1994; Hoogerwerf et al., 
1994; Sandberg and Bridge, 1994; Heim and Mitelman, 1995). These latter anomalies 
appear to be associated with gene amplification (Ladanyi et al., 1993; Ozaki et al.,
1993). Osteosarcoma-associated alterations involving tumor suppressor genes (TSGs) 
include loss or rearrangement of the 13q14 and 17p13 bands, harboring the RB1 and 
TP53 TSGs, respectively (Toguschida et al., 1988; Miller et al., 1990; Mulligan et al., 
1990; Andreassen et al., 1993; Hoogerwerf et al., 1994). It has been suggested by 
Wadayama et al. (1994) that alterations of the RB1 locus in primary osteosarcomas may 
serve as indicators of a poor clinical outcome. More recently, also allelic losses of 
regions 3q26 and 18q21-22 were found to be associated with osteosarcoma development 
(Kruzelock et al., 1997; Nellissery et al., 1998). No relevant TSGs from these latter 
regions have been identified so far.
Comparative genomic hybridization (CGH) serves as a suitable method for the detection 
and mapping of (sub)chromosomal DNA losses, gains, and amplifications in human solid 
tumors, including osteosarcomas (Kallioniemi et al., 1992, 1994; Forus et al., 1995a,b; 
Tarkkanen et al., 1995; Geurts van Kessel et al., 1997, Simons et al., 1997). Although 
this technique is very useful for obtaining overall information on tumor-associated 
genomic imbalances, it has several limitations: it only allows a visualization of 
imbalances and its resolution is limited to approximately 10-20 Mb (Kallioniemi et al.,
1994). Representational difference analysis (RDA; Lisitsyn et al., 1993) overcomes these 
limitations through the direct isolation of altered and/or deleted DNA fragments and 
through the lack of restriction in its detection level. This molecular technique has 
already successfully been used for the isolation of both tumor-associated amplified and 
(homozygously) deleted DNA sequences (Lisitsyn et al. 1995a,b; Simons et al., 1997,
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1999) and for the identification of oncogenes and TSGs (Schutte et al., 1995; Li et al., 
1997).
In principle, the RDA technique is based on subtractive hybridization followed by PCR. 
Subtraction is carried out with representations of two DNA populations (tester and 
driver) of which the differences are the targets (present in the tester) to be isolated. 
Representations are made by restriction enzyme cleavage of genomic DNA, followed by 
adaptor ligation and adaptor-primed PCR amplification. In the application of RDA to 
cancer two approaches can be used: (i) employing tumor DNA as tester and normal DNA 
as driver, and (ii) employing normal DNA as tester and tumor DNA as driver. The first 
approach may be used to isolate DNA fragments that are implicated in point mutations, 
chromosomal rearrangements, amplifications, or to search for the presence of 
pathogens, whereas in the second approach DNA fragments may be isolated from regions 
that are deleted.
In order to get further insight into the molecular genetic changes that are relevant for 
the development of osteosarcomas, we have analyzed an osteosarcoma xenograft by 
both CGH and RDA. A variety of CGH-detectable copy number changes was detected, 
including some described by others. In addition, several homozygously deleted DNA 
fragments, originating from chromosomal region 4q32-q34, were isolated by RDA. 
Subsequent Southern blot and interphase FISH analyses of a larger series of 
osteosarcomas revealed loss of the same chromosomal region in several of them. Our 
data are indicative for the presence of an, as yet unidentified, TSG(s) in this particular 
chromosomal region.
Materials and methods
Tumor m aterial and DNA iso lation
Twenty-seven primary or metastatic osteosarcomas of histological grades I I I  or IV were 
used in this study (Table 1; Forus et al., 1995b). Fresh samples were obtained from 13 
patients. Another 13 tumors were grown subcutaneously as xenografts in nude mice, and 
one tumor was grown as a cell line in tissue culture. High molecular weight genomic 
DNA from all tumor samples was isolated as described before (Forus et al., 1993). 
Genomic DNA from peripheral blood cells of unrelated human controls was isolated using 
standard SDS/proteinase K lysis, phenol/chloroform extractions and ethanol 
precipitations. DNA isolation of cloned RDA fragments and isolated PACs was performed 
using standard procedures (Sambrook et al., 1989).
Comparative genom ic hybridization
CGH analysis was performed as described by Forus et al. (1995a,b) with some 
modifications. Briefly, tumor DNA was labeled with digoxigenin-11-dUTP (Boehringer 
Mannheim) and normal (reference) DNA was labeled with biotin-14-dATP (Gibco BRL).
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Table 1. Stage, grade and origin of 27 osteosarcomas used in this study
tumor stage grade origin
OS4xa Primary tumor IV xenograft
OS51met Metastasis u xenograft
OSI lxa Primary tumor IV xenograft
OS3x Primary tumor IV xenograft
OS21a Metastasis IV patient
OSlx Primary tumor III xenograft
OS14 Primary tumor IV patient
OS13xa Metastasis III-IV xenograft
OS5xb Primary tumor IV xenograft
OS12xa Metastasis IV xenograft
OS41 u u patient
OS 12m Metastasis IV patient
OS15x Primary tumor III xenograft
OS29m Metastasis u patient
OS32 Metastasis IV patient
OS7xa Primary tumor IV xenograft
OS 16m Metastasis u patient
OS28 u u cell line
OS34 Metastasis IV patient
OS29a Primary tumor IV patient
OS6xa Primary tumor IV xenograft
OS9xa u IV xenograft
OS17a Metastasis IV patient
OS20 Primary tumor III-IV patient
OS2xa Primary tumor IV xenograft
OS31a Primary tumor IV patient
OSI met Metastasis u patient
a Forus et al. (1995b); u, unknown.
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Two-hundred ng of each of the labeled probes, a 200-fold excess of human Cot-1 DNA 
(Gibco BRL), and 20 pg of herring sperm DNA (Gibco BRL) were co-precipitated and 
dissolved in 12 pl of hybridization buffer. Metaphase spreads were treated with pepsin 
for 10 minutes at 37 °C (2 %  pepsin in 0.01 N HCl), followed by formaldehyde treatment 
for 10 minutes at room temperature (1 %  formaldehyde in PBS). Subsequently, the probe­
mix was added onto the slide, and after sealing of the coverslip, codenaturation of the 
probe-mix and the target chromosomes was achieved via incubation at 74 °C for 4 
minutes. Hybridization was carried out at 37 °C for 48 hours. Following washing, 
immunocytochemical detection of the probes was achieved with TexasRed-conjugated 
avidine (Vector Laboratories) and fluorescein isothiocyanate (FITC)-conjugated sheep 
anti-digoxigenin (Boehringer Mannheim). Afterwards, the slides were mounted in anti­
fade medium containing DAPI for counterstaining of the chromosomes. Examination of 
chromosome preparations was carried out using QuipsTM CGH analysis software (Vysis, 
Downers Grove, IL, USA). Imbalances were scored as follows: fluorescence ratios below 
the lower threshold of 0.90 were scored as losses and fluorescence ratios above the 
upper threshold of 1.10 were scored as gains (confidence interval of 95%).
Representational difference analysis, cloning and sequencing
RDA was performed basically as described before (Simons et al., 1997; 1999). BglII- 
representations were made from xenograft DNA (OS4x; driver) and from a DNA pool of
15 unrelated control persons (normal; tester). DNA fragments from the third round 
difference product (DP3) were isolated and cloned in pBluescript KS+ I I  plasmid vectors 
(Stratagene). Selected clones were sequenced using the Ready Reaction Dye Terminator 
Cycle Sequencing kit and the automated DNA sequencer AB I 373A (Applied 
Biosystems/Perkin Elmer). Sequences were compared to known sequences using the 
Genbank and European Molecular Biology Laboratory (EMBL) databases.
Southern blot analysis and densitom etric scanning
All Southern blot hybridizations were carried out as described by Forus et al. (1993) and 
Simons et al. (1999). Quantitation of signal intensities was achieved by densitometric 
analysis using a type GS690 Imaging Densitometer (Biorad) and Multi-analyst software 
(Biorad). The net signals from specific bands were corrected for unequal sample loading 
by calibration relative to the signal obtained by a control probe (APOB; human 
apolipoprotein B; Huang et al., 1985). Subsequently, the signals were compared to 
signals from normal control samples (via a tumor/normal ratio value) and interpreted as 
follows: samples with ratio values below 0.75 were considered to exhibit allelic loss 
(AL); samples with ratio values between 0.75 and 2.25 were considered to be normal 
(N).
Primers, PCR analysis and som atic cell hybrids
Based on the nucleotide sequences of RDA clones OSD1 to OSD4, primer sets were 
designed for PCR analysis: OSD1-FOR (5'-CCGAGAGGCTACACGCTGTCTTGT-3') and OSD1-REV
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(5'-CAGCCAGGGAAGATGGAAGTCAAA-3') resulting in a PCR fragment of 156 bp; OSD2-FOR 
(5'-GCCTGAAGCAATGCCTCTGGTTAA-3') and OSD2-REV (5'-TGCTCCTGTCGAGGGGTGAGTTAC-3') 
resulting in a PCR fragment of 302 bp; OSD3-FOR (5'-GGACTTATCCCATGTGCTGGAATG-3') 
and OSD3-REV (5'-CTTCCAAACTTGAGGATCCTTATG-3') resulting in a PCR fragment of 206 
bp; OSD4-FOR (5'-CGTGGCTTTCCATTTCTTTCAGGA-3') and OSD4-REV (5'-GAGTGTGCAGAAG- 
GCTTCCCTGAG-3') resulting in a PCR fragment of 410 bp. PCR analyses were carried out 
as described by Simons et al. (1999). Annealing temperatures for the OSD-derived primer 
sets were 60 °C for OSD1, OSD2 and OSD4 and 53 °C for OSD3. Primers sets used for 
candidate gene analysis were: apopain (Casciola-Rosen et al., 1996), APP-FOR (5 '- 
CATGATTAGCAAGTTACAGTGATGC-3') and APP-REV (5'-CACAGTCTTAAGTGGGGGGA-3'); 
deoxycytidylate deaminase (Weiner et al., 1995), DOCD-FOR (5'-GGGACGCCTGTTGTTTTG- 
3 ') and DOCD-REV (5'-AGAAGAGCTCCGAACACCAA-3'); cyclin H (Fisher and Morgan, 1994), 
CH-FOR (5'-AGCATGAGAAACTTAGTAAAG-3') and CH-REV (5'-TCCTCTTCTTCGTGATTACG-3'); 
interferon regulatory factor 2 (Vaughan et al., 1995), IRF2-FOR (CCTTGACAATAGAA- 
CATTGATTGC-3') and IRF2-REV (5'-CTAGAAACACACGTCTACCAATGG-3'); FAT (Dunne et al.,
1995), FAT-FOR (5'-GCTGTGCCATTTCCCAAC-3') and FAT-REV (5'-GATAATGGCACTGACACCACC- 
3'). All PCR reactions for candidate gene analysis were performed under standard 
conditions. The monochromosomal human/rodent somatic hybrid panel used was 
partially obtained from the Coriell Institute for Medical Research (Camden, NJ, USA) and 
partially prepared in our department of Human Genetics (Nijmegen, The Netherlands). 
The radiation hybrid panel used was the Stanford G3 panel (Stanford Human Genome 
Center, CA, USA).
Metaphase and interphase fluorescence in situ  hybridization
FISH analysis of PACs on metaphase spreads was carried out basically as described before 
(Suijkerbuijk et al., 1994; Simons et al., 1999). Briefly, 200 ng PAC DNA was labeled 
with digoxigenin-11-dUTP (Boehringer Mannheim) by nick translation and preannealed 
with a 50-fold excess of Cot-1 DNA (Gibco BRL). Target slides containing normal 
chromosomal metaphase spreads were pretreated as described previously (Simons et al., 
1999). Hybridizations were carried out at 37 °C overnight. Detection of the probes was 
achieved by using the fluorochrome-conjugated antibodies sheep-anti-digoxigenin-FITC 
(Boehringer Mannheim), rabbit-anti-FITC (Dakopatts) and goat-anti-rabbit-FITC 
(Jackson Immuno Research Laboratories, WestGrove, PA, USA). Afterwards, slides were 
mounted in anti-fade solution with DAPI counterstain, analyzed and pseudocolored with 
the Oncor-image software (Gaithersburgh, MD, USA). Chromosomal identification was 
based on inverted DAPI-banding.
FISH analysis on interphase nuclei was carried out essentially as described before (Forus 
et al., 1998). Briefly, 400 ng PAC DNA labeled with biotin-14-dATP by nick translation 
(Gibco BRL) was prehybridized with a 50-100 fold excess of human Cot-1 DNA (Gibco 
BRL). The centromere probes, digoxygenin-labeled centromere 4 (cen4; D4Z1, Oncor 
Gaithersburg, MD, USA) or Spectrum-Orange-labeled centromere 4 (CEP4, Vysis, Downers 
Grove, IL, USA) were premixed with the same hybridization mix, and prewarmed at 37 °C
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before use. Subsequently, the probes were dissolved in a hybridization mix (50%  
formamide, 10%  dextran sulphate, 300 mM NaCl, 30 mM sodium citrate). Hybridization 
of the probes was carried out overnight at 37°C. After hybridization, the slides were 
washed 3 times for 10 min in 5 0 %  formamide, 2 x SSC at 45°C and then 3 times for 10 
min in 2 x SSC at 60°C. For detection of the digoxigenin we used FITC-conjugated sheep 
anti-digoxigenin (Boehringer Mannheim), followed by an amplification step using FITC- 
or ALEXA488- conjugated donkey anti-sheep antibody (Molecular Probes, Europe, Leiden, 
The Netherlands). For detection of the biotinylated probes, we used Cy3-conjugated 
avidin (Amersham). Alternatively, hybridization signals were detected by deposition of 
biotinylated tyramides (Kerstens et al., 1995; Raap et al., 1995), followed by a layer of 
FITC-labeled streptavidin, essentially as described in the protocol supplied by the 
detection kit (NENTM, Life Science Products, Boston, MA, USA). Hybridized slides were 
examined visually using a Zeiss Axioplan microscope equipped with double-bypass filters 
for excitation of DAPI/FITC and DAPI/Rhodamine (Cy3). The results were interpreted as 
follows: allelic loss (AL) when >2 0 %  of the cells within one tumor showed less PAC signals 
than cen4 signals; normal (N) when the number of PAC and cen4 signals were equal in 
more than 80 %  of the nuclei analyzed. Two persons each independently analyzed 150­
200 nuclei per sample and both scorings were averaged to obtain the final values.
Results
Comparative genom ic hybridization of osteosarcom a xenograft OS4x
DNA from xenograft OS4x, established from a male childhood osteosarcoma after 
chemotherapy, was used for CGH. A complex pattern of chromosomal copy number 
aberrations was obtained (not shown). In summary, losses were found for chromosomes 
or chromosomal regions 1q32-q43, 2p24-p25, 2q23-qter, 3q26-qter, 5q23-qter, 6q25- 
qter, 9, 10, 11p15, 12q24, 13q10-q33, 15q10-q23, 16p, 16q24, 18q, 19q, Xp2 and Xq23- 
q25, whereas gains were found for chromosomes or chromosomal regions 1p22-p32, 
1q21-q31, 2p16-q14, 5p11-p14, 6p11-p12, 6p22-p24, 7, 8, 12p, 14q11-q24, 17p11-p12 
and 17q22-q24. Only chromosomes 4, 20 and 21 did not appear to exhibit any CGH- 
detectable abnormalities. The Y-chromosome did not yield reliable profiles and was, 
therefore, left out of the analysis.
Iso lation  of hom ozygously deleted DNA fragm ents using  RDA
Given the limitations of the CGH technique, we set out to analyze further tumor OS4x 
for the presence of homozygous deletions using RDA. BglII representations of tumor DNA 
(driver) and of a pool of 15 normal unrelated DNAs (tester) were used. Xenograft 
samples are particularly suitable for RDA since they do not contain contaminating 
normal human cells that may interfere with the isolation of homozygously deleted DNA 
fragments. Difference products (DP) obtained after one, two and three rounds of
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subtractive hybridization and PCR amplification are shown in Figure 1A. After the third 
round, background levels were reduced considerably and at least seven clear bands, 
varying in size from 350 bp to 650 bp, could be observed (DP3; Fig. 1A). These seven 
bands were excised from the gel and cloned into plasmid vectors. Subsequently, the 
clone inserts were used as probes on Southern blots containing H ind III- and EcoRI- 
cleaved tester and driver total genomic DNAs. Four clones, OSD1 (osteosarcoma-deleted 
clone 1), OSD2, OSD3 and OSD4, derived from bands 1, 2, 3 and 6, respectively, showed 
hybridization signals in the normal lanes and not in the tumor lanes, indicating that 
these fragments indeed represent homozygously deleted sequences in the original 
xenograft sample (Fig. 1B). Five other clones, derived from bands 2, 4 and 5 turned out 
to represent DNA polymophisms (not shown). No informative clones were obtained from 
band 7. RDA clones OSD1 to OSD4 were sequenced and, subsequently, compared with 
known sequences in databases. No homologies to known genes or sequences could be 
detected. Also, no overlaps or similarities between the sequences of the 4 OSD clones 
were found. Nucleotide sequences of the OSD clones are available from the GenBank 
database under the accession numbers: OSD1: AF091487; OSD2: AF091488; OSD3: 
AF091489; OSD4: AF091490.
«V c 5 OSD2 OSD4
Figure 1. A. RDA results with osteosarcoma OS4x as driver (D, B glII  representation of tumor DNA) and 
normal DNA as tester (T, B g lII representation of a pool of 15 normal DNAs). DP1, DP2, DP3: difference 
products after first, second, and third round of hybridization/amplification. In  DP3 at least seven bands 
are present (1 to 7), which represent target sequences enriched from the tester. m: 100 bp marker. B. 
Hybridization of clones OSD2 and OSD4 to Southern blots containing H in d I I I -  (H) and EcoRI- (E) cleaved 
genomic DNAs of tumor (T) and normal (N) DNA. OSD2 and OSD4 are both absent in the tumor DNA.
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Assignm ent of the isolated RDA fragm ents to chrom osom al region 4q32-q34
The chromosomal localization of the isolated RDA fragments was determined using a 
panel of monochromosomal human/rodent somatic cell hybrids. For PCR analysis of this 
panel, primer sets were designed from the known nucleotide sequences of the OSD 
clones (see Materials and Methods). PCR products of expected sizes were observed in the 
positive controls and, in addition, in the chromosome 4 containing somatic cell hybrid 
only, indicating that all isolated OSD clones map to this chromosome (not shown). To 
confirm the chromosomal origin and to fine-map the isolated clones by FISH, a PAC 
library (RPCI5; BAC-PAC Resources, Roswell Park Cancer Institute, Buffalo, NY, USA) was 
screened with a pool of the four OSD clones. Eight positive PACs were isolated. Southern 
blot analysis showed that PACs 919O4, 904L14 and 992G14 (PAC group I) were positive 
for OSD1 and OSD3, PACs 930G7, 903G17, 1055E24 and 1021F19 (PAC group II)  were 
positive for OSD4, and PAC 963K6 (PAC group I I I )  was positive for OSD2 (Fig. 2A and 
2B). FISH analysis with the eight PACs on normal human metaphase spreads revealed 
positive signals on 4q32-q34 for all of them, thereby confirming the localization of the 
corresponding OSD clones on chromosome 4 and, in addition, refine their assignment to
Figure 2. A. Southern blot analysis of PACs 903G17 to 1055E24 using RDA clones OSD1 to OSD4 as 
probes. B. Schematic representation of the different PACs, divided into groups I, I I  and I I I ,  and the 
location of RDA clones OSD1 to OSD4. C. Chromosomal localization of PAC 963K6 ( I I I )  by FISH on DAPI- 
stained normal metaphase chromosomes. A specific hybridization signal can be seen only on 
chromosome 4, region q32-q34 (arrow head).
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region 4q32-q34 (Fig. 2C). In order to map the OSD clones relative to known genetic 
markers, PCR analysis with the OSD-specific primers was performed on a radiation hybrid 
panel. Significant linkage was found for OSD1 and OSD4 with marker D4S1060 (lod 
scores 4.6 and 4.1, respectively). Clone OSD2 showed linkage with marker D4S2930 (lod 
score 6.0) and OSD3 with marker FB12A4 (lod score 7.8). By combining these data, also 
the order of the isolated PACs and OSD clones could be determined: PAC group I most 
proximal, PAC group I I I  most distal and PAC group I I  in between groups I and I I  with 
clones OSD1 and OSD4 linking PAC groups I and I I  (Fig. 3).
A llelic loss of 4q32-q34  in  other human osteosarcom as
In order to test the involvement of the 4q32-q34 region in other human osteosarcomas, 
we performed Southern blot analyses of 27 tumors (including OS4x) using the 4 OSD 
clones as probes. As an arbitrary control probe APOB, originating from chromosome 2, 
was used (Huang et al., 1985). Allelic loss (AL) of at least one of the OSD clones was 
observed in 17 of the 27 (63% ) tumors tested (schematically depicted in Fig. 3). Tumor 
OS4x showed, as expected, no signals at all with the OSD-probes and was scored to have 
homozygous deletions (HD) for the four OSD-probes (Fig. 3). In  addition, we performed 
interphase FISH analysis with the isolated PACs on five tumors that showed allelic loss 
and on two tumors that were scored normal after Southern blot hybridization. Allelic 
loss of PAC groups I, I I  and I I I  was found in tumors OS3x, OS21 and OS5x, of PAC groups
I and I I  in tumor OS14 and of PAC group I in tumor OS12x. Tumor OS29 did not show 
allelic loss. Tumor OS31, which was scored normal after Southern blot analysis was found 
to exhibit allelic loss of PAC groups I I  and I I I  (summarized in Table 2 and schematically 
presented in Fig. 3). The most frequent patterns of deletion were as follows: for OS3x 
and OS21, three or four cen4 signals and two PAC signals; for OS14, four cen4 signals 
and two PAC signals; for OS5x, four or six cen4 signals and two PAC signals; and for 
OS31, about 5 0 %  of the cells with allelic loss had four cen4 signals and two PAC signals 
and about 3 0 %  had two cen4 signals and no PAC signals (not shown).
Table 2. Interphase FISH results o f PAC groups I, II and III on seven osteosarcomas
tumor group I group II group III
91904 904L14 992G14 930G7 903G17 1055E24 1021F19 963K6
OS3x AL (74%) nd N AL (41%) nd nd nd AL (70%)
OS21 nd AL (47%) AL (22%) AL (62%) nd nd nd AL (27%)
OS14 nd AL (65%) nd AL (44%) nd nd nd N
OS5x AL (95%) nd AL (74%) AL (73%) nd nd nd AL (90%)
OS12X AL (40%) nd N AL (23%) nd N N N
OS29 nd nd N nd nd N nd nd
OS31 nd nd nd AL (67%) AL (80%) nd nd AL (32%)
nd, not determined; AL(%), allelic loss (percentage of cells with loss op PAC); N, normal
Figure 3. Diagram of the distal part of chromosome 4q, the relative positions of the RDA clones (OSD1 to OSD4), linked genetic markers, cytogenetic location 
and the OSD-corresponding PAC groups (I, I I  and I I I ;  hatched bars). A schematic representation of Southern blot (circles; OSD clones) and interphase FISH 
(bars; PAC groups) results on a series of 27 osteosarcomas (OS4x to OSlm et) is  shown at right. Solid symbols represent allelic loss; carved solid symbols 
represent homozygous loss; open symbols indicate no loss (normal)
O
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Candidate gene analysis
Using the Genethon genetic map of human chromosome 4 (ftp://ftp.genethon.fr/pub/ 
Gmap/Nature-1995/data/; Dib et al., 1996) and "The Human Gene Map" of NCBI 
(www.ncbi.nlm.nih.gov/SCIENCE96/) we looked for known candidate genes mapping to 
our region of interest (between markers D4S415 and D4S2930). Several of these genes, 
i.e., apopain (Casciola-Rosen et al., 1996), deoxycytidylate deaminase (Weiner et al., 
1995), cyclin H (Fisher and Morgan, 1994), interferon regulatory factor 2 (Vaughan et 
al., 1995) and FAT, the human homologue of the Drosophila fat tumor suppressor gene 
(Dunne et al., 1995), were subsequently tested by PCR on tumor OS4x and PAC groups 
I, II, and I I I  using specific primer sets. With all primer sets we failed to obtain PCR 
fragments from the PAC clones, whereas in all cases PCR products were obtained from 
the tumor DNA, indicating that none of the sequences tested map within the 
osteosarcoma-associated deleted region.
Discussion
A complex picture of DNA gains and losses was encountered after CGH analysis of a 
human osteosarcoma xenograft (OS4x). Some of these abnormalities were also observed 
in other CGH studies on osteosarcomas, i.e., loss of 2q23-qter, 6q25-qter and 10, and 
gain of 1q21-q31, 6p11-p12, 6p22-p24, 8 and 17p11-p12 (Forus et al., 1995b; Tarkkanen 
et al., 1995; Simons et al., 1997). It should be noted that the profile obtained here is 
more complex than previously reported for this xenograft (Forus et al., 1995b). This 
difference can be attributed to the improved analysis technique used in the present 
investigation. Recently, it was found that OS4x is highly aneuploid (Forus et al., 1998). 
This observation is in agreement with our CGH results and the complex karyotypes usually 
observed in osteosarcomas (Sandberg and Bridge, 1994; Geurts van Kessel et al., 1997). 
RDA analysis of tumor OS4x resulted in the isolation of four unique DNA fragments (OSD1 
to OSD4) which were homozygously deleted as determined by Southern blot analysis. The 
homozygous deletion of the four OSD clones could be confirmed by PCR analysis (not 
shown). All four OSD clones were mapped to human chromosome 4. Screening of a PAC 
library yielded eight PACs, which could be divided into three non-overlapping groups, I, 
I I  and III,  corresponding to the clones OSD1/OSD3, OSD4 and OSD2, respectively. FISH 
analyses with these PACs revealed their localization to chromosomal region 4q32-q34. 
Furthermore, significant genetic linkage of OSD1 and OSD4 to marker D4S1060, OSD2 to 
marker D4S2930 and OSD3 to EST FB12A4 was detected. Combining these data, we 
estimate the size of the homozygous deletion in OS4x to be at least 350 kb. In addition, 
we were able to position the different PACs and OSD clones within the region 4q32-q34 
(Fig. 3). Interphase FISH with a 4q subtelomeric probe (P2663; Vocero et al., 1996) on 
OS4x nuclei revealed positive signals (not shown), indicating that the deletion observed 
must be interstitial. Interestingly, loss of 4q32-q34 material was not detected by CGH in
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this tumor, underlining the moderate sensitivity of this latter method and supporting the 
notion that the homozygously deleted region may be relatively small. Although, the CGH 
results of tumor OS4x showed many chromosomal regions of loss, we failed to isolate 
difference products from all of these regions through RDA. This finding can be explained 
by i) allelic loss but not homozygous loss, which hampers RDA analysis; ii) use of a single 
restriction enzyme (BglII) which may not in all cases lead to fragments of appropriate 
size (100-1,500 bp) for RDA analysis.
In order to evaluate the possible loss of 4q32-q34 sequences in other osteosarcomas, we 
performed Southern blot analysis on a series of 27 tumors using the newly isolated OSD 
clones as probes. Allelic loss was observed in 63 %  of the samples tested, with clone 
OSD3 being most frequently involved (15/27 cases). Seven tumors were studied in more 
detail using interphase FISH analysis. Allelic loss was observed in six of these seven 
tumors, largely in agreement with the Southern blot data. A striking interphase FISH 
finding was that in many cases local variations in PAC and centromere 4 signals were 
observed, indicating heterogeneity (clonal variation) within the tumor samples. In  some 
of our cases (OS14, OS12x, OS31), this phenomenon may explain the partial discrepancies 
in results obtained via Southern blot and interphase FISH analyses (Fig. 3).
In conclusion, we have identified a region on chromosome 4 (q32-q34) that appears to 
be associated with osteosarcoma development through allelic loss. As such, this region 
may harbor a putative, still unidentified, TSG. Previous studies on bladder carcinomas 
(Polascik et al., 1995), esophageal adenocarinomas (Hammoud et al., 1996), head and 
neck squamous cell carcinomas (Pershouse et al., 1997), cervical carcinomas (Larson et 
al., 1997), hepatocellular carcinomas (Piao et al., 1998) and immortal keratinocytes 
(Loughran et al., 1997) revealed loss of heterozygosity (LOH) of the same chromosomal 
region, thereby also in these cases pointing at the possible existence of a TSG(s) in 
4q32-q34. Within the region of deletion that we identified several genes have been 
mapped, among which apopain (Casciola-Rosen et al., 1996), deoxycytidylate 
deaminase (Weiner et al., 1995), cyclin H (Fisher and Morgan, 1994), interferon 
regulatory factor 2 (Vaughan et al., 1995) and FAT, the human homologue of the 
Drosophila fat tumor suppressor gene (Dunne et al., 1995). Based on tumor and PAC 
analyses these sequences could be excluded from being osteosarcoma-related candidate 
TSGs. The newly isolated OSD clones and PACs (in particular OSD3 and PACs 919O4, 
904L14 and 992G14) are currently being used for the isolation and identification of 
novel candidate genes in this region.
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Abstract
Representational difference analysis (RDA) using a human osteosarcoma xenograft 
resulted in the isolation of a tumor-associated homozygously deleted DNA fragment, 
originating from chromosome 5. Subsequent FISH analysis using a PAC corresponding to 
this RDA fragment revealed its localization to the region 5q12.3-q13.1. This RDA 
fragment and PAC clone may be instrumental in the isolation of a putative 
osteosarcoma-associated tumor suppressor gene(s).
Introduction
Representational difference analysis (RDA; Lisitsyn et al., 1993) enables the direct 
isolation of altered and/or deleted DNA fragments using a combination of subtractive 
hybridization, PCR analysis and genomic representations, the latter reducing the 
complexity of the DNA samples (tester and driver) used for subtraction. This molecular 
technique has already successfully been used for the isolation of both tumor-associated 
amplified and (homozygously) deleted DNA sequences (Lisitsyn, 1995; Lisitsyn et al. 
1995; Simons et al., 1997, 1999) and for the identification of some pivotal tumor 
suppressor genes (Schutte et al., 1995; Li et al., 1997). In the application of RDA to 
cancer two approaches can be used: (i) employing tumor DNA as tester and normal DNA 
as driver, and (ii) employing normal DNA as tester and tumor DNA as driver. The first 
approach may be used to isolate DNA fragments that are implicated in point mutations, 
chromosomal rearrangements, amplifications, or to search for the presence of 
pathogens, whereas in the second approach DNA fragments may be isolated from regions 
that are deleted. This paper reports the results obtained after application of RDA to an 
osteosarcoma xenograft in a search for deletions. A homozygously deleted DNA fragment 
was isolated and characterized as being derived from chromosomal region 5q12.3-13.1, 
a novel region of loss. This result points at the position of an as yet unidentified tumor 
suppressor gene(s) that may be associated with osteosarcoma development.
Materials and methods
Tumor m aterial and DNA iso lation
The tumor used in this study was a human male childhood osteosarcoma grown subcutaneously 
as xenograft in a nude mouse, OS4x (Forus et al., 1995; Chapter 5 of this thesis) High 
molecular weight genomic DNA was isolated as described before (Forus et al., 1993). Genomic 
DNA from peripheral blood cells of unrelated human controls was isolated using standard 
SDS/proteinase K lysis, phenol/chloroform extractions and ethanol precipitations. DNA
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isolation of cloned RDA fragments and isolated PACs was performed using standard procedures 
(Sambrook et al., 1989).
Representational difference analysis, cloning and sequencing
RDA was performed as described before (Simons et al., 1997; 1999). BglII-represen- 
tations were made from xenograft DNA (OS4x; driver) and from a DNA pool of 15 
unrelated control persons (normal; tester). DNA fragments from the third round 
difference product (DP3) were isolated and cloned in BamHI-digested pBluescript KS+
I I  plasmid vectors (Stratagene). Clone OSD5 was sequenced using the Ready Reaction 
Dye Terminator Cycle Sequencing kit and the automated DNA sequencer AB I 373A 
(Applied Biosystems/Perkin Elmer). The obtained sequence was compared to known 
sequences using the Genbank and European Molecular Biology Laboratory (EMBL) 
databases.
Southern blot analysis, primers, PCR analysis, som atic cell hybrids, PAC library
Southern blot hybridizations were carried out as described by Forus et al. (1993) and 
Simons et al. (1999). Based on the nucleotide sequences of RDA clone OSD5, a primer 
set was designed for PCR analysis: OSD5-FOR (5'-TCAGCTTTATTGTCATTGGCTCTG-3') and 
OSD5-REV (5'-AACTGTGCTACATCAGGCAAGTGA-3') resulting in a PCR fragment of 278 bp. 
Primers sets used for chromosome 5 marker analysis were: SHGC-13191, 13191- FOR (5'- 
TCTTAGCAATCAGATTTATGGAAGG-3') and 13191-REV (5'-TTGCCCCCCAATTATAAACA-3'), 
resulting in a PCR fragment of 107 bp; SHGC-36907, 36907-FOR (5'-CACAAAACTG- 
TAGCTTTTAATGAAA-3') and 36907-REV (5'-ACAGTTTTTAAACTAGGTTTGTGGG-3'), resulting in 
a 125 bp fragment; SHGC-20276 (=D5S1967), 20276-FOR (5'-CCCACCCTGTGCTAGATG-3') 
and 20276-REV (5'-TGTCCTAATGGACCTGGAG-3'), resulting in a 311 bp fragment. All PCR 
reactions were carried out under standard conditions. The monochromosomal 
human/rodent somatic cell hybrid panel used was partially obtained from the Coriell 
Institute for Medical Research (Camden, NJ, USA) and partially prepared in our 
department of Human Genetics (Nijmegen, The Netherlands). The radiation hybrid panel 
used was the Stanford G3 panel (Stanford Human Genome Center, CA, USA). The PAC 
library (RPC15) used was obtained from BAC-PAC Resources (Roswell Park Cancer 
Institute, Buffalo, NY, USA).
Fluorescence in situ hybridization (F ISH )
FISH analysis on metaphase spreads was carried out basically as described before 
(Suijkerbuijk et al., 1994; Simons et al., 1999). Briefly, 200 ng PAC DNA was labeled 
with digoxigenin-11-dUTP (Boehringer Mannheim) by nick translation and pre-annealed 
with a 50-fold excess of Cot-1 DNA (Gibco BRL). Target slides containing normal 
chromosomal metaphase spreads were pretreated as described previously (Simons et al., 
1999). Hybridizations were carried out at 37 °C overnight. Detection of the probes was 
achieved by using the fluorochrome-conjugated antibodies sheep-anti-digoxigenin-FITC 
(Boehringer Mannheim), rabbit-anti-FITC (Dakopatts) and goat-anti-rabbit-FITC
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(Jackson Immuno Research Laboratories). Afterwards, slides were mounted in anti-fade 
solution with DAPI counterstain, analyzed and pseudocolored with the Oncor-image 
software (Gaithersburgh, MD, USA). Chromosomal identification was based on inverted 
DAPI-banding.
Results and Discussion
We set out to analyze tumor OS4x for the presence of homozygous deletions using RDA. 
BglII representations of tumor DNA (driver) and of a pool of 15 normal unrelated DNAs 
(tester) were used. Difference products (DP) were obtained after one, two and three 
rounds of subtractive hybridization and PCR amplification. After the third round at least 
seven clear bands, varying in size from 350 bp to 650 bp, could be observed (see 
Chapter 5, Figure 1A). These seven bands were excised from the gel and cloned into 
plasmid vectors. Subsequently, the clone inserts were used as probes on Southern blots 
containing H ind III- and EcoRI-cleaved tester and driver total genomic DNAs. Besides the 
four clones described in Chapter 5, another clone was isolated, OSD5 (osteosarcoma- 
deleted clone 5), derived from band 5 (see Figure 1A in Chapter 5). Also this clone 
showed hybridization signals in the normal lanes and not in the tumor lanes after 
Southern blot analysis, indicating that it represents a DNA fragment that is 
homozygously deleted in the original xenograft sample (Figure 1). This clone was 
sequenced and, subsequently, compared with known sequences in databases. No 
homologies to known genes or sequences could be detected. The 359 bp sequence of 
this OSD5 clone with the BglII/Bam HI cloning sites in italic and the positions of two 
sequence derived primers (OSD5-FOR and OSD5-REV; see materials and methods) 
underlined, reads as follows:
GA7~CTTTATTGAAACAGAATAATAAGTCTGAACAAATCAGCTTTATTGTCATTGGCTCTGGTGTGGTTTGGAT-
TAATTTCAGCTTTATATTTCTAAAGGATTGCCTAAGAGGTGATGCTCCCCAATTCCAGGTTATGTAAAG-
GAAGGGAGAGAACTGACATACCTTAAGTAACTACTAAGTGTCAGGAGCTTGCCTGCATTATCTCAATTACTTTTC-
CTAACAATCCAATAAAGTCGTTGTTCCTCCATTCATCTTACTGATGAGAAAACGGAGGTGCTGAGAGGGT-
CATTCACTTGCCTGATGTAGCACAGTTAGGAATACAGCTGTGGAGTACAATTGGTTTGTTTCATCTTAGATC
The chromosomal localization of the isolated RDA fragment was determined using a 
panel of monochromosomal human/rodent somatic cell hybrids. For PCR analysis of this 
panel, primer sets were designed from the known nucleotide sequences of the OSD5 
clone (see Materials and methods). PCR products of expected size were observed in the 
positive controls and, in addition, in the chromosome 5 containing somatic cell hybrid 
only, indicating that this OSD5 clone maps to this chromosome (not shown). To confirm 
the chromosomal origin and to fine-map OSD5 by FISH, a PAC library was screened with 
this clone yielding one positive PAC, 1155H10. FISH analysis with this PAC on normal
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human metaphase spreads revealed positive signals on 5q12.3-q13.1, thereby 
confirming the localization of the corresponding OSD5 clone on chromosome 5 and, in 
addition, refine its assignment to the region 5q12.3-q13.1 (Figure 2). In order to map 
OSD5 relative to known genetic markers, PCR analysis was performed on a radiation 
hybrid panel. Significant linkage was found with the chromosome 5 markers SHGC- 
13191, SHGC-36907 and SHGC-20276 (=D5S1967) (lod scores 12.53, 9.22 and 9.08, 
respectively). Testing of these markers on tumor material and on PAC 1155H10 revealed 
that only marker SHGC-13191 was located on the PAC and that none of the markers was 
deleted in the tumor DNA. This would mean that only part of the PAC is deleted in the 
tumor. Interphase FISH analysis with the PAC on tumor nuclei did not reveal allelic loss 
(not shown), which is consistent with this latter notion. The 5q deletion was not 
detected by comparative genomic hybridization as described in Chapter 5. Again, this 
result nicely demonstrates the power of the RDA technique to detect and isolate 
(homozygously) deleted genomic fragments that are relatively small.
a  ^  OS4x Normal
H  E  H  E
Figure 1. Hybridization of clone OSD5 to Southern blots containing BgHI representations (left panel) 
and HindIII- and EcoRI-cleaved total genomic (right panel) DNAs of driver (OS4x, tumor) and tester 
(Normal). OSD5 sequences are present in normal and deleted in tumor DNA. Fragment sizes are deduced 
from co-electrophoresed DNA markers (not shown).
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The 5q12.3-13.1 region has not before been reported as a target region in 
osteosarcomas, but there are reports in the literature pointing at the presence of a 
tumor suppressor gene(s) in or close to this region (Inokuchi et al., 1995; Moskaluk et 
al., 1998; Dolan et al., 1998; Peng et al., 1999). Interestingly, the human mismatch 
repair gene MSH3 is located within this chromosomal region, turning it into a candidate 
gene for osteosarcoma development (Inokuchi et al., 1995; Dolan et al., 1998). The 
isolated OSD5 clone may serve as a novel sequence tagged site (STS) and, as such, may 
be used for the analysis of additional osteosarcoma samples. It may also be used, 
together with its corresponding PAC clone 1155H10, for the identification of additional 
candidate genes in the region.
rh m m f i tn m i*  S
Figure 2. Chromosomal localization of PAC clone 1155H10 by FISH on DAPI-stained normal metaphase 
chromosomes (right panel). Chromosome identification was based on inverted DAPI-banding (left 
panel). A specific hybridization signal (white dots) can be seen only on chromosome 5, region q12.3- 
13.1 (arrows)
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Abstract
Representational difference analysis of a human glioblastoma xenograft resulted in the 
isolation of five tumor-associated homozygously deleted DNA fragments, all originating 
from chromosome 9, region p21. Subsequent analysis of a series of 10 glioblastomas 
using our newly isolated RDA fragments in conjunction with a series of known 9p21 DNA 
markers revealed homozygous deletions in 9 of the 10 (90% ) tumors. These deletions 
encompass the p15/p16 complex and two additional putative tumor suppressor loci. The 
RDA fragments correspond to the latter two loci. Taken together, these results suggest 
the involvement of multiple tumor suppressor genes from the 9p21 region in 
glioblastoma tumorigenesis. The novel RDA fragments will be instrumental in the 
isolation of the relevant genes.
Introduction
Representational difference analysis (RDA; Lisitsyn et al., 1993) is a powerful method 
for the isolation of tumor-specific genetic rearrangements. Basically, RDA allows the 
isolation of differences between two closely related genomes through subtractive 
hybridization and polymerase chain reaction (PCR) amplification. The subtractions are 
carried out with representations of two DNA populations (tester and driver) of which the 
differences are the targets (present in the tester) to be isolated. Representations are 
made by restriction enzyme cleavage of genomic DNA, followed by adaptor ligation and 
adaptor-primed PCR amplification. Both tumor-associated amplified sequences and 
homozygously deleted sequences have been isolated from various tumor types using RDA 
(Lisitsyn et al., 1992; Schutte et al., 1995; Simons et al., 1997; Li et al., 1997). 
Homozygously deleted DNA fragments turned out to be particularly useful for the 
mapping and positional cloning of genes that are inactivated in tumors as was e.g. 
demonstrated for BRCA2 (Schutte et al., 1995) and PTEN (Li et al., 1997).
Gliomas are the most frequently occurring primary tumors of the adult brain, the most 
common of which are the astrocytic tumors. From clinical observations it is known 
that low-grade astrocytic and oligodendroglial tumors tend to progress into more 
malignant lesions, the most malignant one being glioblastoma multiforme (GBM; 
Kleihues et al., 1993; Louis et al., 1995). Genetic events underlying glioma 
tumorigenesis have been studied extensively and multiple genetic pathways leading 
to GBM have been identified. Genetic alterations reported include allelic losses or 
rearrangements of 9p, 10, 13q, 17p, 19q and 22q (Louis et al., 1995; von Deimling et 
al., 1995; van de Kelft, 1997; Kon et al., 1998). Several genetic changes are shared 
among different gliomas, whereas others appear to be more characteristic for a certain 
subtype. Furthermore, it is thought that particular genetic aberrations act as early 
events in glial tumor development, whereas others are thought to play a role(s) in
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later stages. In  oligodendrogliomas allelic losses of 1p and 19q are preferentially 
observed (Reifenberger et al., 1994; Maier et al., 1997). Higher-grade anaplastic 
oligodendrogliomas and GBMs show increasing numbers of chromosomal abnormalities 
including allelic losses of 9p and 10 (Louis et al., 1995; von Deimling et al., 1995; 
van de Kelft, 1997; Kon et al., 1998).
Here, we have applied the RDA technique to isolate glioblastoma-associated 
homozygously deleted DNA fragments using a xenograft of a GBM with oligodendroglial 
differentiation. Subsequent molecular characterization of five isolated fragments 
revealed their 9p21 origin. Fine-mapping of this chromosomal region in the xenograft 
and the additional characterization of a series of glioblastoma xenografts suggest that 
multiple tumor suppressor genes (TSGs) from the 9p21 region, including the p15/p16 
complex (Kamb et al., 1994), may be involved in the development of glioblastomas.
Materials and methods
Tumor samples, DNA preparation and Southern blot analysis
Tumor xenograft samples used in this study were all histopathologically diagnosed as 
GBMs (grade IV tumors). One glioblastoma (E34) showed some oligodendroglial differ­
entiation and loss of 1p and 19q, the other glioblastomas (E18, E49, E80, E102, E106, 
E110, E120, E168, E98) showed astrocytic differentiation, while unequivocal oligoden­
droglial features and loss of 1p and 19q were absent. The presence or absence of 1p loss 
and 19q loss was determined by CGH (unpublished results). High molecular weight 
genomic DNA from tumor tissues and from peripheral blood cells of 2 unrelated human 
controls was isolated using methods described by Miller et al. (1988) and Sambrook et 
al. (1989). Southern blot experiments and hybridization of the human PAC library 
(RPC15; BAC-PAC Resources, Roswell Park Cancer Institute, Buffalo, NY, USA) were 
performed as described by Weterman et al. (1996).
Representational difference analysis, cloning and sequencing of RDA fragm ents
RDA was performed essentially as described by Lisitsyn et al.(1993,1995). DNA bands 
from RDA difference product 3 (DP3) were isolated from agarose gels and cloned into 
pBluescript KS+II plasmid vectors (Stratagene). Nucleotide sequencing was performed as 
described by Weterman (1996). Database searches were performed using the Genbank 
and European Molecular Biology Laboratory (EMBL) databases.
Fluorescence in situ  hybridization (F ISH )
FISH analysis was performed as described before (Suijkerbuijk et al., 1994). Briefly, 150 
ng digoxigenin-11-dUTP labeled PAC DNA was, prior to overnight hybridization at 37 °C, 
preannealed with a 40-fold excess of Cot-1 DNA (Gibco). Target slides containing normal 
chromosomal metaphase spreads were pre-treated according to standard protocols.
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Immunocytochemical detection was performed using sheep-anti-digoxigenin-FITC 
(Boehringer Mannheim) and donkey-anti-sheep-FITC (Jackson Immuno Research 
Laboratories). Afterwards, slides were analyzed using the Oncor-image software 
(Gaithersburgh MD).
Primers, genetic markers, probes and clones
Based on the nucleotide sequences of RDA clones DO1 to DO5, primer sets were 
designed for PCR analysis: DO1-FOR (= UOK132-12.1 [Lisitsyn et al., 1995]; 5'-GCCCCTC- 
TAAAAGATAAGGTCTTGGT-3') and DO1-REV (5'-GATCTGAGCCTCTGGAAGAAGTTAG-3'); DO2- 
FOR (5'-GAGCCTTGAGAGAATCCAAC-3') and DO2-REV (5'-CCTTATGTGTATAGCTCACG-3'); DO3- 
FOR (5'-ATCATCCAGACCAATGCGAC-3') and DO3-REV (5'-GACTGTGGAAGTGATGATAG-3'); DO4- 
FOR (5'-TAACTTAGGGCATCCTTTCC-3') and DO4-REV (5'-AGATGCTGCTATTACTGACC-3'); DO5- 
FOR (5'-CTGAGATCAAGCAGTCTTTG-3') and DO5-REV (5'-CTATGAGAGTTCCAGCTACC-3'). 
Genetic markers used were IFNA (Genome Database [GDB] accession number 1046300), 
D9S1749 (GDB 595876) D9S1748 (GDB 595589), D9S1752 (GDB 595993), D9S171 (GDB 
188218), D9S259 (GDB 199130), D9S270 (GDB 199467), and D9S104 (GDB 180701). A 
primer set from exon 2 of the von Hippel-Lindau gene (VHL), G712F2/G713R1, was used 
as an internal control (Bodmer et al., 1998). A p16 cDNA probe and the p15/p16 
complex-containing P1 (1062 and 1063) and cosmid (c5) clones (Kamb et al., 1994) 
were generously provided by Dr. A. de Klein (Erasmus University Rotterdam, The 
Netherlands).
Som atic cell hybrid panel and radiation hybrid panel
The monochromosomal human/rodent somatic cell hybrid panel used was partially 
obtained from the Coriell Institute for Medical Research (Camden, NJ, USA) and partially 
prepared in our department of Human Genetics (Nijmegen, The Netherlands). The 
radiation hybrid panel used was the Stanford G3 panel (Stanford Human Genome center, 
CA, USA).
PCR analysis
PCR analyses were carried out under standard conditions using 100 ng template DNA, 50 
ng FOR-primer and 50 ng REV-primer in 25 pl reaction volume and according to the 
protocol: 30-35 cycles of 30 sec at 94 °C, 45 sec at annealing temperature (61 °C for 
DO1, 55 °C for DO2 to DO5), and 45 or 60 sec at 72 °C, followed by a final extension 
of 5 min at 72 °C. Duplex-PCR reactions were performed under the same conditions 
except for addition of 50 ng of the G712F2 primer and 50 ng of the G713R1 primer and 
for the annealing temperature of 55 °C. Radiation hybrid panel mapping was performed 
under standard conditions using 100 ng template DNA and 25 ng of each primer in a 10 
pl reaction volume; PCR: pre-denaturation for 5 min at 94 °C, 35 cycles of 1 min at 
94°C, 1 min at 55 °C and 1.5 min at 72 °C, performed in a microtiterplate PCR apparatus 
(MJ Research). After PCR, 10 pl of each reaction mixture was loaded on a 2 %  agarose 
gel and subjected to electrophoresis.
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Results
Iso lation  of glioblastom a-associated hom ozygously deleted DNA fragm ents
BglII representations of DNA from glioblastoma xenograft E34 (D; driver) and a pool of
2 normal unrelated DNAs (Ta and Tb; tester) were used for the isolation of glioblastoma- 
associated homozygously deleted DNA fragments via RDA. Difference products (DP) 
obtained after one, two and three rounds of subtractive hybridization and PCR 
amplification are shown in Figure 1A. At least 8 clear bands, varying in size from
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Figure 1. (A) RDA results of a pool of 2 normal DNAs as tester (T, BglII representation) and glioblastoma 
xenograft E34 as driver (D, B g lII representation). DP1, DP2, and DP3: difference products after first, 
second, and third round of hybridization/amplification. In  DP3 at least 8 bands are present (1 to 8) 
which represent target sequences enriched from the tester. m: 100 bp marker. (B) Hybridization of clone 
DO4 to Southern blots containing BglII-representations (left panel) and EcoRI-cleaved total genomic 
(right panel) DNAs of driver (D, tumor) and tester (T, normal). DO4 sequences are present in the normal 
and deleted in the tumor DNA. Fragment sizes are deduced from co-electrophoresed 100 bp and 1 kb 
markers (not shown).
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350 bp to 700 bp, could be observed in the round 3 difference product (DP3) while 
background levels were reduced considerably. These bands were cloned into plasmid 
vectors and clone inserts were used as probes on Southern blots containing tester and 
driver, both representation and total genomic, DNAs. Five clones, DO1 (deleted in 
glioblastoma with oligodendroglial features), DO2, DO3, DO4, and DO5, derived from 
bands 1, 2, 2, 4, and 5, respectively, showed hybridization signals in the tester lanes 
(T; normal) and not in the driver lanes (D; tumor), indicating that these fragments 
represent homozygously deleted sequences in the original xenograft sample (Figure 1B). 
Two additional clones, derived from band 4, turned out to represent DNA polymorphisms 
(not shown). No informative clones were obtained from bands 3, 6, 7, and 8.
Identification of isolated RDA fragm ents
The 5 DO-clones were sequenced and, subsequently, compared with known sequences in 
databases. No homologies were found except for clone DO1 which showed a 100 %  
identity over 26 bp to primer UOK132-12.1 (GDB 567171) and 9 6 %  identity over 25 bp 
to primer UOK132-12.2 (GDB 567171). These primers were derived from a BglII 
restriction fragment, called clone UOK132-12, which was previously found to be 
homozygously deleted in the human renal cell carcinoma cell line UOK132 (Lisitsyn et 
al., 1995). In our DO1 sequence 221 nt are present between the 26 bp and 25 bp regions 
of identity, yielding a 272 bp PCR fragment which was also obtained by Lisitsyn et al. 
(1995) when using the UOK132-12.1/2 primer set. Although the complete UOK132-12 
nucleotide sequence is not available to us, we assume that clone DO1 is identical to 
UOK132-12. No overlaps or similarities between the sequences of the 5 DO-clones could 
be found. DO-derived nucleotide sequences are available at the GenBank database under 
the accession numbers: DO1: AF078672; DO2: AF078673; DO3: AF078674; DO4: 
AF078676 and AF078677; DO5: AF078675.
Assignm ent of the isolated RDA fragm ents to chrom osom al region 9p21
To establish the chromosomal localization of the isolated RDA fragments a panel of 
monochromosomal human/rodent somatic cell hybrids was used for PCR analysis with 
DO-clone derived primer sets (Figure 2A). In all cases PCR products of expected sizes 
were observed in the chromosome 9 containing somatic cell hybrid only, indicating that 
all isolated DO-clones map to this chromosome. The homozygously deleted status of the 
five DO-clones in the original glioblastoma xenograft sample, as previously determined 
by Southern blot analysis, could also be confirmed (Figure 2A). These latter PCR 
analyses were performed in a duplex-PCR format in which the VHL-primer set (G712F2 
and G713R1) was added as an internal control for PCR-able quality of the template DNA. 
DO-specific fragments of expected sizes were only seen in the tester (T; normal) but not 
in de driver (D; tumor) DNA, whereas the 241 bp internal VHL control fragment was 
consistently seen in both DNAs (summarized in Table I).
To fine-map the isolated clones by FISH, a PAC library was screened with clones DO1 to 
DO5. Three positive PACs were isolated: 973N20 and 1054F14 which were both positive
Glioblastoma 103
for clone DO1, and 1026F9 which was positive for clone DO5 (see Table I). FISH analysis 
with the three PACs on normal human metaphase spreads revealed positive signals on 
9p21 only (Figure 2B), thereby confirming the localization of the corresponding DNA 
fragments (DO1 and DO5) on chromosome 9 and, in addition, refining their assignment 
to region 9p21. No PACs were isolated with the clones DO2, DO3 and DO4. Clones DO2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 m
Figure 2. (A) Chromosomal localization of clone DO2. Specific primers were used for PCR analysis of 
monochromosomal somatic cell hybrid lines (1 to 22, x and y). Driver (D, tumor), tester (T, normal), 
clone DO2 and H2O (-) were used as controls, performed in a duplex-PCR together with the VHL 
G712F2/G713R1 primer set. A DO2-specific PCR product of expected size (342 bp) is  observed only in 
the chromosome 9 containing hybrid, indicating that clone DO2 maps to this chromosome. Furthermore, 
a 342 bp PCR product is seen in the positive control (DO2) and the tester (T), but not in the driver (D), 
thus, confirming the homozygously deleted status of clone DO2 in tumor E34. m: 100 bp marker.(B) 
Chromosomal localization of PAC clone 1054F14 by FISH on DAPI-stained normal metaphase 
chromosomes. A specific hybridization signal can be seen only on chromosome 9, region p21 (arrow 
heads).
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Table I. Marker analysis o f tumor samples, PAC, P l and cosmid clones. 9p21 DNA markers are listed in the same order as on 
the genetic map (IFNA distal and D9S104 proximal). The relative positions o f the two putative tumor suppressor regions (1 and 
2) as described by Hamada et al. (1998) are indicated.
STS/Marker PACs P l/cosm “ Normal G liob las tom a xenografts
1054F14 973N20 I026F9 62/63/C5 Ta/Tb
(Tester)
o b
E34
(Driver)
A c
E49
Ac
E80
Ac
E168
Ac
E102
Ac
E106
Ac
E110
A c
E98
Ac
E120
Ac
E18
D O l + + - - + - - - + + + + + + +
D 0 2 - - . - - + - + + + + + + +
D 0 3 - - - - + - + + + + + + + + +
D 0 4 - - - - + - - - + + + + - - +
D 0 5 - - + - + - - + + + + + + + +
IFNA nd nd nd + + + + + + + + + + +
D9S1749 - - - + _ - _ - + . + nd + +
p l 6 _ - _ +d + - nd nd nd nd nd nd nd nd nd
D9S1748 - - _ + + - - - - - - + - - +
p l 5 nd nd nd +d nd nd nd nd nd nd nd nd nd nd nd
D9S1752 - - - + + - - - - - - - - - +
r e g io n !
D9S171 + + - - + - - - + + + + + + +
D9S259 - - - . + - - + + + + + + + +
r e g i o n i
D9S270 - - - - + - + + + + + + + + +
D9S263 nd nd nd nd nd nd nd nd nd nd nd nd nd nd nd
D9S104 - - - - + + + + + + + + + + +
“P l clones 1062 and 1063 and cosmid clone c5 (Kamb et al., 1994)b GBM with oligodendroglial differentiation, °GBM with only astrocytic differentiation 
das determined by Kamb et al., 1994; +, present; -, absent; nd, not determined
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and DO3 could be mapped via PCR analysis of a radiation hybrid panel. Significant 
linkage was found with markers D9S263 (lod score 4.7) and D9S270 (lod score 10), 
respectively (not shown), also mapping within region 9p21 (see Table 1). Clones DO1 
and DO4 could not be fine-mapped using either method.
Hom ozygously deleted 9p21 region includes p15/p16 and two add itional candidate 
tum or suppressor loci
The p15/p16 tumor suppressor complex is located at 9p21 (Kamb et al., 1994) and since 
the p16 gene is known to be frequently involved (homozygously deleted or mutated) in 
higher grade gliomas (Moulton et al., 1995; Kyritsis et al., 1996; Barker et al., 1997; 
Arap et al., 1997), we decided to investigate whether this complex is included in the 
E34 glioblastoma xenograft 9p21 deletion. To this end, Southern blot analysis of 
genomic tumor and normal control DNAs was performed using a p16 cDNA probe (Figure 
3). A 4 kb fragment was visualized in the two normal control DNAs (Ta and Tb), as 
expected, but not in the E34 tumor DNA (D), indicating that this locus is indeed 
homozygously deleted in the xenograft sample. The same p16 probe was also tested on 
the 3 isolated PACs, but no hybridizing signal was observed, demonstrating that the 
three PACs do not cover the p16 gene (Table I). To test in reverse whether our DO-clones 
(including also DO2, DO3 and DO4) are linked to the p16 gene, DO-specific PCR reactions
p!6
D Ta Tb
4 kb
EcoRI
Figure 3. Southern blot containing fcoRI-cleaved tumor E34 (D) and normal (Ta and Tb) genomic 
DNAs hybridized with a p16  cDNA probe. Hybridizing fragments are only observed in the two normal 
lanes and not in the tumor lane, indicating a homozygous deletion of the p16  gene in tumor E34. The 
fragment size is deduced from a co-electrophoresed 1kb marker (not shown).
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were performed on P1 clones 1062 and 1063 and cosmid clone c5, which are known to 
contain the complete p15/p16 complex (Kamb et al., 1994). No PCR products were 
obtained from these clones, again indicating that DO1 and DO5, and additionally, DO2, 
DO3 and DO4, are not physically linked to the p15 and p16 genes (Table I).
A recent investigation of human lung carcinomas by Hamada and co-workers (1998) 
suggested the presence in 9p21 of at least two regions containing putative TSGs, other 
than p15/p16. These regions, denoted region 1 and region 2, were mapped between the 
markers D9S1752 and D9S171 (region 1) and D9S259 and D9S270 (region 2), and are 
both located centromeric to p15/p16 (Table I). We investigated the presence or absence 
of these markers and marker D9S1748, which maps in between p16 and p15, in our 
glioblastoma xenograft sample. Additionally, the markers IFNA (distal marker; from the 
interferon alpha gene cluster at 9p22), D9S1749 (just distal to the p16 gene) and 
D9S104 (proximal marker; located below region-2-flanking marker D9S270) were tested 
by duplex-PCR. Homozygous deletions were observed in tumor E34 for all tested markers 
except IFNA and D9S104. The same PCR analyses were also carried out on the 3 isolated 
PACs, P1 clones 1062 and 1063, and cosmid clone c5. Only for marker D9S171 PCR 
products were obtained from the DO1-positive PACs 1054F14 and 973N20. P1 clones 
1062 and 1063 and cosmid clone c5 (p15/p16-positive) yielded PCR products with only 
the markers D9S1748 and D9S1752, as expected (Table I).
In summary, the p16 gene and all 9p21 markers tested covering the p15/p16 complex 
and the regions 1 and 2, were homozygously deleted in the glioblastoma xenograft E34, 
whereas the most proximal (D9S104) and most distal (IFNA) markers tested were 
retained. DO1-positive PACs 1054F14 and 973N20 could be mapped between the markers 
D9S1752 and D9S259.
Figure 4. Duplex-PCR analysis (DO1 and VHL) of the total series of glioblastomas (E18 to E98, 
including E34 (= D)). Normal DNA (T), glioblastoma E34 DNA (D), clone DO1 and H2O (-), were included 
as controls. The VHL-specific 241 bp PCR fragment (internal control for PCR-able quality of the 
templates) is present in all tumors tested. The tumors E34 (=D), E49 and E80 are negative for DO1 (272 
bp), indicating a homozygous deletion of this fragment in these samples. m: 100 bp marker.
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Frequent 9p21 hom ozygous deletions in  other human glioblastom as
To determine the involvement of the DNA sequences mentioned above in other related 
brain tumors, a series of 9 additional glioblastoma xenograft samples was tested by PCR 
using DO- and 9p marker-specific primers (Table I; Figure 4). Glioblastomas E168, E102, 
E106, E110, and E18 were all positive for the five DO-markers. Tumors E49, E80, E98, 
and E120 were homozygously deleted for subsets of the DO-clones. The most distal and 
the most proximal genetic markers, IFNA and D9S104, respectively, were both present in 
all tumors. Marker D9S270 was present in all samples, marker D9S259 was present in all 
samples except in E49, marker D9S171 was present in all samples except in E49 and E80, 
marker D9S1752 was present only in E18, marker D9S1748 was present only in E110 and 
E18, and marker D9S1749 was present only in E102, E110, E120, and E18. This latter 
marker was not tested on E98 due to lack of further material from this tumor. Through 
this analysis, homozygous deletion of DO-clones and/or other tested 9p21 markers was 
revealed in 8 out of the 9 additional glioblastomas tested (Table I; Figure 5).
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Figure 5. Homozygous deletion map of chromosomal region 9p21-22 in glioblastoma xenografts E34 to 
E18. A schematic representation of Southern blot and PCR results of genetic markers and positioning of 
DO, cosmid and P1 (c5, 1062, 1063) and PAC (1054F14, 973N20, 1026F9) clones is shown. Solid and 
open circles indicate absence and presence of the genetic markers/DO-clones, respectively. Dashed 
circles (p15/p16 on cosmid and P1 clones) represent data described elsewhere (Kamb et al., 1994). 
Estimated genetic distances are indicated at the left (K, Kamb et al., 1994; D, Dib et al., 1996; H, 
Hamada et al., 1998). The two putative tumor suppressor regions 1 and 2 (Hamada et al., 1998) are 
marked.
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Position ing of RDA clones w ith in 9p21 genetic map
Combining all results from the genetic marker- and DO-specific PCR reactions on the 
total series of 10 tumors, PACs, P1 clones and cosmid c5 we were able to position the 
DO-clones in the 9p21 map as depicted in Figure 5: DO4 and DO1 within region 1, where 
DO4 is located distal to DO1; DO5 within region 2; DO2 and DO3 close to markers D9S270 
and D9S263, most likely also within region 2.
Discussion
In this study, we successfully applied the technique of representational difference 
analysis (RDA) to a glioblastoma xenograft sample (E34) using tumor DNA as driver and 
normal DNA as tester. Five distinct glioblastoma-associated homozygously deleted DNA 
fragments (DO1 to DO5) were isolated. Two additional RDA clones appeared to represent 
polymorphisms, which can be explained by the fact that the tumor and normal DNA 
samples used were obtained from unrelated individuals.
The five deleted RDA fragments were all derived from chromosomal region 9p21. 
Interestingly, we did not isolate RDA fragments from the oligodendroglioma-associated 
(Reifenberger et al., 1994; Maier et al., 1997) chromosomal regions 1p and/or 19q, in 
spite of the fact that we did observe 1p and 19q loss in this tumor using CGH analysis 
(unpublished results). One might speculate that in these latter cases only one allele was 
lost in the tumor and that the remaining allele has prohibited efficient enrichment 
during the RDA procedure.
Since the p15/p16 tumor suppressor gene complex is located at 9p21 (Kamb et al., 
1994) and since the p16 gene is known to be frequently involved in higher-grade 
gliomas (Moulton et al., 1995; Kyritsis et al., 1996; Barker et al., 1997; Arap et al., 
1997) we performed Southern blot analysis on glioblastoma E34 and, indeed, observed 
complete absence of the p16 gene. Subsequently, we tested a series of genetic markers 
flanking the p15 and p16 genes (Kamb et al., 1994) and markers flanking two additional 
putative tumor suppressor loci in 9p21, denoted regions 1 and 2 (Hamada et al., 1998). 
In tumor E34 all markers tested between IFNA and D9S104 were homozygously deleted, 
indicating that the deleted region in tumor E34 is relatively large (estimated to be at 
least 8.5 cM; Kamb et al., 1994; Dib et al., 1996; Hamada et al., 1998).
To determine the involvement of the DNA sequences mentioned above in other related 
brain tumors, a series of 9 additional glioblastoma xenograft samples was tested by PCR. 
In several of these tumors homozygous deletions for the clones DO1, DO4 and DO5 were 
observed, whereas DO2 and DO3 were never found to be deleted. The other genetic 
markers tested showed a diverse distribution of deletions among the different 
glioblastomas (Table I; Figure 5). The involvement of the putative tumor suppressor 
regions 1 and/or 2 (Hamada et al., 1998) can be suggested in 8 out of 9 glioblastomas. 
Remarkably, in 7 of these 8 tumors a combined deletion of p16 and/or p15 with region 
1 and/or region 2 was observed, showing that in these tumors multiple genes from 9p21
Glioblastoma 109
may be involved. The p16 gene is assumed to play an important role in high-grade glial 
tumors (Moulton et al., 1995; Kyritsis et al., 1996; Barker et al., 1997; Arap et al.,
1997). However, in one tumor (E110) the p16 gene does not seem to be deleted, since 
its closely flanking markers D9S1749 and D9S1748 are still present. The only 
homozygously deleted marker in this tumor is D9S1752, proximally flanking region 1. 
This may suggest the involvement in this tumor of a putative TSG(s) located near or 
within region 1, although it can not be ruled out at this stage that more subtle p16 
(point) mutations, resulting in the inactivation of the p16 gene (Arap et al., 1997), are 
associated with the development of tumor E110.
Homozygous deletions of DNA sequences from chromosome region 9p21 is a frequently 
occurring event, not only in glioblastomas (Moulton et al., 1995; Kyritsis et al., 1996; 
Barker et al., 1997; Arap et al., 1997), but also in breast cancers (An et al., 1996), small 
cell lung cancers (Cairns et al., 1997), squamous cell carcinomas (Wiest et al., 1997), 
pituitary adenomas (Farrell et al., 1997), melanomas (Wagner et al., 1998), and non­
small cell lung carcinomas (Hamada et al., 1998). The proposed clustering of several 
tumor suppressor loci to this restricted chromosomal region may provide a mechanistic 
basis for this observation, i.e., the concerted loss of more than one tumor suppressor 
gene via homozygous deletion of relatively large chromosomal fragments may require 
less genetic modification steps than the subsequent mutation and/or deletion of all the 
individual (allelic) loci involved.
Although they do not exemplify expressed sequences, the DO-clones represent novel 
sequence tagged sites (STSs) from the 9p21 region that may be used as markers for the 
analysis of other tumors. In addition, the newly isolated RDA fragments and their 
corresponding PACs will be instrumental in the isolation of candidate TSG(s) from the 
9p21 region.
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General discussion and future prospects
The detection, identification and isolation of recurrent chromosomal aberrations in 
tumors exhibiting complex chromosomal constitutions has so far been cumbersome. 
Classical cytogenetic analysis of such tumors usually remained insufficient or even 
completely unsuccessful due to e.g. limited microscopic resolutions and/or problems 
with bringing the tumors into tissue culture. In addition, Southern blot, FISH and/or 
PCR analyses are usually not useful in the first stages of analyzing complex tumors, for 
the simple reason that there is no clue where or what to look for. Our main objective 
was to investigate whether the application of novel molecular (cyto)genetic techniques, 
in particular CGH and RDA, to human solid tumors with complex chromosomal 
constitutions would be of help in creating order in the genomic complexity of these 
tumors, or even in the identification of (novel) tumor-associated DNA sequences and/or 
genes. The potential of both techniques in cancer research has been described in 
Chapter 1. The experimental work presented in this thesis shows that these techniques 
are both very useful and complementary: CGH points towards the chromosomal regions 
of interest, whereas RDA provides the tool to directly isolate the DNA sequences 
involved. Besides these two, relatively novel, techniques we also used cytogenetic, 
FISH, Southern blot, DNA sequence and PCR analyses. Each individual molecular 
(cyto)genetic technique provided unique and valuable information but also had its 
limitations, thus making combinations of the different techniques highly recommended 
for obtaining the most relevant information for each subject (tumor) studied.
In chapter 2 cytogenetic analysis, CGH and whole chromosome painting FISH were used 
to elucidate, for the first time, the genetic constitution of a human malignant 
mesenchymoma. In this tumor supernumerary ring and rod-shaped chromosomes were 
observed. In addition, it was found that these chromosomes carried amplified sequences 
derived from chromosomal regions 1q21-q25 and 12q14-15. Both regions were 
previously shown to be amplified in various human sarcomas, including liposarcomas 
(Forus et al., 1993, 1998). Therefore, we assume that the observed anomalies may be 
associated with the liposarcomatous component of this combined tumor. A 
comprehensive study of a series of 34 malignant fibrous histiocytomas using a 
combination of cytogenetic, CGH, and Southern blot analyses is presented in chapter 3. 
Among other abnormalities a clear and frequent loss of chromosomal region 9p21 and a 
corresponding gene, p16INK4A, was observed. We also extensively compared our CGH data 
with those of others, yielding both similarities and discrepancies. However, a few points 
should be noted when interpreting and comparing CGH results. First, it is not always 
known (or possible to trace back) how much normal cells were present within the tumor 
samples analyzed. If  the percentage of normal cells within a sample is high the 
detection of losses and/or gains may be hampered. Second, many tumors, including 
MFHs, are known to display intratumor heterogeneity, which may interfere with the 
detection of clonal abnormalities. Third, when comparing CGH results of different
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studies at the quantitative level, one should consider the hybridization conditions, 
image acquisition methods, analysis programs and thresholds for gains and losses used 
in the different studies. Based on our own combined data, we investigated whether the 
histological sub-classification of MFHs correlated with CGH-detectable copy number 
aberrations or whether, based on CGH findings alone, it would be possible to distinguish 
genetically different MFH subtypes. Although our series of tumors was not optimal (i.e., 
many tumors consisted of more than one histological subtype and sample biases may 
have occurred due to the often large size and heterogeneous composition of the tumors 
used) we obtained preliminary indications that CGH-based genotyping of MFH subtypes 
may indeed be feasible.
The technique of RDA, in combination with several of the other molecular (cyto)genetic 
techniques mentioned above, plays a central role in the studies presented in chapters 4 
to 7. RDA was successfully applied to the isolation of osteosarcoma-associated amplified 
sequences as described in chapter 4. Thus, several fragments derived from an amplicon 
at 19q12-13.1 were isolated, but we failed to obtain sequences from another amplicon 
at 17p11.2-12 that was also found to be present in the tumor (determined by CGH and 
FISH). It should be noted that the successful application of this technique largely 
depends on the presence of suitable DNA fragments (generated by the restriction 
enzyme used and of the right size, between 100 bp to 1.5 kb preferably) in the represen­
tations prior to subtraction. To increase the chance of covering the whole genome in the 
RDA procedure it is recommended to perform parallel experiments using different 
restriction enzyme-based representations. Additionally, in all our studies we isolated as 
much false-positive as real-positive subtraction fragments. This problem appears to be 
intrinsic to the RDA technique and is, as yet, difficult to overcome (Lisitsyn et al., 1993; 
Lisitsyn et al., 1995; Schutte et al., 1995a).
The genetic constitution of amplicons is variable and difficult to predict. In  general, it 
appears that amplicons not only contain high copy numbers of relatively small DNA 
fragments, but also low copy numbers of DNA fragments that are relatively large in size 
(up to several Mb; see Brodeur and Hogarty, 1998). If  via RDA part of such a latter DNA 
fragment is isolated, the RDA-probe may still be located far away from the target 
(onco)gene. Nevertheless, such fragments may be useful as sequence-tagged-sites 
(STSs) for further molecular analyses. In contrast to amplified DNA fragments, 
homozygously deleted DNA fragments are usually small (less than a few Mb; Kohno et 
al., 1995; Schutte et al., 1995a, 1995b; Takei et al., 1998). Therefore, RDA may be 
particularly useful for the isolation of DNA fragments that are closely associated with 
(novel) tumor suppressor genes. This was already shown by the groups of Schutte 
(1995), Li (1997) and Mollenhauer (1997) through the isolation of the BRCA2, PTEN and 
DMBT1 genes, respectively. In our search for (novel) candidate tumor suppressor loci, 
we used an osteosarcoma xenograft sample (chapters 5 and 6). In chapter 5 we 
presented the isolation of four RDA-fragments which were homozygously deleted in this 
tumor. Interestingly, all four fragments were derived from the same chromosomal region, 
4q32-34, which after Southern blot analysis of 27 osteosarcomas and interphase FISH
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analysis of 7 additional osteosarcoma samples appeared to show allelic loss in 6 3 %  of 
the tumors tested. Such a finding is indicative for the presence of a (novel) tumor 
suppressor gene in this region important for osteosarcoma development. The 4q32-34 
deletion in the xenograft sample was estimated to be at least 350 kb, but at maximum 
a few Mb in size since the deletion was not detectable by CGH: an example showing the 
surplus value of using a combination of different techniques. Chapter 5 shortly describes 
the isolation of an additional RDA-fragment from chromosomal region 5q12.3-13.1, 
using the same osteosarcoma xenograft sample. Although this fragment was 
homozygously deleted in the tumor studied, it remains to be investigated whether this 
region is also affected in other osteosarcomas. In addition to the 4q32-34 region, also 
this latter region may harbor a tumor suppressor gene(s). Both regions have been found 
to be deleted in other tumor types (see below). The newly isolated RDA and PAC clones 
may be used to examine whether the regions of loss overlap in these different tumors. 
In addition, they may be instrumental in the isolation of the genes involved.
A similar approach as described in chapters 5 and 6 was used in our search for 
homozygously deleted fragments in a brain tumor (glioblastoma) xenograft. Also here 
we were successful in the isolation of several RDA fragments, all deriving from 
chromosomal region 9p21. After PCR analysis of a series of 9 additional glioblasoma 
xenografts, it was found that in 8 of these tumors (89% ) this region was (partly) 
homozygously deleted. Although this region is known to contain the tumor suppressor 
genes p15 and p16INK4A (and p19ARF), our results are indicative for the presence of 
additional tumor suppressor genes in this chromosomal region relevant for glioblastoma 
development. Again, this suggestion could only be made using a combination of 
molecular (cyto)genetic techniques.
Important for the use of RDA in the search for deletions is the availability for pure and 
intact tumor DNA (which is used as driver), since contaminating normal cells might 
interfere with the enrichment of target fragments from the tester (which is normal DNA). 
Such DNA is sometimes difficult to obtain, because not all tumors are suitable for the 
generation of cell lines and/or xenografts or for flow sorting and microdissection. In 
addition, flow sorted or microdissected samples are usually too small to yield sufficient 
quantities of DNA. These considerations may hamper the use of the RDA technique, 
although some investigators are working successfully on improvements in this field 
(Lucito et al., 1998). Another issue is the preferred use of normal (tester) DNA derived 
from the same individual as where the tumor sample (cell line, xenograft; driver) was 
derived from. If  not available, however, normal DNA from any other individual(s) can be 
used. Obviously, this will yield false positive results due the presence of DNA 
polymorphisms in the different tissue samples employed. This was also noted in our 
studies, both on the osteosarcoma and the glioblastoma xenografts.
The studies described in this thesis revealed genetic abnormalities in malignant 
fibrous histiocytomas, osteosarcomas and glioblastomas, which were not reported 
before in these tumors. In  case of the osteosarcomas, the region of allelic loss on
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4q32-34 (Chapter 5) may be of particular interest, since this region is believed to 
contain a tumor suppressor gene(s) (Polascik et al., 1995; Hammoud et al., 1996; 
Larson et al., 1997; Loughran et al., 1997; Pershouse et al., 1997; Piao et al., 1998). 
Recently two additional studies were published pointing at the existence of such a 
gene(s) in this region (Shivapurkar et al., 1999; Bando et al., 1999). Bando et al. 
(1999) correlated loss of this region with tumor progression. We initially detected this 
deletion in an osteosarcoma xenograft. Such xenografts usually represent aggressive 
tumors in advanced stages of progression. In addition, in our extended series allelic 
losses were mostly found in tumors in advanced stages and/or in xenografts. So, in 
osteosarcomas this genetic aberration may also be associated with aggressive 
behavior, progression into more advanced stages or metastasis. Besides the RDA- 
isolated 4q32-34 derived fragments, we also isolated a fragment from 5q12.3-13.1 
that showed homozygous loss (Chapter 6). This 5q region has not before been 
associated with this type of tumor, but there are reports in the literature suggesting 
the existence of a tumor suppressor gene(s) in or close to this region (Inokuchi et al., 
1995; Moskaluk et al., 1998; Dolan et al., 1998; Peng et al., 1999). Interestingly, the 
human mismatch repair gene MSH3 is located within this chromosomal region and, as 
such, may be considered as a candidate gene (Inokuchi et al., 1995; Dolan et al.,
1998). The amplified 19q13.1 and 17p11.2-12 regions as detected in one of our 
osteosarcomas (Chapter 4) were previously reported to show frequent cytogenetic 
breaks and/or amplifications (Cheng et al., 1992; Thompson et al., 1996; Bridge et 
al., 1997). Also, several candidate genes have been located in these regions, 
including a very recently discovered novel member of the trx/MLL family of genes 
(MLL2; FitzGerald and Diaz, 1999; Fujii et al., 1986; Cheng et al., 1992; Hatada et al., 
1992; Thompson et al., 1996). It remains to be investigated whether these genes are 
included in the amplicons of the osteosarcoma tested. Our search for genomic 
imbalances in malignant fibrous histiocytomas (MFHs; Chapter 3) yielded clear 
indications for the involvement of one or more tumor suppressor genes from the 9p21 
region, of which the p16INK4A gene was studied in more detail and found to be 
frequently deleted. The significance of this chromosomal region and the p16INK4A gene 
in MFHs was not noted before. Elaborating on this finding and on observations 
published by others, we postulated that in order for MFH to develop at least one of 
the major cell cycle regulatory pathways (RB1- and/or TP53-pathways) has to be 
affected. In Chapter 7 novel glioblastoma-associated deleted DNA sequences were 
described. These sequences (STSs) were derived from two putative tumor suppressor 
loci within (again) the 9q21 region, but distinct from the known tumor suppressor 
genes p15, p16INK4A and p19ARF. Although these isolated RDA fragments did not 
represent transcribed sequences they may serve as tools for the identification and 
isolation of (novel) candidate tumor suppressor genes from this region. In line with 
our findings, it was recently suggested by others that additional genes relevant to 
cancer development must be located in this region (Watson et al., 1999; van der 
Velden et al., 1999).
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Figure 1. This figure is  adapted from Figure 2 of Chapter 1. The different cell cycle regulatory genes are 
now linked to their involvement in the different tumor types studied in this thesis (grey boxed squares). 
Top: inserted grey box, depicting the role of E2F in the S-phase (see text; Lees and Weinberg, 1999; 
Chen et al., 1999).
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The RB1- and TP53- cell cycle regulatory pathways play important roles in many types 
of cancer, including the four tumor types studied in this thesis. The involvement of 
several of the RB1/TP53 pathway associated genes in these four tumor types, as based 
on our results and those of others, is depicted in Figure 1. As it turns out, most of 
these genes may be affected in the tumors studied here, i.e., osteosarcoma, MFH and 
glioblastoma. For malignant mesenchymomas such elaborate information is not yet 
available, but based on our results we speculate that at least the MDM2 and/or CDK4 
genes on 12q may be affected (amplified). In addition, all tumor types which may act 
as components of malignant mesenchymomas, such as liposarcoma, 
rhabdomyosarcoma, osteosarcoma and chondrosarcoma have been described to exhibit 
impairments in one or more of the genes listed in Figure 1 (examples in Yamaguchi et 
al., 1996; Dei Tos et al., 1997; Kanoe et al., 1998). Of note is the enigmatic 
involvement of p19ARF as depicted in Figure 1. Although not yet described in the 
literature and not studied in this thesis, it is likely that this factor is involved in MFH, 
osteosarcoma and glioblastoma development, since these tumors frequently show 
p16INK4A deletions and, consequently, loss of p19ARF (see Chapter 1). Several different 
genes of the two cell cycle regulatory pathways are affected in different tumor types 
and, thus, these gene alterations do not seem to be tumor type-specific. It remains to 
be established, however, whether comprehensive information on the genomic and/or 
expression status of the different genes involved in these RB1/TP53 pathways may be 
of diagnostic and/or prognostic value. To address this question, one might think of 
making use of the recently developed DNA chip technology, in which all of the relevant 
genes can be tested in a single experiment, resulting in detailed genomic and/or 
expression fingerprints (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Gerhold et al.,
1999). Interestingly, it appears that whatever gene from these cell cycle regulatory 
pathways is affected, either through amplification/overexpression or 
deletion/mutation/ inactivation, it inevitably results in the activation of the 
transcription factor E2F (Figure 1). As briefly mentioned in Chapter 1, E2F factors are 
transcription factors regulating a cohort of target genes whose products are required 
for S-phase entrance and advance (Müller, 1995; Weinberg, 1995; Sherr, 1996; Lees and 
Weinberg, 1999). Just after the cell has passed the G1/S transition checkpoint E2F 
becomes, normally, inactivated by cyclin A/CDK2 complexes (Figure 1, grey insert; Lees 
and Weinberg, 1999). This inactivation of E2F is necessary for progression through the 
cell cycle. It has also been found that cells overexpressing E2F, or with alterations in 
the cyclin A/CDK2 complex hampering the inactivation of E2F, are triggered to go into 
apoptosis (Lees and Weinberg, 1999 and references therein). As suggested by Chen et 
al. (1999), inhibition of cyclin A/CDK2 complex-induced inactivation of E2F may, 
therefore, be a very effective way to drive cancer cells to apoptosis, irrespective of the 
upstream RB1/TP53 cell cycle pathway gene(s) affected. This notion, in conjunction 
with the diagnosis that either one of the two cell cycle regulatory pathways is affected 
in a given tumor sample, may thus have important implications for the future design 
of more specifically targeted treatment strategies.
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Several human hematologic and solid tumors carry relatively simple recurrent 
chromosomal aberrations, some of which turned out to be very suitable as specific 
diagnostic and/or prognostic markers. In addition, several of these aberrations have 
successfully been used as (cyto)genetic landmarks to positionally clone the genes 
involved. However, there are also many tumors that exhibit complex chromosomal 
constitutions. For most of these tumors no recurrent chromosomal abnormalities are 
known. Tumors falling into this category and which were studied in this thesis are the 
sarcomas malignant mesenchymoma (Chapter 2), malignant fibrous histiocytoma 
(Chapter 3) and osteosarcoma (Chapters 4, 5 and 6), and the brain tumor glioblastoma 
(Chapter 7).
Our objective was to identify and characterize recurrent genetic aberrations and/or their 
related genes in these cytogenetically complex tumors. To obtain such information, we 
made use of a variety of molecular (cyto)genetic techniques such as karyotyping, 
fluorescence in situ hybridization (FISH), Southern blot and polymerase chain reaction 
(PCR) analyses and, in addition, two relatively novel techniques, i.e., comparative 
genomic hybridization (CGH) and representational difference analysis (RDA). CGH is a 
technique which enables, in a single experiment, the screening of a whole tumor 
genome for over- and/or underrepresentations (gains and/or losses) of chromosomes 
and/or chromosomal (sub)regions. This technique is very useful for the identification of 
regions that are affected in a particular tumor type and, as such, may point at the 
location of related oncogenes and/or tumor suppressor genes (Chapters 2, 3 and 4). RDA 
is a PCR-based subtraction method enabling the isolation of differences between two 
genomes (e.g., tumor versus normal). This method is very suitable for the identification 
and isolation of aberrant DNA fragments which may serve as tumor-related markers or, 
alternatively, may constitute part(s) of the affected genes. These fragments can readily 
be characterized by DNA sequence analysis (Chapters 4, 5, 6 and 7). In the studies 
described in this thesis it became apparent that various combinations of these different 
techniques are most informative for the analysis of tumors with complex karyotypes. Our 
studies yielded, besides some confirmatory data, several novel findings. The powerful 
combination of CGH and RDA analysis was demonstrated in our study on DNA 
amplifications in osteosarcomas as described in Chapter 4. Also for osteosarcomas we 
described, for the first time, the frequent occurrence of 4q32-34-associated 
(homozygous) deletions, a region believed to contain an as yet unidentified tumor 
suppressor gene(s) (Chapter 5). Additionally, a 5q12.3-13.1-associated homozygously 
deleted region was encountered in an osteosarcoma xenograft. Such a deletion was not 
described before (Chapter 6). For malignant fibrous histiocytomas, we observed a 
frequently occurring loss of 9p21, a region containing the p16INK4A tumor suppressor gene 
(Chapter 3). The malignant mesenchymoma study (Chapter 2) is the first of its kind on 
this tumor type, describing the occurrence and characterization of ring and rod-shaped 
marker chromosomes. Finally, our study on glioblastomas (Chapter 7) provided strong
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evidence for the existence of multiple tumor suppressor genes in the 9p21 region.
The different studies presented in this thesis yielded DNA probes corresponding to, and 
providing important tools for the isolation and identification of, novel tumor-related 
genes.
Finally, we discussed the role of the RB1- and TP53- cell cycle regulatory pathways and 
their corresponding genes, such as RB1, TP53, p16INK4A, p19ARF, MDM2, CDK4 and cyclinD 
in normal and abnormal (cancer) cellular growth (Chapters 1 and 8). We propose that 
one or more of these genes is affected in each of the cytogenetically complex tumor 
types studied in this thesis.
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Verscheidene humane hematologische en solide tumoren vertonen relatief eenvoudige 
en specifieke chromosomale afwijkingen. Sommige van deze afwijkingen bleken erg 
waardevol als specifieke diagnostische en/of prognostische merkers. Bovendien werden 
verschillende van deze afwijkingen succesvol gebruikt als (cyto)genetisch beginpunt 
voor de positionele klonering van de betrokken genen. Er zijn echter ook veel tumoren 
met zeer complexe afwijkende chromosoom-samenstellingen. Voor de meeste van deze 
tumoren zijn geen specifieke afwijkingen bekend. Tumoren welke in deze categorie 
vallen en welke zijn bestudeerd in dit proefschrift zijn de sarcomen maligne 
mesenchymoom (Hoofdstuk 2), maligne fibreuze histiocytoom (Hoofdstuk 3) en 
osteosarcoom (Hoofdstukken 4, 5 en 6), en de hersentumor glioblastoom (Hoofdstuk 7). 
Onze doelstelling was het identificeren en karakteriseren van specifieke genetische 
afwijkingen en/of gerelateerde genen in deze cytogenetisch complexe tumoren. Om deze 
informatie te verkrijgen hebben we gebruik gemaakt van een scala aan moleculair 
(cyto)genetische technieken zoals karyotypering, fluorescentie in situ hybridizatie 
(FISH), Southern blot en polymerase ketting reactie (PCR) analyses, en twee relatief 
nieuwe technieken, "comparative genomic hybridization (CGH)" en "representational 
difference analysis (RDA)". CGH is een techniek die het mogelijk maakt om in een enkel 
experiment een volledig tumor genoom te screenen op over- en/of ondervertegenwoor­
digingen (winst en/of verlies) van chromosomen en/of chromosomale (sub)regio's. Deze 
techniek is zeer geschikt voor de identificatie van aangedane chromosomale gebieden 
in een bepaalde tumor en, als zodanig, voor de bepaling van de positie van mogelijk 
gerelateerde oncogenen en/of tumorsuppressorgenen (Hoofdstukken 2, 3 en 4). RDA is 
een PCR-gebaseerde subtractiemethode die het mogelijk maakt om verschillen tussen 
twee genomen (bijvoorbeeld tumor versus normaal) te isoleren. Deze methode is zeer 
geschikt om afwijkende DNA fragmenten te identificeren en te isoleren, welke kunnen 
dienen als tumorgerelateerde merkers of welke deel uit kunnen maken van aangedane 
genen. Zulke fragmenten kunnen eenvoudig worden gekarakteriseerd met behulp van 
DNA sequentie analyse (Hoofdstukken 4, 5, 6 en 7).
Uit de studies die beschreven zijn in dit proefschrift werd duidelijk dat het gebruik van 
verschillende combinaties van bovengenoemde technieken het meest geschikt is voor de 
analyse van tumoren met complexe chromosomale samenstellingen. Onze onderzoeken 
leverden, naast enkele bevestigende resultaten, ook nieuwe bevindingen op. De 
krachtige combinatie van de CGH en RDA methodes werd gedemonstreerd in een studie 
over DNA amplificaties in osteosarcomen, zoals beschreven in Hoofdstuk 4. Voor 
osteosarcomen hebben we bovendien voor het eerst het frequent voorkomen van 4q32- 
q34-geassocieerde (homozygote) deleties aangetoond. Dit chromosomale gebied bevat 
zeer waarschijnlijk een of meer nog niet gedïentificeerde tumorsuppressorgenen 
(Hoofdstuk 5). Verder werd een 5q12.3-13.1-geassocieerde homozygoot gedeleteerde 
regio gevonden in een osteosarcoom-xenograft. Zo'n deletie is nooit eerder beschreven 
voor dit tumor type (Hoofdstuk 6). Voor maligne fibreuze histiocytomen vonden we een
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frequent voorkomend verlies van 9p21, een gebied dat onder andere het p16INK4A 
tumorsuppressorgen bevat (Hoofdstuk 3). De studie over het maligne mesenchymoom 
(Hoofdstuk 2) is de eerste in zijn soort over dit tumor type. Het beschrijft de 
aanwezigheid en karakterisatie van ring- en staafvormige merker chromosomen. De 
studie over de hersentumor glioblastoom (Hoofdstuk 7) leverde krachtig bewijs voor de 
aanwezigheid van meerdere tumorsuppressorgenen in het 9p21 gebied. De verschillende 
studies beschreven in dit proefschrift resulteerden in de isolatie van DNA probes die 
corresponderen met, en kunnen fungeren als belangrijke hulpstukken voor de isolatie en 
identificatie van, nieuwe tumorgerelateerde genen.
Tot slot hebben we de rol van de RB1- en TP53- celcyclus-regulerende routes en enkele 
corresponderende genen zoals RB1, TP53, p16INK4A, p19ARF, MDM2, CDK4 en cyclinD 
bediscussieerd in het kader van normale en abnormale (kanker) cellulaire groei 
(Hoofdstukken 1 en 8). We concluderen dat een of meer van deze genen is aangedaan 
in elk van de cytogenetisch complexe tumor types beschreven in dit proefschrift.
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